MALT1 inhibitor as well as composition and application thereof
By developing compounds that can inhibit the activity of MALT1 protease, the drug resistance of MALT1-related diseases such as ABC-DLBCL to existing therapeutic methods is solved, and a new treatment method is provided, especially in diseases with abnormal expression of MALT1 protease. Significantly improves the therapeutic effect.
Patent Information
- Application Number
- CN202410665991.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-04-12
- Filing Date
- 2024-05-27
- Publication Date
- 2024-11-26
AI Technical Summary
The existing treatment methods are resistant to activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL) therapy and lack effective treatment methods. MALT1 plays an important role in the pathogenesis of this tumor, and it is of great significance to find MALT1 inhibitors.
Develop a compound that inhibits MALT1 protease activity and its pharmaceutically acceptable salts for the treatment of diseases associated with abnormal expression or activity of MALT1 protease, including cancer, autoimmune and inflammatory diseases, by inhibiting MALT1 Treatment of related diseases may be combined with BTK inhibitors.
A novel approach to treating ABC-DLBCL and other MALT1-related diseases is provided, potentially improving therapeutic effects, especially in drug-resistant diseases by inhibiting MALT1 protease activity.
Smart Images

Figure CN119019412A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medicine and relates to a compound containing a urea structure, a preparation method and its application in the field of medicine. The present invention relates to pharmaceutically active compounds, deuterated compounds (hydrogen is replaced by deuterium), and pharmaceutically acceptable salts, which may be useful in treating or preventing diseases related to MALT1 or NF-kB signaling pathways, such as cancer, tumors, autoimmune diseases, inflammation and other diseases. Background Art
[0002] Mucosa-associated-lymphoid-tissue lymphoma-translocation protein 1 (MALT1) is an important protein in the NF-kB signaling pathway. MALT1 protein, BCL10 and CARD11 form a CBM complex that regulates lymphocyte proliferation and activation and the expression of factors required for immune response. Abnormal MALT1-mediated NF-κB signaling pathway is involved in a variety of diseases, including MALT lymphoma, diffuse large B-cell lymphoma (DLBCL) and other related diseases. Among them, MALT lymphoma has been confirmed to have B cell origin and has a common cytological immunophenotype with marginal zone B cells. MALT lymphoma was officially classified as MALT extranodal marginal zone B cell lymphoma by the World Health Organization in 2002. In terms of pathogenesis, chromosomal translocation t(11;18)(q21;q21) was first reported in lacrimal gland and gastric lymphomas, and was later confirmed in MALT lymphoma. It is the most common chromosomal aberration. In 1999, the structure of the API2-MALT1 fusion protein caused by the t(11;18)(q21;q21) translocation was determined, opening up the study of the precise role of MALT1 in various biological pathways.
[0003] Activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL), referred to as ABC-DLBCL, is strongly resistant to standard immunochemotherapy and is the most malignant subtype with the worst prognosis. There is currently no effective treatment, which seriously threatens the life safety of patients. Therefore, it is of great significance to develop effective drug treatments for ABC-DLBCL. MALT1 plays a vital role in the pathogenesis of ABC-DLBCL tumors and is considered to be an ideal drug target.
[0004] Studies have shown that the types of diseases associated with MALT1 protein include (but are not limited to): tumors (such as bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, prostate cancer); hematopoietic-related malignancies (non-Hodgkin's lymphoma (including marginal zone lymphoma, mantle cell lymphoma, transformed follicular lymphoma, follicular lymphoma, Waldenstrom macroglobulinemia, diffuse large B-cell lymphoma) and chronic lymphocytic leukemia / small lymphocytic lymphoma); other neoplasms (such as glioblastoma, melanoma and rhabdomyosarcoma); autoimmune diseases and inflammatory diseases, such as rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus or vasculitis.
[0005] These results suggest that it is of great significance to identify and synthesize MALT1 inhibitors, which may provide a novel treatment for patients with tumors harboring MALT1 abnormalities. Summary of the invention
[0006] The present invention relates to compounds having the ability to inhibit the activity of MALT1 protease and pharmaceutically acceptable salts thereof, which can be used to treat various diseases associated with abnormal expression or activity of MALT1 protease. The present invention also discloses a pharmaceutical composition comprising such compounds and a method for treating diseases that can be treated by inhibiting MALT1.
[0007] The present invention adopts the following technical solution:
[0008] The first aspect of the present invention provides a compound, which is a compound represented by formula (I), or an isomer, isotope derivative, polymorph, prodrug, chelate, non-covalent complex, pharmaceutically acceptable salt or solvate thereof:
[0009]
[0010] in,
[0011] X is O or S;
[0012] R 1 and R 2 are independently selected from H, halogen, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl and C 1-6 haloalkoxy; in some embodiments, R 1 is H; in some embodiments, R 2 is halogen; in some embodiments, R 2 is F, Cl, Br or I;
[0013] M 1is C or N; in some embodiments, M 1 is N;
[0014] When M 1 When N, R 3 does not exist;
[0015] When M 1 When C, R 3 Selected from H, halogen, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl and C 1-6 Haloalkoxy;
[0016] R 4 Selected from hydrogen, C 1-6 Alkyl, C 1-6 Alkoxy and C 3-6 Cycloalkyl, wherein the C 1-6 Alkyl, C 1-6 Alkoxy and C 3-6 The cycloalkyl group is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 groups independently selected from halogen, cyano, nitro, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , hydroxyl, R 4a AND-OR 4a wherein R 4a Selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, -N,N-di-C 1-6 Alkylamino, -N-mono-C 1-6 Alkylamino, C 6-10 Aryl and C 5-10 Heteroaryl, the C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, -N,N-di-C 1-6 Alkylamino, -N-mono-C 1-6 Alkylamino, C 6-10 Aryl and C 5-10The heteroaryl group is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 groups independently selected from halogen, cyano, nitro, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 and substituted with a hydroxy substituent;
[0017] In some embodiments, R 4 Selected from C 1-6 Alkyl and C 1-6 Alkoxy, the C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 groups independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy and C 1-6 The substituents of the haloalkoxy group are substituted; in some embodiments, R 4 Selected from C 1-3 Alkoxy, C 1-3 Alkylene-OC 1-3 Alkyl, C 1-3 Alkylene-OC 1-3 haloalkyl; in some embodiments, R 4 -C(CH 3 )-O-CH 3 or -C(CH 3 )-O-CHF 2 ; R 5 is hydrogen or C 1-6 Alkyl; or
[0018] R 4 and R 5 The atoms connected together form a five-membered or six-membered heterocyclic ring, or a 7-12-membered spirocyclic ring, wherein the five-membered or six-membered heterocyclic ring or the 7-12-membered spirocyclic ring is optionally substituted by 0-3 independently selected from halogen, cyano, amino, hydroxyl, -C(=O)OC 1-6 Alkyl, -C 1-6 Alkylene -OH, -C 1-6 Alkylene-OC 1-6 Alkyl, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, -N,N-di-C 1-6Alkylamino, -N-mono-C 1-6 Alkylamino, -C(=O)NH-alkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl and -OC 3-6 In some embodiments, the five-membered or six-membered heterocyclic ring or the 7-12-membered spirocyclic ring is optionally substituted by 0, 1, 2, or 3 independently selected from halogen, hydroxyl, -C(=O)OC 1-6 Alkyl, -C 1-6 Alkylene -OH, -C 1-6 Alkylene-OC 1-6 Alkyl, C 1-6 Alkyl and C 1-6 In some embodiments, the five-membered or six-membered heterocyclic ring or the 7-12-membered spirocyclic ring is a heterocyclic ring or spirocyclic ring containing one N and is optionally substituted by 0, 1 or 2 independently selected from F, Cl, Br, I, hydroxyl, -C(=O)OC 1-3 Alkyl, -C 1-3 Alkylene-OH, C 1-3 Alkyl, -C 1-3 Alkylene-OC 1-3 Alkyl, C 1-3 Alkoxy and C 1-3 Substitution of haloalkyl groups;
[0019] Ring A is selected from the group consisting of the structural formulae (II), (III), (IV), (V), (VI), (VII) and (VIII):
[0020]
[0021] R 6a and R 6b , or R 8a and R 8b , or R 8a and R 8c , or R 9a and R 9b , or R 10a and R 10b , or R 11a and R 11b The atoms connected together form a four-membered, five-membered, six-membered or seven-membered saturated or unsaturated carbocyclic ring or a heterocyclic ring containing 1, 2 or 3 N atoms, wherein the carbocyclic ring or the N-containing heterocyclic ring is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 independently selected from halogen, oxo, NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , hydroxyl, cyano, amino, carboxyl, haloalkyl, alkoxy, -C1-6 Alkylene carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 、-OC 1-6 Alkyl, C 1-6 Alkyl, C 3-6 Cycloalkyl and -C 1-6 In some embodiments, the carbocyclic ring or N-containing heterocyclic ring is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 independently selected from halogen, oxo, haloalkyl, C 1-6 Alkyl, C 3-6 Cycloalkyl and -C 1-6 substituted by a substituent of alkylene-OH; or
[0022] R 6b Selected from hydrogen, halogen, hydroxyl, cyano, nitro, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, alkoxy, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl and C 1-6 Haloalkyl; wherein the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl and C 1-6 The haloalkyl group is optionally substituted with 0, 1, 2, 3, 4, 5 or 6 groups independently selected from halogen, hydroxy, cyano, amino, carboxyl, haloalkyl, alkoxy, -COOC 1-6 Alkyl, -C 1-6Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 In some embodiments, the R 6b Selected from hydrogen, halogen, hydroxyl, C 3-6 Cycloalkyl, C 1-6 Alkyl, and C 1-6 Haloalkyl;
[0023] R 6a Selected from -OC 1-6 Alkyl, C 3-10 Cycloalkyl, C 3-10 Heterocyclic group, Said-OC 1-6 Alkyl, C 3-10 Cycloalkyl, C 3-10 The heterocyclic group is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 groups independently selected from halogen, hydroxy, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, halogenated alkyl, alkoxy, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , C 1-6 Alkyl and -C 1-6 In some embodiments, the C 3-10 The heterocyclyl group contains 1, 2, 3 or 4 heteroatoms independently selected from O, N, P and S;
[0024] R 7 Selected from hydrogen, halogen, hydroxyl, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, halogenated alkyl, alkoxy, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , C 1-6 Alkyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC2-6 Alkynyl, -OC 3-6 Cycloalkyl, Wherein C 1-6 Alkyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 The cycloalkyl group is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 groups independently selected from halogen, hydroxy, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 In some embodiments, R 7 Selected from hydrogen, halogen, hydroxyl, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, C 1-6 Haloalkyl and alkoxy groups;
[0025] When the A ring is a structure of Formula III, R 4 and R 5 The atoms connected together form a five-membered or six-membered heterocyclic ring, or a 7-12-membered spirocyclic ring, wherein the five-membered or six-membered heterocyclic ring or the 7-12-membered spirocyclic ring is optionally substituted by 0, 1, 2, or 3 independently selected from halogen, cyano, amino, hydroxyl, -C(=O)OC 1-6 Alkyl, -C 1-6 Alkylene -OH, -C 1-6 Alkylene-OC 1-6 Alkyl, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, -N,N-di-C 1-6 Alkylamino, -N-mono-C 1-6 Alkylamino, -C(=O)NH-alkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl and -OC 3-6In some embodiments, the five-membered or six-membered heterocyclic ring or the 7-12-membered spirocyclic ring is optionally substituted by 0, 1, 2, or 3 independently selected from halogen, hydroxyl, -C(=O)OC 1-6 Alkyl, -C 1-6 Alkylene -OH, -C 1-6 Alkylene-OC 1-6 Alkyl, C 1-6 Alkyl and C 1-6 In some embodiments, the five-membered or six-membered heterocyclic ring or the 7-12-membered spirocyclic ring is a heterocyclic ring or spirocyclic ring containing one N and is optionally substituted by 0, 1 or 2 independently selected from F, Cl, Br, I, hydroxyl, -C(=O)OC 1-3 Alkyl, -C 1-3 Alkylene-OH, C 1-3 Alkyl, -C 1-3 Alkylene-OC 1-3 Alkyl, C 1-3 Alkoxy and C 1-3 Substitution of the haloalkyl substituent; and
[0026] When the A ring is a structure of formula III, R 4 and R 5 When the atoms connected to them form a five-membered heterocyclic ring, the five-membered heterocyclic ring is not simultaneously substituted by methyl and -CF 3 replace;
[0027] R 8a Selected from
[0028] R 8b , R 8c , R 8d are independently selected from hydrogen, halogen, hydroxyl, cyano, nitro, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 ,-COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , carboxyl, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl and -C1-3 Haloalkyl;
[0029] When R 8a yes or R 8a and R 8b , or R 8a and R 8c When R and the atoms connected to it form a four-membered, five-membered, six-membered or seven-membered saturated or unsaturated carbon ring or a nitrogen-containing heterocyclic ring, 4 It is not isopropyl;
[0030] When R 4 and R 5 The atoms connected to it form a five-membered heterocycloalkyl group, which is simultaneously substituted by methyl and -CF 3 When replaced, R 8a Not -S(O)-CH 3 and -O-CH 3 ;
[0031] R 9a , R 9b are independently selected from hydrogen, halogen, hydroxyl, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 ,-COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , carboxyl, C 1-6 Alkyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, Wherein C 1-6 Alkyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl is optionally substituted by 0-6 independently selected from halogen, hydroxy, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 ,-COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , substituted by a substituent of the carboxyl group;
[0032] R 10a , R 10b are independently selected from hydrogen, halogen, hydroxyl, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 ,-COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkylCONH 2 , carboxyl, C 1-6 Alkyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, Wherein C 1-6 Alkyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 The cycloalkyl group is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 groups independently selected from halogen, hydroxy, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , substituted by a substituent of the carboxyl group;
[0033] R 11a , R 11b are independently selected from hydrogen, halogen, hydroxyl, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene-NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , carboxyl, C 1-6 Alkyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, Wherein C 1-6 Alkyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 The cycloalkyl group is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 groups independently selected from halogen, hydroxy, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 ,-COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , substituted by a substituent of the carboxyl group;
[0034] In some embodiments, R 11b Selected from hydrogen, halogen, hydroxyl, C 1-6 Alkyl and C 3-6 Cycloalkyl; R 11a Selected from hydrogen, halogen, hydroxyl, C 1-6 Alkyl, C 3-6 Cycloalkyl and The C 1-6 Alkyl and C 3-6 Cycloalkyl is optionally substituted with 0, 1, 2, 3, 4, 5 or 6 substituents independently selected from halogen, hydroxy, cyano, amino, carboxyl, ester;
[0035] Y 1 , Y 2 , Y 3 , Y 4 are independently selected from C, N and S; in some embodiments, Y 2 and Y 4 C, and / or Y 1 and Y 3 are independently selected from C, N and S;
[0036] R 12 Selected from hydrogen, halogen, hydroxyl, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 ,-COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , carboxyl, C 1-6 Haloalkyl, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 5-10 Heteroaryl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, Wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 5-10 Heteroaryl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 The cycloalkyl group is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 groups independently selected from halogen, hydroxy, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 ,-COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , substituted by a substituent of the carboxyl group;
[0037] The condition is that when Y 1 It's S, Y 3 When N is 12 Yes - CF 3 When R 4 no
[0038] The condition is that when Y 1 It's S, Y 4 When N is 12 Yes - CF 3 or -CH 3 When R 4 no
[0039] The condition is that when Y 3 Is S or N, Y 4 When N is 12 Not-CF 3 , -CHF 2 ;
[0040] In some embodiments, Y 1 YesS,Y 2 YesC,Y 3 YesN,Y 4 It is C;
[0041] In some embodiments, R 12 Selected from hydrogen, halogen, hydroxyl, cyano, amino, C 1-6 Haloalkyl, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 3-6 Cycloalkyl,
[0042] n6, n7, n8, n9, n10, n11, n12 are independently selected from 1, 2, 3 and 4;
[0043] R 6c1 , R 6c2 , R 7c1 , R 7c2 , R 8d1 , R 8d2 , R 9c1 , R 9c2 , R 10c1 , R 10c2 , R 11c1 , R 11c2 , R 12c1 , R 12c2 are independently selected from hydrogen, hydroxyl, C 1-6 Alkyl, C 1-6 Alkyleneamino, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Heterocycloalkyl, pyrazolyl, phenoxy, cyano, C 1-6 Alkoxy, C2-6 Alkenyloxy, C 2-6 Alkynyloxy, -OC 3-6 Cycloalkyl, C 6-10 Aryl and C 5-10 Heteroaryl, wherein the C 1-6 Alkyl, C 1-6 Alkylamino, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, pyrazolyl, phenoxy, cyano, C 1-6 Alkoxy, C 2-6 Alkenyloxy, C 2-6 Alkynyloxy, -OC 3-6 Cycloalkyl, C 6-10 Aryl and C 5-10 Heteroaryl is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 groups independently selected from halogen, oxo, nitro, hydroxy, cyano, furan, C 3-6 Cycloalkyl, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 1-6 Haloalkyl, -OC 3-6 Cycloalkyl, -alkoxy-3-6 membered heterocyclic ring, C 3-8 Cycloalkenyloxy, C 6-10 The aryl group and the C group containing 1 to 4 heteroatoms independently selected from N, O, P and S 5-10 is substituted by a substituent of a heteroaryl group; or
[0044] R 6c1 and R 6c2 , R 7c1 and R 7c2 , R 8d1 and R 8d2 , R 9c1 and R 9c2 , R 10c1 and R 10c2 , R 11c1 and R 11c2 , R 12c1 and R12c2 The N atoms to which they are connected independently form a 3-6 membered heterocyclic ring, wherein the heterocyclic ring is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 independently selected from halogen, oxo, hydroxyl, nitro, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkyl NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkyl-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkylCONH 2 、-C(O)-NH-C 1-6 Alkoxy, C 1-6 Alkyl, -C 1-6 Alkylene-hydroxyl, C 1-6 Alkoxy, C 2-6 Alkenyloxy, C 2-6 Alkynyloxy, C 3-6 Cycloalkoxy, 3-6 membered heterocycloalkoxy, C 3-8 Cycloalkenyloxy, C 6-10 Aryl and C 5-10 wherein the -C(O)-NH-C 1-6 Alkoxy, C 1-6 Alkyl, C 1-6 Alkoxy, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, -alkoxy-3-6 membered heterocyclic group, C 3-8 Cycloalkenyloxy, C 6-10 Aryl and C 5-10 The heteroaryl group is optionally substituted with 0, 1, 2, 3, 4, 5 or 6 substituents independently selected from halogen, hydroxy, oxo, nitro and cyano; in some embodiments, the heterocycle is optionally substituted with 0, 1, 2, 3, 4, 5 or 6 substituents independently selected from halogen, oxo, hydroxy, nitro, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkyl NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkyl-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkylCONH 2 、--C(O)-NH-C 1-6 Alkoxy, C 1-6 Alkyl, C 1-6 Alkoxy, C2-6 Alkenyloxy, C 2-6 Alkynyloxy, C 3-6 Cycloalkoxy, 3-6 membered heterocycloalkoxy, C 3-8 Cycloalkenyloxy, C 6-10 Aryl and C 5-10 wherein the -C(O)-NH-C 1-6 Alkoxy, C 1-6 Alkyl, C 1-6 Alkoxy, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, -alkoxy-3-6 membered heterocyclic group, C 3-8 Cycloalkenyloxy, C 6-10 Aryl and C 5-10 Heteroaryl is optionally substituted with 0, 1, 2, 3, 4, 5 or 6 substituents independently selected from halogen, hydroxy, oxo, nitro and cyano; in some embodiments, R 6c1 and R 6c2 , R 7c1 and R 7c2 , R 8d1 and R 8d2 , R 9c1 and R 9c2 , R 10c1 and R 10c2 , R 11c1 and R 11c2 , R 12c1 and R 12c2 The N atoms to which they are connected independently form a 4-5 membered heterocyclic ring, wherein the 4-5 membered heterocyclic ring is optionally substituted by 0, 1, or 2 independently selected from halogen, hydroxyl, C 1-3 Alkyl, C 1-3 Alkylene-hydroxyl, C(O)-NH-C 1-6 substituted by an alkoxy substituent;
[0045] R 6d , R 7d , R 8e , R 9d , R 10d , R 11d , R 12d are independently selected from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl and C 3-6 Cycloalkyl, wherein the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl and C 3-6Cycloalkyl is optionally substituted by 0-6 independently selected from halogen, hydroxy, oxo, nitro, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyloxy, C 2-6 Alkynyloxy, C 3-6 Cycloalkoxy, 3-6 membered heterocycloalkoxy, C 3-8 Cycloalkenyloxy, C 6-10 Aryl and C 5-10 In some embodiments, R 6d , R 7d , R 8e , R 9d , R 10d , R 11d , R 12d are independently selected from hydrogen, C 1-3 alkyl; in some embodiments, R 6d , R 7d , R 8e , R 9d , R 10d , R 11d , R 12d Each independently selected from methyl and ethyl;
[0046] Y 5 , Y 6 , Y 7 , Y 8 are independently selected from C and N; in some embodiments, Y 6 Yes N, Y 5 , Y 7 , Y 8 Different from all N;
[0047] R 6e , R 6f , R 6g , R 7e , R 7f , R 7g , R 8f , R 8g , R 8h , R 9e , R 9f , R9g , R 10e , R 10f , R 10g , R 11e , R 11f , R 11g , R 12e , R 12f , R 12g are independently absent or selected from hydrogen, halogen, hydroxyl, cyano, nitro, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, carboxyl, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -C 2-6 Alkynyl-NH 2 、-OC 3-6 Cycloalkyl, -C(O)NH-OC 1-6 Alkyl, -C(=O)NH-OC 2-6 Alkenyl, -C(=O)NH-OC 2-6 Alkynyl, -C(=O)NH-OC 3-6 Cycloalkyl, -NH-C(=O)-C 2-6 Alkynyl, -NH-C(=O)-C 1-6 Alkyl, -NH-C(=O)-C 3-6 Cycloalkyl, -NH-C(=O)-C 3-6 Heterocycloalkyl, the C 3-6 The heterocycloalkyl group contains 1, 2, 3 or 4 heteroatoms independently selected from N, O, P and S, -NH-C(=S)-C 3-6 Heterocycloalkyl, the C 3-6 The heterocycloalkyl group contains 1, 2, 3 or 4 heteroatoms independently selected from N, O, P and S, -NH-C(=O)-C 1-6 Alkylene-OC 1-6 Alkyl, -NH-C(=O)-C 1-6 Alkylene-OC(=O)-C 1-6 Alkyl, -NH-C(=O)-C 1-6 Alkylene-SC 1-6Alkyl, -NH-C(=O)-C 2-6 Alkenyl, -NH-C(=O)-C 2-6 Alkynyl, -C(=O)NH-C 1-6 Alkyl, -NH-C(=O)-N-(C 1-6 alkyl) 2 、-C(=O)NH-C 2-6 Alkenyl, -C(=O)NH-C 2-6 Alkynyl, -C(=O)NH-C 3-6 Cycloalkyl, -NH-C 1-6 Alkyl, -NH-C(=O)-NH-C 1-6 Alkyl, -NH-C(=O)-C 5-10 Heteroaryl, the C 5-10 The membered heteroaryl group contains 1, 2, 3 or 4 heteroatoms independently selected from N, O, P and S, -NH-C(=O)-C 6-10 Aryl, C 6-10 The aryl group and the C group containing 1 to 4 heteroatoms independently selected from N, O, P and S 5-10 Heteroaryl, wherein the -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, carboxyl, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, -C(O)NH-OC 1-6 Alkyl, -C(=O)NH-OC 2-6 Alkenyl, -C(=O)NH-OC 2-6 Alkynyl, -C(=O)NH-OC 3-6 Cycloalkyl, -NH-C(=O)-C 1-6 Alkyl, -NH-C(=O)-C 1-6 Alkynyl, -NH-C(=O)-C 3-6 Cycloalkyl, -NH-C(=O)-C 3-6 Heterocycloalkyl, -NH-C(=S)-C 3-6 Heterocycloalkyl, -NH-C(=O)-C 1-6 Alkylene-OC1-6 Alkyl, -NH-C(=O)-C 1-6 Alkylene-OC(=O)-C 1-6 Alkyl, -NH-C(=O)-C 1-6 Alkylene-SC 1-6 Alkyl, -NH-C(=O)-C 2-6 Alkenyl, -NH-C(=O)-C 2-6 Alkynyl, -C(=O)NH-C 1-6 Alkyl, NH-C(=O)-N-(C 1-6 alkyl) 2 、-C(=O)NH-C 2-6 Alkenyl, -C(=O)NH-C 2-6 Alkynyl, -C(=O)NH-C 3-6 Cycloalkyl, -NH-C 1-6 Alkyl, -NH-C(=O)-NH-C 1-6 Alkyl, -NH-C(=O)-C 5-10 Heteroaryl, -NH-C(=O)-C 6-10 Aryl, C 6-10 Aryl and C containing 1, 2, 3, 4 heteroatoms independently selected from N, O, P and S 5-10 Heteroaryl, optionally substituted by 0, 1, 2, 3, 4, 5 or 6 groups independently selected from halogen, hydroxy, nitro, cyano, amino, -N(CH 3 ) 2 , C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and C 3-6 In some embodiments, when Y 6 and Y 7 N, Y 8 C or N, Y 9 When C, R 6e , R 6f , R 6g , R 7e , R 7f , R 7g , R 8f , R 8g , R 8h , R 9e , R 9f , R 9g , R 10e , R 10f , R 10g , R 11e , R 11f, R 11g , R 12e , R 12f , R 12g are independently absent or selected from hydrogen, halogen, -NHC 1-6 Alkyl, -COOC 1-6 Alkyl, C 2-6 Alkynyl, -C(O)NH-OC 1-6 Alkyl, -NH-C(=O)-N-(C 1-6 alkyl) 2 、-C(=O)NH-OC 2-6 Alkenyl, -C(=O)NH-OC 2-6 Alkynyl, -C(=O)NH-OC 3-6 Cycloalkyl, -NH-C(=O)-C 1-6 Alkynyl, -NH-C(=O)-C 1-6 Alkyl, -NH-C(=O)-C 3-6 Cycloalkyl, -NH-C(=O)-C 3-6 Heterocycloalkyl, the C 3-6 The heterocycloalkyl group contains 1, 2, 3 or 4 heteroatoms independently selected from N, O, P and S, -NH-C(=S)-C 3-6 Heterocycloalkyl, the C 3-6 The heterocycloalkyl group contains 1, 2, 3 or 4 heteroatoms independently selected from N, O, P and S, -NH-C(=O)-C 1-6 Alkylene-OC 1-6 Alkyl, -NH-C(=O)-C 1-6 Alkylene-OC(=O)-C 1-6 Alkyl, -NH-C(=O)-C 1-6 Alkylene-SC 1-6 Alkyl, -NH-C(=O)-C 2-6 Alkenyl, -NH-C(=O)-C 2-6 Alkynyl, -C(=O)NH-C 1-6 Alkyl, -NH-C(=O)-N-(C 1-6 alkyl) 2 、-C(=O)NH-C 2-6 Alkenyl, -C(=O)NH-C 2-6 Alkynyl, -C(=O)NH-C 3-6 Cycloalkyl, -NH-C 1-6 Alkyl, -NH-C(=O)-NH-C 1-6 Alkyl, -NH-C(=O)-C 5-10 Heteroaryl, the C 5-10The membered heteroaryl group contains 1, 2, 3 or 4 heteroatoms independently selected from N, O, P and S, -NH-C(=O)-C 6-10 Aryl, C 6-10 The aryl group and the C group containing 1, 2, 3 or 4 heteroatoms independently selected from N, O, P and S are 5-10 Heteroaryl, wherein the -NHC 1-6 Alkyl, -COOC 1-6 Alkyl, C 2-6 Alkynyl, -C(O)NH-OC 1-6 Alkyl, -C(=O)NH-OC 2-6 Alkenyl, -C(=O)NH-OC 2-6 Alkynyl, -C(=O)NH-OC 3-6 Cycloalkyl, -NH-C(=O)-C 1-6 Alkynyl, -NH-C(=O)-C 1-6 Alkyl, -NH-C(=O)-C 3-6 Cycloalkyl, -NH-C(=O)-C 3-6 Heterocycloalkyl, the C 3-6 The heterocycloalkyl group contains 1, 2, 3 or 4 heteroatoms independently selected from N, O, P and S, -NH-C(=S)-C 3-6 Heterocycloalkyl, the C 3-6 The heterocycloalkyl group contains 1, 2, 3 or 4 heteroatoms independently selected from N, O, P and S, -NH-C(=O)-C 1-6 Alkylene-OC 1-6 Alkyl, -NH-C(=O)-C 1-6 Alkylene-OC(=O)-C 1-6 Alkyl, -NH-C(=O)-C 1-6 Alkylene-SC 1-6 Alkyl, -NH-C(=O)-C 2-6 Alkenyl, -NH-C(=O)-C 2-6 Alkynyl, -C(=O)NH-C 1-6 Alkyl, -C(=O)NH-C 2-6 Alkenyl, -C(=O)NH-C 2-6 Alkynyl, -C(=O)NH-C 3-6 Cycloalkyl, -NH-C 1-6 Alkyl, -NH-C(=O)-NH-C 1-6 Alkyl, -NH-C(=O)-C 5-10 Heteroaryl, the C 5-10 The membered heteroaryl group contains 1, 2, 3 or 4 heteroatoms independently selected from N, O, P and S, -NH-C(=O)-C 6-10 Aryl, C 6-10The aryl group and the C group containing 1 to 4 heteroatoms independently selected from N, O, P and S 5-10 Heteroaryl, optionally substituted by 0, 1, 2, 3, 4, 5 or 6 groups independently selected from halogen, hydroxy, nitro, cyano, amino, -N(CH 3 ) 2 , C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and C 3-6 is substituted by a cycloalkyl substituent; and R 6e and R 6f , or R 7e and R 7f , or R 8f and R 8g , or R 9e and R 9f , or R 10e and R 10f , or R 11e and R 11f , or R 12e and R 12f Not H at the same time or not present;
[0048] R 6h , R 7h , R 8i , R 9h , R 10h , R 11h , R 12h are independently selected from hydrogen, halogen, hydroxyl, cyano, amino, carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, -C(=O)N-(R 6h2 )R 6h3 and C 6-10 Aryl, wherein the -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, -C(=O)N-(R6h2 )R 6h3 and C 6-10 Aryl is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 groups independently selected from halogen, hydroxy, oxo, nitro, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, C 3-6 Cycloalkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , C 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, -OC 3-6 Heterocyclic group, C 3-8 cycloalkenyloxy, 6-10 membered aryl and 6-10 membered heteroaryl substituents; wherein R 6h2 , R 6h3 are independently selected from hydrogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and C 3-6 Cycloalkyl; or
[0049] R 6h2 and R 6h3 The N atom to which they are commonly connected forms a 3-8 membered heterocyclic ring, wherein the 3-8 membered ring is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 independently selected from halogen, hydroxyl, C 1-6 Alkoxy, -C 1-6 Alkylene - hydroxyl, nitro, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , C 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, -OC 3-6 Heterocycloalkyl, C 3-8Cycloalkenyloxy, C 6-10 Aryl and C 5-10 The substituents of the heteroaryl group are substituted; in some embodiments, R 6h2 and R 6h3 The N atom to which they are commonly connected forms a 4-membered heterocyclic ring, wherein the 4-membered ring is optionally substituted by 0, 1 or 2 independently selected from halogen, hydroxyl, -C 1-6 Substitution of alkylene-hydroxy groups;
[0050] The condition is that when R 6b When selected from Cl, R 6a no
[0051] The condition is that when R 6b is CHF 2 When R 6a no
[0052] The condition is that when R 6a yes When X is S; or when X is O, the compound is selected from
[0053]
[0054] The condition is that Y 5 , Y 6 Both are N, and Y 7 , Y 8 When both are C, R 6e , R 6f , R 6g Not H at the same time or not present;
[0055] The condition is that Y 5 , Y 6 Both are N, and Y 7 , Y 8 Both are C, and R 6e and R 6g When all are H or do not exist, R 6f Not -OH, -C≡N, CH 2 OH, -COO-C 2 H 5 , CH 2 NH 2 ;
[0056] The condition is that when Y 5 , Y 6 Both are N, and R 6f When H, R 6e or R 6g Not -C≡N.
[0057] In some embodiments, X is O or S; in some embodiments, X is O; and / or
[0058] R 1 and R 2 are independently selected from H and halogen; in some embodiments, R 1 Yes H, R 2 is halogen, the halogen is selected from Cl, Br and F; preferably selected from Cl, F; and / or
[0059] M 1 Yes N, R 3 Does not exist; R 4 It is for -C 1-6 Alkyl-C 1-6 Alkoxy or -C 1-6 Alkyl-OC 1-6 haloalkyl; further in some embodiments, R 4 -C(CH 3 )-O-CH 3 or -C(CH 3 )-O-CHF 2 ; and / or
[0060] R 5 is hydrogen or C 1-6 alkyl; in some embodiments, R 5 It is hydrogen;
[0061] or
[0062] R 4 and R 5 The atoms connected together form a five-membered or six-membered heterocyclic ring, or a 7-12-membered spirocyclic ring, wherein the five-membered or six-membered heterocyclic ring or the 7-12-membered spirocyclic ring is optionally substituted by 0, 1, 2 or 3 independently selected from halogen, hydroxyl, -C(=O)OC 1-6 Alkyl, -C 1-6 Alkylene-OH, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 The substituents of haloalkyl are substituted; in some embodiments, R 4 and R 5 The atoms connected together form the following structure: and / or
[0063] In some embodiments, Ring A of the present invention is selected from Formula (II), Formula (III), Formula (IV), Formula (VII) and Formula (VIII);
[0064] R 6a and R 6b , or R 8a and R8b , or R 8a and R 8c , or R 9a and R 9b , or R 10a and R 10b , or R 11a and R 11b The atoms connected to it together form a four-membered, five-membered, six-membered or seven-membered saturated or unsaturated carbocyclic ring or a heterocyclic ring containing 1-3 N atoms, wherein the C atoms or N atoms on the carbocyclic ring or the N-containing heterocyclic ring are optionally substituted by 0-6 independently selected halogen, oxo, haloalkyl, C 1-6 Alkyl, C 3-6 Cycloalkyl and -C 1-6 In some embodiments, the carbon atom or the N atom on the carbocyclic ring or the N-containing heterocyclic ring is optionally substituted by 0-2 independently selected C 1-3 Alkyl, C 1-3 substituted by a substituent of alkylene-OH; or
[0065] R 6b Selected from hydrogen, halogen, hydroxyl, C 3-6 Cycloalkyl and C 1-6 haloalkyl; in some embodiments, said R 6b Selected from chlorine, fluorine, hydroxyl, C 3-6 Cycloalkyl, C 1-3 Alkyl and C 1-3 Haloalkyl;
[0066] R 6a Selected from -OC 1-6 Alkyl, C 3-10 Cycloalkyl, heterocyclic group, The -OC 1-6 Alkyl, C 3-10 The cycloalkyl group is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 groups independently selected from halogen, hydroxy, cyano, amino, carboxyl, ester, C 1-6 Alkyl and -C 1-6 In some embodiments, the -OC 1-6 The alkyl group is -OC 1-3 Alkyl; preferably -O-methyl; and / or
[0067] R 7 Selected from hydrogen, halogen, hydroxyl, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, C 1-6 Haloalkyl and alkoxy; preferably -CF3 ;
[0068] and / or
[0069] R 8a Selected from and / or
[0070] R 8b , R 8c , R 8d are independently selected from hydrogen, halogen, hydroxyl, cyano, nitro, amino, carboxyl, ester, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl and -C 1-3 haloalkyl; in some embodiments, said R 8b , R 8c , R 8d are independently selected from hydrogen, halogen and -OC 1-6 Alkyl; In some embodiments, the R 8b , R 8c , R 8d are independently selected from hydrogen, F, Cl and -OC 1-6 Alkyl; and / or
[0071] Y 5 , Y 6 , Y 7 , Y 8 At least 2 of them are N and the rest are C; and / or R 11b Selected from hydrogen, halogen, hydroxyl, C 1-6 Alkyl and C 3-6 Cycloalkyl; R 11a Selected from hydrogen, halogen, hydroxyl, C 1-6 Alkyl, C 3-6 Cycloalkyl and The C 1-6 Alkyl and C 3-6 Cycloalkyl is optionally substituted by 0-6 substituents independently selected from halogen, hydroxy, cyano, amino, carboxyl, ester; and / or
[0072] Y 2 and Y 4 For C, Y 1 and Y 3 are independently selected from N and S; in some embodiments, Y 1 It's S, Y 3is N; and / or
[0073] R 12 Selected from hydrogen, halogen, hydroxyl, cyano, amino, carboxyl, ester, C 1-6 Haloalkyl, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 5-10 Aryl, C 5-10 Heteroaryl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, Wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 5-10 Aryl, C 5-10 Heteroaryl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl is optionally substituted by 0-6 substituents independently selected from halogen, hydroxy, cyano, amino, carboxyl, ester; and / or
[0074] n6, n8, n11, n12 are independently selected from 1, 2 and 3; and / or
[0075] R 6c1 , R 7c1 , R 8d1 , R 9c1 , R 10c1 , R 11c1 , R 12c1 are independently selected from hydrogen, hydroxyl, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkylene-NC 1-6 Alkyl, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -OC 1-6 Alkylene hydroxyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 1-3 Alkylene-OC 1-3 Alkyl, -OC 1-3 Alkylene-OC 2-6 Alkenyl, -OC 1-3Alkylene-NC 1-6 Alkyl, C 3-6 Cycloalkyl, C substituted by 1-3 halogens 3-6 Cycloalkyl, -OC 3-6 Cycloalkyl, -OC 1-6 Alkylene-C 3-6 Cycloalkyl, -OC 1-6 Alkylene-C 3-6 Heterocycloalkyl, -OC 3-6 Heterocycloalkyl, -O-aryl, -OC 1-3 Alkylene-C 5-7 Heteroaryl, the heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O, S, -C 5-7 Heteroarylene-C 1-6 The heteroarylene group contains 1, 2 or 3 heteroatoms selected from N, O, S and the C 1-6 Alkyl is substituted by 0-3 halogens, -OC 1-3 Alkylene-cyano, -OC 3-6 Cycloalkyl-OC 1-6 Alkyl, R 6c2 , R 7c2 , R 8d2 , R 9c2 , R 10c2 , R 11c2 , R 12c2 is hydrogen or C 1-3 alkyl; in some embodiments, R 6c1 , R 7c1 , R 8d1 , R 9c1 , R 10c1 , R 11c1 , R 12c1 are independently selected from hydroxyl, methyl, ethyl, propyl, R 6c2 , R 7c2 , R 8d2 , R 9c2 , R 10c2 , R 11c2 , R 12c2 is hydrogen or methyl, or
[0076] R 6c1 and R 6c2 , R 7c1 and R 7c2 , R 8d1 and R 8d2 , R 9c1 and R 9c2 , R 10c1 and R 10c2 , R11c1 and R 11c2 , R 12c1 and R 12c2 The N atoms to which they are connected independently form a 3-6 membered heterocyclic ring, wherein the heterocyclic ring is optionally substituted by 1, 2, 3, 4, 5 or 6 groups independently selected from halogen, oxo, hydroxyl, nitro, cyano, amino, -NHC 1-4 Alkyl, -C 1-4 Alkyl NH 2 , carboxyl, -COOC 1-4 Alkyl, -C 1-4 Alkyl-COO-C 1-6 Alkyl, -NHCOC 1-4 Alkyl, -C 1-4 AlkylCONH 2 、-C(O)-NH-C 1-4 Alkoxy, C 1-4 Alkyl, C 1-6 Alkylene-hydroxyl, C 1-4 Alkoxy, C 2-4 Alkenyloxy, C 2-4 Alkynyloxy, C 3-6 Cycloalkoxy, 3-6 membered heterocycloalkoxy, C 3-6 Cycloalkenyloxy, C 6-8 Aryl and C 5-8 wherein the -C(O)-NH-C 1-6 Alkoxy, C 1-6 Alkyl, C 1-6 Alkoxy, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, -alkoxy-3-6 membered heterocyclic group, C 3-8 Cycloalkenyloxy, C 6-10 Aryl and C 5-10 Heteroaryl is optionally substituted with 0, 1, 2 or 3 substituents independently selected from halogen, hydroxy, oxo, nitro and cyano; in some embodiments, R 6c1 and R 6c2 , R 7c1 and R 7c2 , R 8d1 and R 8d2 , R 9c1 and R 9c2 , R 10c1 and R 10c2 , R 11c1 and R 11c2 , R 12c1 and R 12c2The N atoms to which they are connected independently form a 4-5 membered heterocyclic ring, wherein the 4-5 membered heterocyclic ring is optionally substituted by 0-2 independently selected from F, Cl, hydroxyl, C 1-3 Alkyl, C 1-3 The alkylene-hydroxy group is substituted with an alkylene-hydroxy group.
[0077] In some embodiments, Ring A of the present invention is selected from the following structures:
[0078]
[0079]
[0080]
[0081]
[0082]
[0083]
[0084]
[0085] In some embodiments, the compounds of the invention are selected from the following structures:
[0086]
[0087]
[0088]
[0089]
[0090]
[0091]
[0092]
[0093]
[0094] The second aspect of the present invention provides a pharmaceutical composition, which comprises a therapeutically effective dose of the compound described in the first aspect and a pharmaceutically acceptable carrier or excipient.
[0095] The third aspect of the present invention provides a pharmaceutical use, wherein the compound described in the first aspect of the present invention or the pharmaceutical composition described in the second aspect of the present invention is used to prepare a drug for treating MALT1-related diseases, or can be used in combination with a BTK inhibitor to treat diseases related to abnormal expression of MALT1 targets or abnormal expression of NF-kB signaling pathways.
[0096] In some embodiments, the disease associated with abnormal expression of the MALT1 target or abnormal expression of the NF-kB signaling pathway is an autoimmune disease, an inflammatory disease, cancer or a tumor.
[0097] In some embodiments, the autoimmune disease and inflammatory disease are rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus or vasculitis, etc.
[0098] In some embodiments, the compound of the first aspect of the present invention or the pharmaceutical composition of the second aspect of the present invention is used to prevent or inhibit the metastasis of general tumors.
[0099] In some embodiments, the compound described in the first aspect of the present invention or the pharmaceutical composition described in the second aspect of the present invention can be used in combination with a BTK inhibitor to treat diseases related to abnormal expression of the MALT1 target or abnormal expression of the NF-kB signaling pathway, such as autoimmune diseases, inflammatory diseases, tumors, cancer, etc.
[0100] The fourth aspect of the present invention provides a treatment method, which comprises administering to the patient a therapeutically effective amount of the compound of the first aspect of the present invention or the pharmaceutical composition of the second aspect of the present invention; in some embodiments, the MALT1-related disease is an autoimmune disease, an inflammatory disease, cancer or a tumor.
[0101] A fifth aspect of the present invention provides a pharmaceutical composition for treating a MALT1-related disease; in some embodiments, the MALT1-related disease is an autoimmune disease, an inflammatory disease, a cancer or a tumor. DETAILED DESCRIPTION
[0102] The present invention is further described below in conjunction with examples, which are only illustrative and do not limit the scope of the present invention in any way. Various changes made by those skilled in the art based on the teachings of the present invention should be within the scope of protection required by the claims of this application.
[0103] definition:
[0104] Unless otherwise stated, the following terms used in the specification and claims are defined for the purposes of this application and have the following meanings:
[0105] "Halogen" refers to fluorine, chlorine, bromine, and iodine. Preferred halogen groups include F, Cl, Br, and I.
[0106] "Alkyl" refers to a saturated monovalent hydrocarbon radical having a straight or branched portion. For example, the alkyl radical includes methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 3-(2-methyl)butyl, 2-pentyl, 2-methylbutyl, neopentyl, n-hexyl, 2-hexyl and 2-methylpentyl, etc. Similarly, C1-8 alkyl is defined as a group having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms in a straight or branched arrangement. Those skilled in the art will recognize that the term "alkyl" may include an "alkylene" group.
[0107] "Alkenyl" refers to branched and straight chain alkenes having 2 to 12 carbon atoms or alkenes containing aliphatic hydrocarbon groups containing double bonds. 2-6 “Alkenyl” means an alkenyl group having 2, 3, 4, 5 or 6 carbon atoms. Examples of alkenyl groups include, but are not limited to, vinyl, allyl, 1-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methylbut-2-enyl, 3-methylbut-1-enyl, 1-pentenyl, 3-pentenyl and 4-hexenyl.
[0108] "Alkynyl" refers to branched and straight chain alkynyls having 2 to 12 carbon atoms or alkynes containing aliphatic hydrocarbon groups containing triple bonds. Examples include ethynyl, propynyl (e.g., 1-propynyl, 2-propynyl), 3-butynyl, pentynyl, hexynyl, and 1-methylpent-2-ynyl. Alkynyl groups may be substituted or unsubstituted, and substituents may be substituted at any chemically feasible active site.
[0109] "Cycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, the cycloalkyl ring containing 3 to 12 carbon atoms, preferably 3 to 6 carbon atoms. Non-limiting examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, etc.; polycyclic cycloalkyls include cycloalkyls of spirocyclic, fused and bridged rings. Cycloalkyls may be substituted or unsubstituted, and the substituents may be substituted on any chemically realizable active site.
[0110] The substituents of the above "alkyl", "alkenyl", "alkynyl" and "cycloalkyl" are preferably one or more of the following groups, independently selected from halogen, hydroxy, oxo, nitro, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyloxy, C 2-6 Alkynyloxy, C 3-6 Cycloalkoxy, 3- to 6-membered heterocycloalkoxy, C 3-8cycloalkenyloxy, 5 to 6 membered aryl or heteroaryl, the C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Oxygen, C 2-6 Alkynyloxy, C 3-6 Cycloalkoxy, 3 to 6 membered heterocycloalkoxy, C 3-8 The cycloalkenyloxy, 5- to 6-membered aryl or heteroaryl may be optionally substituted by one or more groups selected from halogen, hydroxy, oxo, nitro and cyano.
[0111] "Alkoxy" refers to a -OR group where R is alkyl as defined above, for example methoxy, ethoxy, propoxy or 2-propoxy, n-, iso- or tert-butoxy and the like.
[0112] "Haloalkyl" refers to an alkyl group as defined above substituted with 1 to 5 halogen atoms, such as fluorine or chlorine atoms, including groups substituted with different halogens, such as -CH 2 Cl, -CF 3 , -CHF 2 、-CH 2 CF 3 , -CF 2 CF 3 、-CF(CH3) 2 When an alkyl group is substituted only with fluorine, it may be referred to as a fluoroalkyl group in the present application.
[0113] "Aryl" refers to a 6- to 14-membered all-carbon monocyclic or fused polycyclic group with a conjugated π electron system. The preferred aryl group is a monocyclic or bicyclic 6-10 membered aromatic ring system. Phenyl and naphthyl are the preferred aryl groups. The most preferred aryl group is phenyl.
[0114] "Aralkyl" refers to a -(alkylene)-R radical where R is aryl as defined above, eg, benzyl, phenethyl, and the like.
[0115] "Heteroaryl" refers to a heteroaromatic five-membered or six-membered monocyclic aromatic ring system containing 1 to 4 heteroatoms, 5 to 14 ring atoms, or an unsubstituted or substituted nine-membered or ten-membered benzofused heteroaromatic ring system or a bicyclic heteroaromatic ring system, which consists of carbon atoms and 1-4 heteroatoms selected from N, O or S, wherein the nitrogen or sulfur heteroatom may be optionally oxidized and the nitrogen heteroatom may be optionally quaternized. The heteroaryl group may be attached at any heteroatom or carbon atom that results in a stable structure. Examples of heteroaryl groups include, but are not limited to, thienyl, furanyl, imidazolyl, isoxazolyl, oxazolyl, pyrazolyl, pyrrolyl, thiazolyl, thiadiazolyl, triazolyl, pyridinyl, pyridazinyl, indolyl, azaindolyl, indolyl, benzimidazolyl, benzofuranyl, benzothienyl, benzisoxazolyl, benzoxazolyl, benzopyrazolyl, benzothiazolyl, benzothiadiazolyl, benzotriazolyl, quinolinyl, or isoquinolinyl.
[0116] "Hydroxyalkyl" refers to a linear monovalent hydrocarbon radical having 1 to 6 carbon atoms or a branched monovalent hydrocarbon radical having 3-6 carbon atoms substituted by one or two hydroxyl groups, provided that if two hydroxyl groups are present, they are not simultaneously on the same carbon atom. Representative examples include, but are not limited to, hydroxymethyl, 2-hydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, 1-(hydroxymethyl)-2-methylpropyl, 2-hydroxybutyl, 3-hydroxybutyl, 4-hydroxybutyl, 2,3-dihydroxypropyl, 1-(hydroxymethyl)-2-hydroxyethyl, 2,3-dihydroxybutyl, 3,4-dihydroxybutyl, and 2-(hydroxymethyl)-3-hydroxypropyl.
[0117] "Substituted" refers to a group in which one or more hydrogen atoms are independently replaced by the same or different substituents. Typical substituents include, but are not limited to, halogen (F, Cl, Br or I), C 1-8 Alkyl, C 3-12 Cycloalkyl, -OR 1 , SR 1 , =O, =S, -C(O)R 1 、-C(S)R 1 , =NR 1 、-C(O)OR 1 、-C(S)OR 1 、-NR 1 R 2 、-C(O)NR 1 R 2 , cyano, nitro, -S(O) 2 R 1 、-OS(O 2 )OR 1 、-OS(O) 2 R 1 、-OP(O)(OR 1 )(OR 2 );where R 1 and R 2 In some embodiments, the substituent is selected from -F, -Cl, -Br, -I, -OH, trifluoromethoxy, ethoxy, propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, -SCH 3 , -SC 2 H 5 , formaldehyde, -C(OCH 3 ), cyano, nitro, CF 3 、-OCF 3 , amino, dimethylamino, methylthio, sulfonyl and acetyl.
[0118] "Alkenyloxy" refers to an -O-(alkenyl) group wherein alkenyl is as previously described.
[0119] "Alkynyloxy" refers to an -O-(alkynyl) group wherein alkynyl is as previously described.
[0120] "Cycloalkoxy" refers to an -O-(cycloalkyl) group wherein cycloalkyl is as previously described.
[0121] "Hydroxy" refers to an -OH group.
[0122] "Halogen" refers to fluorine, chlorine, bromine or iodine.
[0123] "Cyano" refers to -CN.
[0124] "Nitro" refers to -NO 2 .
[0125] "Oxo" refers to a =0 substituent.
[0126] "Thio" refers to a =S substituent.
[0127] "Pharmaceutically acceptable salt" refers to a salt prepared from a pharmaceutically acceptable non-toxic base or acid. When the compound of the present invention is acidic, its corresponding salt can be conveniently prepared from a pharmaceutically acceptable non-toxic base, including inorganic bases and organic bases. Such inorganic base-derived salts include aluminum, ammonium, calcium, copper (divalent and monovalent), iron, ferrous iron, lithium, magnesium, manganese (divalent 18 and monovalent), potassium, sodium, zinc and the like. Particularly preferred are ammonium salts, calcium salts, magnesium salts, potassium salts and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary and tertiary amines, as well as cyclic amines and substituted amines, such as naturally occurring and synthetic substituted amines. Other pharmaceutically acceptable organic non-toxic bases that can form salts include ion exchange resins, such as arginine, betaine, caffeine, choline, N', N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucosamine, glucosamine, histidine, hydramine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purine, theobromine, triethylamine, trimethylamine tripropylamine, tromethamine, etc. The pharmaceutically acceptable salts of the compounds described in the present disclosure can be selected from inorganic salts or organic salts.
[0128] Any isotope-labeled derivatives of the compounds or pharmaceutically acceptable salts thereof or isomers thereof described in the present disclosure are covered by the present disclosure. Atoms that can be isotopically labeled include, but are not limited to, hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, chlorine, iodine, etc. They can be labeled with isotopes. 2 H(D), 3 H. 11 C. 13 C. 14 C.15 N. 18 F. 31 P. 32 P. 35 S. 36 Cl and 125 I etc. instead.
[0129] The present disclosure also includes various deuterated compounds. Each available hydrogen atom connected to a carbon atom can be independently replaced by a deuterium atom. Those skilled in the art can synthesize deuterated compounds with reference to relevant literature. Commercially available deuterated starting materials can be used when preparing deuterated compounds, or they can be synthesized using deuterated reagents using conventional techniques, and deuterated reagents include but are not limited to deuterated borane, trideuterated borane tetrahydrofuran solution, deuterated lithium aluminum hydride, deuterated ethyl iodide and deuterated methyl iodide, etc.
[0130] The compounds of the present invention may also exist in the form of pharmaceutically acceptable salts. When used medically, the salts of the compounds of the present invention refer to non-toxic "pharmaceutically acceptable salts". Pharmaceutically acceptable salt forms include pharmaceutically acceptable acidic / anionic or alkaline / cationic salts. Pharmaceutically acceptable acidic / anionic salts generally adopt the form of protonation of basic nitrogen with inorganic or organic acids. Representative organic or inorganic acids include hydrochloric acid, hydrobromic acid, hydroiodic acid, perchloric acid, sulfuric acid, nitric acid, phosphoric acid, acetic acid, propionic acid, glycolic acid, lactic acid, succinic acid, maleic acid, fumaric acid, malic acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, isethionic acid, benzenesulfonic acid, oxalic acid, pamoic acid, 2-naphthalenesulfonic acid, p-toluenesulfonic acid, cyclohexanesulfonic acid, salicylic acid, sugar or trifluoroacetic acid. Pharmaceutically acceptable alkaline / cationic salts include, but are not limited to, aluminum, calcium, chloroprocaine, choline, diethanolamine, ethylenediamine, lithium, magnesium, potassium, sodium and zinc.
[0131] When the compound of the present invention is basic, its corresponding salt can be conveniently prepared with pharmaceutically acceptable non-toxic acids, including inorganic acids and organic acids. Such acids include, for example, acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethanesulfonic acid, formic acid, fumaric acid, gluconic acid, glutamic acid, hydrobromic acid, hydrochloric acid, hydroxyethyl, lactic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, mucic acid, nitric acid, palmitic acid, pantothenic acid, phosphoric acid, succinic acid, sulfuric acid, tartaric acid, p-toluenesulfonic acid, etc. Citric acid, hydrobromic acid, formic acid, hydrochloric acid, maleic acid, phosphoric acid, sulfuric acid and tartaric acid are preferred, and formic acid and hydrochloric acid are particularly preferred.
[0132] The compounds of the present disclosure may exist in specific geometric or stereoisomeric forms. The present disclosure contemplates all such compounds, including cis and trans isomers, - and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, and racemic mixtures and other mixtures thereof, such as mixtures enriched in enantiomers or diastereomers, all of which are within the scope of the present disclosure. All of these isomers and their mixtures are included within the scope of the present disclosure. The compounds of the present disclosure containing asymmetric carbon atoms can be isolated in optically pure form or in racemic form. Optically pure forms can be resolved from racemic mixtures or synthesized by using chiral starting materials or chiral reagents.
[0133] Optically active (R)- and (S)-isomers, as well as D and L isomers, can be prepared by chiral synthesis or chiral reagents or other conventional techniques. If one enantiomer of a compound of the present disclosure is desired, it can be prepared by asymmetric synthesis or derivatization with a chiral auxiliary, wherein the resulting diastereomeric mixture is separated and the auxiliary groups are cleaved to provide the pure desired enantiomer. Alternatively, when the molecule contains a basic functional group (such as an amino group) or an acidic functional group (such as a carboxyl group), diastereomeric salts are formed with an appropriate optically active acid or base, followed by diastereomeric resolution by conventional methods known in the art, and then the pure enantiomer is recovered. In addition, separation of enantiomers and diastereomers is typically accomplished by using chromatography, which employs a chiral stationary phase and is optionally combined with chemical derivatization (e.g., carbamate formation from an amine).
[0134] Tautomers are structural isomers of organic compounds that readily interconvert through a chemical reaction known as tautomerization. This reaction often results in the formal migration of hydrogen atoms or protons, accompanied by the conversion of single bonds and adjacent double bonds. Some common tautomers are: keto-enol, lactam-lactim.
[0135] All tautomeric forms are within the scope of the present invention. The naming of compounds does not exclude any tautomers.
[0136] "Pharmaceutically acceptable carrier or excipient" refers to a carrier or excipient that can be used to prepare a pharmaceutical composition, is generally safe, non-toxic and not biologically or otherwise undesirable, and includes carriers or excipients that are acceptable for veterinary use as well as human pharmaceutical use. "Pharmaceutically acceptable carrier / excipient" as used in the specification and claims includes one or more such excipients.
[0137] As used herein, "disease" is intended to be generally synonymous with the terms "disorder," "condition," and "condition" (as in medical condition) and are used interchangeably because they all reflect an abnormal condition of the human or animal body or a part thereof that impairs the normal functioning, usually manifests itself as distinctive signs and symptoms, and results in a shortened life span or reduced quality of life in the human or animal.
[0138] "Patient" is often synonymous with the term "subject" and, as used herein, includes all mammals, including humans. Examples of patients include humans, livestock (e.g., cattle, goats, sheep, pigs, and rabbits), and companion animals (e.g., dogs, cats, rabbits, and horses). In some embodiments, the patient is a human.
[0139] As used herein, "in need of treatment" refers to a judgment made by a physician or other caregiver that a subject requires or will benefit from treatment. This judgment is based on a variety of factors within the physician's or caregiver's expertise.
[0140] The abbreviations of professional terms used in the embodiments and their corresponding full names are as follows:
[0141] ACN: acetonitrile;
[0142] CDI: Carbonyldiimidazole
[0143] DAST: diethylaminosulfur trifluoride;
[0144] DCM: dichloromethane;
[0145] DIEA: N,N-diisopropylethylamine;
[0146] Dioxane: 1,4-dioxane;
[0147] DMAc:N,N-dimethylacetamide
[0148] DMF: N,N-dimethylformamide;
[0149] DMF-DMA: N,N-dimethylformamide dimethyl acetal
[0150] DPPA: diphenylphosphoryl azide;
[0151] EA: ethyl acetate;
[0152] HATU: O-(7-azabenzotriazole)-N,N,N`,N`-tetramethyluronium hexafluorophosphate;
[0153] HCl: hydrochloric acid;
[0154] H 2 O: water;
[0155] H2 SO 4 :sulfuric acid;
[0156] HOAc: acetic acid;
[0157] K 2 CO 3 : Potassium carbonate;
[0158] LCMS: liquid chromatography-mass spectrometry;
[0159] MeOH: methanol;
[0160] NaOH: sodium hydroxide;
[0161] Na 2 CO 3 : sodium carbonate;
[0162] Pd(dppf)Cl 2 :1,1'-bis(diphenylphosphino)ferrocenepalladium dichloride;
[0163] PE: petroleum ether;
[0164] Pd / C: palladium on carbon;
[0165] TEA: triethylamine;
[0166] TFA: trifluoroacetic acid;
[0167] THF:Tetrahydrofuran
[0168] TLC: Preparative Thin Layer Chromatography
[0169] TMSI: trimethylsilyl iodide.
[0170] Embodiment 1:
[0171] Synthesis of common intermediate compound 1d:
[0172]
[0173] Step 1: Synthesis of Compound 1-3
[0174]
[0175] Compound 1-1 (10 g, 96 mmol) was dissolved in tetrahydrofuran (120 mL), N, N'-carbonyldiimidazole (17.12 g, 105.6 mmol) was added dropwise at 0 ° C, and stirred at room temperature for 3 hours. In addition, tert-butyl malonate 1-2 (23.06 g, 144 mmol) was dissolved in tetrahydrofuran (120 mL), nitrogen was replaced, isopropylmagnesium chloride (144 mL, 288 mmol, 2M) was added dropwise at 0 ° C, and stirred at room temperature for 3 hours. This mixture was added dropwise to the above reaction solution and stirred at room temperature for 1 hour. TLC monitored the reaction to be complete. Quenched with 10% citric acid, extracted with ethyl acetate (500 mL*3), the organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 4:1) to obtain compound 1-3 (16.62 g, 85.7%).
[0176] Step 2: Synthesis of Compounds 1-5
[0177]
[0178] Compound 1-3 (12 g, 59.3 mmol) was dissolved in N,N-dimethylformamide dimethyl acetal (7.07 g, 59.3 mmol), and the mixture was reacted in an oil bath at 120°C for 1 hour, cooled to room temperature, 3-chloro-1H-pyrazole-5-amine was dissolved in ethanol (75 mL), and added dropwise to the above reaction solution, and reacted in an oil bath at 85°C for 1 hour. LCMS monitored the reaction to be complete. The crude product was concentrated and purified by column chromatography (petroleum ether: ethyl acetate = 4:1) to obtain compound 1-5 (13.26 g, 71.9%). MS: 312.7 [M+H] + .
[0179] Step 3: Synthesis of compound 1d
[0180]
[0181] Compound 1-5 (13.26 g, 42.6 mmol) was dissolved in dichloromethane (60 mL), trifluoroacetic acid (30 mL) was added thereto, and the mixture was stirred at room temperature overnight. LCMS monitored the reaction to be complete. After concentration, the mixture was slurried with ethyl acetate to obtain compound 4 (10 g, 92.1%) as a white solid. MS: 256.6 [M+H] + . Synthesis of Compound 1, (S)-2-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)thiazole-5-carboxamide:
[0182]
[0183] Step 1: Synthesis of compound 1b
[0184]
[0185] 1a (250 mg, 1.02 mmol) was dissolved in methanol, 0.2 mL of concentrated sulfuric acid was added dropwise, and the reaction solution was heated to 80°C for 16 hours. LCMS monitored the reaction to be complete. The reaction solution was concentrated to obtain a crude compound which was directly used in the next step.
[0186] Step 2: Synthesis of compound 1c
[0187]
[0188] Dissolve 1b (250 mg crude product) in dichloromethane solution, add trifluoroacetic acid, and stir at room temperature for 4 hours. LCMS monitors the reaction to be complete. Concentrate the reaction solution, dissolve it in 20 mL of water, adjust the pH to 7-8 with sodium bicarbonate aqueous solution, extract with ethyl acetate (20 mL*3), combine the organic phases, dry over anhydrous sodium sulfate, and purify the crude product obtained by column separation, ethyl acetate: petroleum ether ~70%, to obtain 118 mg of compound 1c as a yellow solid, MS: 159.1 [M+H] + .
[0189] Step 3: Synthesis of Compound 1f
[0190]
[0191] 1c (100 mg, 0.39 mmol) was dissolved in 1,4-dioxane, triethylamine (118 mg, 1.18 mmol) and DPPA (129 mg, 0.47 mmol) were added, stirred at room temperature for 30 minutes, 1d (74 mg, 0.47 mmol) was added, and the system temperature was raised to 100 °C for 10 minutes. TLC / LCMS monitored the reaction to be complete. The reaction solution was naturally cooled to room temperature, poured into water, extracted with ethyl acetate (30 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated. The crude product was separated and purified by column chromatography, petroleum ether: ethyl acetate ~ 1:2, to obtain 6 mg of compound 1f as a light yellow solid, MS: 411.8 [M+H] + (The dioxane in the figure is 1,4-dioxane)
[0192] Step 4: Synthesis of compound 1g
[0193]
[0194] 1f (100 mg, 0.24 mmol) was dissolved in a mixed solvent of tetrahydrofuran and water (2:1), and lithium hydroxide (12 mg, 0.64 mmol) was added. The reaction was allowed to react at room temperature for 16 hours. LCMS monitored the reaction to be complete. The reaction solution was concentrated to remove tetrahydrofuran, and then diluted to 10 mL with deionized water. The pH was adjusted to 4-5 with 1N dilute hydrochloric acid. A white solid precipitated. The white solid was collected by filtration, and the solid was washed with water 3 times. It was lyophilized to obtain 52 mg of crude product compound 1 g of white solid, which was used directly in the next step. MS: 397.8 [M+H] + .
[0195] Step 5: Synthesis of Compound 1
[0196]
[0197] Dissolve 1g (30mg, 0.075mmol) in a mixed solvent of DMF and THF, add TEA (15mg, 0.15mmol) and HATU (34mg, 0.09mmol) and react for 30 minutes under nitrogen atmosphere, add ammonium chloride (8mg, 0.15mmol), and react for 4 hours. LCMS monitors the reaction to be complete. After the reaction solution is concentrated to remove THF, it is diluted with water and extracted with ethyl acetate (10mL*3). The organic phases are combined and dried over anhydrous sodium sulfate. The crude product obtained by concentration is separated and purified by column chromatography, methanol: water ~1:1, to obtain 12mg of product compound 1 as a white solid, MS: 396.8 [M+H] + . 1 H NMR (600MHz, DMSO-d6): δppm 11.99(s,1H), 8.98(s,1H), 8.85(br,1H), 7.97(s,1H), 7.84(br,1H), 7.31(br,1H), 6.94(s,1H), 5.39-5.42(q,1H), 3.32(s,3H), 1.56(d,3H).
[0198] Embodiment 2:
[0199] (S)-2-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)-N,N-dimethylthiazole-5-carboxamide
[0200]
[0201] Compound 1 (30 mg, 0.075 mmol) was dissolved in a mixed solvent of DMF and THF, TEA (15 mg, 0.15 mmol) and HATU (34 mg, 0.09 mmol) were added and reacted for 30 minutes under nitrogen atmosphere, 2b (12 mg, 0.15 mmol) was added, and the reaction was completed for 4 hours. LCMS monitored the reaction to be complete. After the reaction solution was concentrated to remove THF, it was diluted with water and extracted with ethyl acetate (10 mL*3). The organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentration was separated and purified by column chromatography, methanol: water ~1:1, to obtain 18 mg of product compound 2 as a white solid, MS: 424.8 [M+H] + . 1 H NMR (600MHz, DMSO-d6): δppm11.79(s,1H), 8.95(s,1H), 8.74(s,1H), 7.83(s,1H), 6.95(s,1H), 5.41-5.44(q,1H), 3.31(s,6H), 1.56(d,3H).
[0202] Embodiment 3:
[0203] 1-(2-chloro-7-((S)-1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)-3-(5-(2,2,2-trifluoro-1-hydroxyethyl)thiazol-2-yl)urea
[0204]
[0205] Step 1: Synthesis of compound 3b
[0206]
[0207] 3a was dissolved in tetrahydrofuran solution, DMAP was added under ice-water bath, stirred for 10 minutes, and then Boc 2 O, the reaction solution was heated to 60°C for 2 hours. TLC monitored the reaction to be complete. The reaction solution was cooled to room temperature naturally, then poured into water, extracted with ethyl acetate (50 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and purified and separated by column chromatography, ethyl acetate: petroleum ether ~60%, to obtain 1.28 g of yellow solid compound 3b, MS: 129.1 [M+H] + .
[0208] Step 2: Synthesis of compound 3d
[0209]
[0210] 3b (500 mg, 2.19 mmol) and 3c (467 mg, 3.28 mmol) were dissolved in tetrahydrofuran solution, TBAF (1 M, 0.5 mL) was added at -40 °C, and then stirred at -40 °C for 30 minutes, and then naturally warmed to room temperature for 6 hours. The reaction solution was poured into water and allowed to stand overnight. TLC monitored the reaction to be complete and the product was generated. The system was extracted with ethyl acetate (50 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, and the crude product obtained after concentration was purified by column separation, ethyl acetate: petroleum ether ~40%, to obtain 92 mg of product compound 3d, MS: 299.2 [M+H] + .
[0211] Step 3: Synthesis of compound 3e
[0212]
[0213] 3d (142 mg, 0.47 mmol) was dissolved in dichloromethane solution, trifluoroacetic acid was added, and the mixture was stirred at room temperature for 4 hours. TLC monitored the reaction to be complete. The reaction solution was poured into a sodium bicarbonate aqueous solution and extracted with ethyl acetate (50 mL*3). The organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained after concentration was purified by column separation, ethyl acetate: petroleum ether ~65%, to obtain 80 mg of yellow solid compound 3e, MS: 199.1 [M+H] + .
[0214] Step 3: Synthesis of compound 3
[0215]
[0216] 3e (50 mg, 0.19 mmol) was dissolved in 1,4-dioxane, triethylamine (60 mg, 0.59 mmol) and DPPA (65 mg, 0.23 mmol) were added, stirred at room temperature for 30 minutes, 1d (46 mg, 0.23 mmol) was added, and the system temperature was raised to 100 °C for 10 minutes. TLC / LCMS monitored the reaction to be complete. The reaction solution was naturally cooled to room temperature, poured into water, extracted with ethyl acetate (30 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated. The crude product was separated and purified by column chromatography, petroleum ether: ethyl acetate ~ 1:2, to obtain 6 mg of compound 3 as a white solid, MS: 451.8 [M+H] + . 1H NMR (600MHz, DMSO-d6): δppm11.61(s,1H), 8.94(s,1H), 8.73(s,1H), 7.48(s,1H), 7.1 2-7.14(m,1H), 6.95(s,1H), 5.47(t,1H), 5.40-5.44(q,1H), 3.32(s,3H), 1.54(d,3H).
[0217] Embodiment 4:
[0218] (S)-1-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)-3-(5-(trifluoromethyl)thiazol-2-yl)urea
[0219]
[0220] Step 1: Synthesis of compound 4
[0221]
[0222] 1d (100 mg, 0.39 mmol) was dissolved in 1,4-dioxane, triethylamine (118 mg, 1.17 mmol) and DPPA (129 mg, 0.039 mmol) were added, and the mixture was stirred at room temperature for 30 minutes. 4a (174 mg, 0.39 mmol) was added, and the system temperature was raised to 100°C for 10 minutes. TLC / LCMS monitored the reaction to be complete. The reaction solution was naturally cooled to room temperature, poured into water, and extracted with ethyl acetate (30 mL*3). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated. The crude product was separated and purified by column chromatography, petroleum ether: ethyl acetate ~1:2, to obtain 112 mg of compound 4 as a light yellow solid, MS: 421.8 [M+H] + . 1 H NMR (600MHz, DMSO-d6): δppm 12.13(s,1H), 8.93(s,1H), 8.79(s,1H), 8.04(d,1H), 6.96(s,1H), 5.40-5.44(q,1H), 3.32(s,3H), 1.56(d,3H).
[0223] Embodiment 5:
[0224] (((((S)-3-chloro-5-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)-N-ethoxypicolinamide 5
[0225]
[0226] Step 1: Synthesis of compound 5b
[0227]
[0228] Compound 5a (2.1 g) was dissolved in a mixed solvent of tetrahydrofuran and water, and iron powder (2.7 g) and ammonium chloride (1.04 g) were added at room temperature. After the addition was completed, the temperature was raised to 80°C and the reaction was allowed to proceed for 4 hours. The reaction was monitored by LCMS / TLC to be complete. The reaction solution was naturally cooled to room temperature, poured into 100 mL of water, filtered to remove solid impurities, and the filter cake was washed with ethyl acetate for more than 3 times. The filtrate was extracted (ethyl acetate / water), and the obtained organic phases were combined, dried over anhydrous sodium sulfate, concentrated, separated and purified by column chromatography, petroleum ether: ethyl acetate ~1:1, to obtain yellow solid compound 5b, MS: 187.6 [M+H] + .
[0229] Step 2: Synthesis of compound 5c
[0230]
[0231] 5b (80 mg, 0.31 mmol) was dissolved in 1,4-dioxane, triethylamine (95 mg, 0.94 mmol) and DPPA (103 mg, 0.37 mmol) were added, stirred at room temperature for 30 minutes, 1d (72 mg, 0.37 mmol) was added, and the system temperature was raised to 100 °C for 10 minutes. TLC / LCMS monitored the reaction to be complete. The reaction solution was cooled to room temperature naturally, poured into water, extracted with ethyl acetate (30 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated. The crude product was separated and purified by column chromatography, petroleum ether: ethyl acetate ~ 1:2, to obtain 96 mg of product 5c as a light yellow solid, MS: 440.2 [M+H] + .
[0232] Step 3: Synthesis of compound 5d
[0233]
[0234] 5c (96 mg, 0.21 mmol) was dissolved in a mixed solvent of tetrahydrofuran and water (2:1), and lithium hydroxide (15 mg, 0.64 mmol) was added. The reaction was allowed to react at room temperature for 4 hours. LCMS monitored the reaction to be complete. The reaction solution was concentrated to remove tetrahydrofuran, and then diluted to 10 mL with deionized water. The pH was adjusted to 4-5 with 1N dilute hydrochloric acid. A white solid precipitated. The white solid was collected by filtration, and the solid was washed with water 3 times. It was lyophilized to obtain 83 mg of crude product 5d as a white solid, which was used directly in the next step. MS: 426.2 [M+H] + .
[0235] Step 4: Synthesis of compound 5
[0236]
[0237] 5d (35 mg, 0.08 mmol) was dissolved in a mixed solvent of DMF and THF, DIEA (21 mg, 0.16 mmol) and HATU (37 mg, 0.09 mmol) were added and reacted for 30 minutes under nitrogen atmosphere, and 5e (15.7 mg, 0.16 mmol) was added and reacted for 4 hours. LCMS monitored the reaction to be complete. After the reaction solution was concentrated to remove THF, it was diluted with water and extracted with ethyl acetate (10 mL*3). The organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentration was separated and purified by column chromatography, methanol: water ~1:1, to obtain 17.06 mg of product compound 5 as a white solid, MS: 469.3 [M+H] + . 1 H NMR (600MHz, DMSO-d6): δppm 11.57(s,1H), 10.20(s,1H), 8.94(s,1H), 8.52(d,1H), 8.26(d,1H), 6.94(s,1H), 5 .40-5.44(q,1H), 3.92-3.96(q,2H), 3.33(s,3H), 1.59(d,3H), 1.20-1.22(t,3H).
[0238] Embodiment 6:
[0239] (S)-3-Chloro-5-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)-N-(2-(dimethylamino)ethyl)-N-methylpicolinamide 6
[0240]
[0241] Step 1: Synthesis of compound 6
[0242]
[0243] 5d (20 mg, 0.035 mmol) was dissolved in a mixed solvent of DMF and THF, DIEA (12 mg, 0.09 mmol) and HATU (35 mg, 0.09 mmol) were added and reacted for 30 minutes under nitrogen atmosphere, 6b (9 mg, 0.07 mmol) was added and reacted for 4 hours. LCMS monitored the reaction to be complete. After the reaction solution was concentrated to remove THF, it was diluted with water and extracted with ethyl acetate (10 mL*3). The organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentration was separated and purified by column chromatography, methanol: water ~1:1, to obtain 7 mg of compound 6 as a white solid, MS: 510.3 [M+H] +.
[0244] Embodiment 7:
[0245] 1-(5-chloro-6-(3-hydroxy-3-methylpyrrolidine-1-carbonyl)pyridin-3-yl)-3-(2-chloro-7-((S)-1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)urea 7
[0246]
[0247] Step 1: Synthesis of compound 7
[0248]
[0249] Compound 5d (20 mg, 0.035 mmol) was dissolved in a mixed solvent of DMF and THF, DIEA (12 mg, 0.09 mmol) and HATU (35 mg, 0.09 mmol) were added and reacted for 30 minutes under nitrogen atmosphere, 7b (9 mg, 0.07 mmol) was added and reacted for 4 hours. LCMS monitored the reaction to be complete. After the reaction solution was concentrated to remove THF, it was diluted with water and extracted with ethyl acetate (10 mL*3). The organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentration was separated and purified by column chromatography, methanol: water ~1:1, to obtain 7 mg of compound 7 as a white solid, MS: 509.3 [M+H] + .
[0250] Embodiment 8:
[0251] (S)-3-Chloro-5-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)-n-hydroxypyridineamide 8
[0252]
[0253] Step 1: Synthesis of compound 8c
[0254]
[0255] 5d (35 mg, 0.08 mmol) was dissolved in a mixed solvent of DMF and THF, and DIEA (21 mg, 0.16 mmol) and HATU (37 mg, 0.09 mmol) were added to react for 30 minutes under nitrogen atmosphere, and 8b (15.7 mg, 0.16 mmol) was added to react for 4 hours. The reaction was complete when monitored by LCMS. After the reaction solution was concentrated to remove THF, it was diluted with water and extracted with ethyl acetate (10 mL*3). The organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentration was separated and purified by column chromatography, methanol: water ~1:1, to obtain 30 mg of crude product 8c as a white solid, MS: 525.3 [M+H] + .
[0256] Step 2: Synthesis of compound 8
[0257]
[0258] 8c (30 mg crude product) was dissolved in 6 mL tetrahydrofuran, and 6 M hydrochloric acid was added dropwise under ice-water bath conditions, and the reaction was maintained under ice-water bath conditions for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was concentrated to remove tetrahydrofuran, and then 2 mL acetonitrile was added. Column chromatography was used for separation and purification, MeOH:H2O~1:3, to obtain 5 mg of the final compound 8 as a white solid, MS: 441.2 [M+H] + .
[0259] Embodiment 9:
[0260] (((((S)-3-Chloro-5-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido))-N-(2,2,2-trifluoroethyl)picolinamide 9
[0261]
[0262] Step 1: Synthesis of compound 9
[0263]
[0264] 5d (20 mg, 0.035 mmol) was dissolved in a mixed solvent of DMF and THF, DIEA (12 mg, 0.09 mmol) and HATU (35 mg, 0.09 mmol) were added and reacted for 30 minutes under nitrogen atmosphere, 9b (9 mg, 0.07 mmol) was added and reacted for 4 hours. The reaction was complete after LCMS monitoring. After the reaction solution was concentrated to remove THF, it was diluted with water and extracted with ethyl acetate (10 mL*3). The organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentration was separated and purified by column chromatography, methanol: water = 1:1, to obtain 7 mg of compound 9 as a white solid, MS: 507.2 [M+H]+ .
[0265] Embodiment 10:
[0266] (S)-1-(5-chloro-6-(3-fluoro-3-(hydroxymethyl)azetidine-1-carbonyl)pyridin-3-yl)-3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)urea 10
[0267]
[0268] first step:
[0269]
[0270] 5d (19 mg, 0.045 mmol) was dissolved in a mixed solvent of DMF and THF, DIEA (12 mg, 0.09 mmol) and HATU (34 mg, 0.09 mmol) were added and reacted for 30 minutes under nitrogen atmosphere, 10b (12 mg, 0.09 mmol) was added, and the reaction was completed for 4 hours. LCMS monitored the reaction to be complete. After the reaction solution was concentrated to remove THF, it was diluted with water and extracted with ethyl acetate (10 mL*3). The organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentration was separated and purified by column chromatography, methanol: water ~1:1, to obtain 3.28 mg of compound 10 as a white solid, MS: 513.3 [M+H] + .
[0271] Embodiment 11:
[0272] (S)-3-Chloro-5-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)-N-(2-hydroxyethoxy)picolinamide 11
[0273]
[0274] first step:
[0275]
[0276] 5d (20 mg, 0.035 mmol) was dissolved in a mixed solvent of DMF and THF, DIEA (12 mg, 0.09 mmol) and HATU (35 mg, 0.09 mmol) were added and reacted for 30 minutes under nitrogen atmosphere, 11b (9 mg, 0.07 mmol) was added, and the reaction was completed for 4 hours. LCMS monitored the reaction to be complete. After the reaction solution was concentrated to remove THF, it was diluted with water and extracted with ethyl acetate (10 mL*3). The organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentration was separated and purified by column chromatography, methanol: water ~1:1, to obtain 7 mg of compound 11 as a white solid, MS: 485.2 [M+H] + . 1 H NMR (600MHz, DMSO-d6): δppm 11.70(s,1H), 10.19(s,1H), 8.94(s,1H), 8.54(s,1H), 8.52(d,1H), 8.26(d,1H), 6.95(s, 1H), 5.40-5.44(q,1H), 4.74(s,1H), 3.92(t,1H), 3.62(t,1H), 3.33(s,3H), 1.58(d,3H).
[0277] Embodiment 12:
[0278] 3-Chloro-5-(3-(2-chloro-7-((S)-1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)-N-(2,2-difluorocyclopropyl)picolinamide 12
[0279]
[0280] Step 1: Synthesis of compound 12
[0281]
[0282] 5d (35 mg, 0.08 mmol) was dissolved in a mixed solvent of DMF and THF, DIEA (21 mg, 0.16 mmol) and HATU (37 mg, 0.09 mmol) were added and reacted for 30 minutes under nitrogen atmosphere, 12b (15.7 mg, 0.16 mmol) was added, and the reaction was continued for 4 hours. The reaction was completed by LCMS monitoring. After the reaction solution was concentrated to remove THF, it was diluted with water and extracted with ethyl acetate (10 mL*3). The organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentration was separated and purified by column chromatography, methanol: water ~1:1, to obtain 17.06 mg of compound 12 as a white solid, MS: 501.2 [M+H] + .
[0283] Embodiment 13:
[0284]
[0285] Step 1: Synthesis of compound 13
[0286]
[0287] 5d (35 mg, 0.08 mmol) was dissolved in a mixed solvent of DMF and THF, DIEA (21 mg, 0.16 mmol) and HATU (37 mg, 0.09 mmol) were added and reacted for 30 minutes under nitrogen atmosphere, 13b (15.7 mg, 0.16 mmol) was added, and the reaction was continued for 4 hours. The reaction was completed by LCMS monitoring. After the reaction solution was concentrated to remove THF, it was diluted with water and extracted with ethyl acetate (10 mL*3). The organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentration was separated and purified by column chromatography, methanol: water ~1:1, to obtain 17.06 mg of compound 13 as a white solid, MS: 523.2 [M+H] + .
[0288] Embodiment 14:
[0289] (S)-N-(allyloxy)-3-chloro-5-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)pyridineamide 14
[0290]
[0291] first step:
[0292]
[0293] 5d (35 mg, 0.08 mmol) was dissolved in a mixed solvent of DMF and THF, DIEA (21 mg, 0.16 mmol) and HATU (37 mg, 0.09 mmol) were added and reacted for 30 minutes under nitrogen atmosphere, 14b (15.7 mg, 0.16 mmol) was added, and the reaction was continued for 4 hours. The reaction was completed by LCMS monitoring. After the reaction solution was concentrated to remove THF, it was diluted with water and extracted with ethyl acetate (10 mL*3). The organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentration was separated and purified by column chromatography, methanol: water ~1:1, to obtain 17.06 mg of compound 14 as a white solid, MS: 481.3 [M+H] + . 1H NMR (600MHz, DMSO-d6): δppm 11.51(s,1H), 10.07(s,1H), 8.94(s,1H), 8.51(s,1H), 6.93(s,1H), 5.94-6 .04(m,1H), 5.24-5.45(m,4H), 4.39-4.41(d,2H), 3.32(s,3H), 1.57(d,3H).
[0294] Embodiment 15:
[0295] (S)-3-chloro-5-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)-N-(2-(vinyloxy)ethoxy)picolinamide 15
[0296]
[0297] first step:
[0298]
[0299] 5d (35 mg, 0.08 mmol) was dissolved in a mixed solvent of DMF and THF, DIEA (21 mg, 0.16 mmol) and HATU (37 mg, 0.09 mmol) were added and reacted for 30 minutes under nitrogen atmosphere, 15b (15.7 mg, 0.16 mmol) was added, and the reaction was continued for 4 hours. The reaction was completed by LCMS monitoring. After the reaction solution was concentrated to remove THF, it was diluted with water and extracted with ethyl acetate (10 mL*3). The organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentration was separated and purified by column chromatography, methanol: water ~1:1, to obtain 17.06 mg of compound 15 as a white solid, MS: 511.3 [M+H] + .
[0300] Embodiment 16:
[0301] (((((S)-3-chloro-5-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)-N-(2-(methylamino)ethoxy)picolinamide 16
[0302]
[0303] Step 1: Synthesis of compound 16c
[0304]
[0305] 16a (2.0 g) and SM2 (1.86 g) were dissolved in tetrahydrofuran, placed in an ice-water bath, triphenylphosphine (3.0 g) was added, and then DEAD (2.3 g) was added dropwise. The mixture was reacted at room temperature for 16 hours under a nitrogen atmosphere. The reaction was complete when monitored by LCMS / TLC. The reaction solution was slowly poured into ice water, and ethyl acetate (30 mL*3) was added for extraction. The organic phases were combined, dried over anhydrous sodium sulfate, concentrated, separated and purified by column chromatography, petroleum ether: ethyl acetate ~ 3:1, to obtain solid compound 16c, MS: 321.3 [M+H] + .
[0306] Step 2: Synthesis of compound 16d
[0307]
[0308] Compound 16d (3.2 g) was dissolved in 1,4-dioxane solution, and 1,4-dioxane hydrochloric acid solution (4 M) was added, and the reaction was carried out at room temperature for 12 hours. LCMS / TLC monitored the reaction to be complete. After the reaction was complete, a large amount of white solid was present. The white solid was filtered, and the solid filter cake was washed with 1,4-dioxane solution for 5 consecutive times. The white solid was dried to obtain 2.1 g of white solid compound 16d, MS: 221.2 [M+H] + .
[0309] Step 3: Synthesis of compound 16f
[0310]
[0311] Compound 16d (2.1 g) was dissolved in dichloromethane, and hydrazine hydrate was added dropwise at room temperature. After the addition was complete, the mixture was reacted at room temperature for 18 hours. A white solid was precipitated during the reaction. TLC monitoring showed that SM1 was completely consumed. The reaction solution was filtered, the filter cake was washed with dichloromethane three times, the filtrate was diluted with 0.1 M aqueous sodium hydroxide solution, and then extracted with dichloromethane / water. The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to obtain oily compound 16f.
[0312] Step 4: Synthesis of compound 16
[0313]
[0314] 5d (35 mg, 0.08 mmol) was dissolved in a mixed solvent of DMF and THF, DIEA (21 mg, 0.16 mmol) and HATU (37 mg, 0.09 mmol) were added and reacted for 30 minutes under nitrogen atmosphere, 16f (15.7 mg, 0.16 mmol) was added, and the reaction was continued for 4 hours. The reaction was completed by LCMS monitoring. After the reaction solution was concentrated to remove THF, it was diluted with water and extracted with ethyl acetate (10 mL*3). The organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentration was separated and purified by column chromatography, methanol: water ~1:1, to obtain 17.06 mg of compound 16 as a white solid, MS: 498.3 [M+H] + . 1 H NMR (600MHz, DMSO-d6): δppm 11.69(s,1H), 10.20(s,1H), 8.94(s,1H), 8.56(s,1H), 8.52(d,1H), 8.26(d,1H), 6.95(s,1H ), 5.40-5.44(q,1H), 3.99(s,2H), 3.43-3.46(t,3H), 2.90(d,2H), 1.59(d,3H), 1.40(s,3H).
[0315] Embodiment 17:
[0316] (((((S)-3-chloro-5-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)-n-methoxypicolinamide 17
[0317]
[0318] Step 1: Synthesis of compound 17
[0319]
[0320] Compound 5d (50 mg, 0.12 mmol) was dissolved in tetrahydrofuran (2 ml) and N,N-dimethylformamide (1 ml), and N,N-diisopropylethylamine (31 mg, 0.24 mmol) and O-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (53.2 mg, 0.14 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. O-methylhydroxylamine hydrochloride 17b (14.8 mg, 0.18 mmol) was added to the above reaction system, and then the reaction system was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was separated and purified by C18 reverse phase column chromatography (acetonitrile: water = 40%) to obtain compound 17 (20 mg, purity 98%) as a white solid. MS: 454 [M + H] + .1 H NMR (600MHz, DMSO-d6): δppm 11.69(s,1H), 10.51(s,1H), 8.90(s,2H), 8.54(d,1H), 8.24(d,1H), 7.22(t,1H), 5.36-5.51(q,1H), 3.70(s,3H), 3.33(s,3H), 1.58(d,3H).
[0321] Embodiment 18:
[0322] (S)-3-chloro-5-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)-N-(1-(2-fluoroethyl)-1h-pyrazol-4-yl)pyridineamide 18
[0323]
[0324] Step 1: Synthesis of compound 18c
[0325]
[0326] 18a was dissolved in DMF and K 2 CO 3 , then 1-bromo-2-fluoroethane was added dropwise to the system, and after the addition was complete, the temperature was raised to 60°C for 12 hours. TLC monitored the reaction to be complete. The reaction solution was cooled to room temperature naturally, poured into 200 mL of water, extracted with ethyl acetate (100 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and separated and purified by column chromatography, petroleum ether: ethyl acetate ~3:1, to obtain a yellow solid 18c, MS: 160.1 [M+H] + .
[0327] Step 2: Synthesis of compound 18d
[0328]
[0329] 18c was dissolved in a mixed solvent of tetrahydrofuran and water, iron powder and ammonium chloride were added, the temperature was raised to 80°C, and the reaction was allowed to proceed for 4 hours. TLC and LCMS monitored the reaction to be complete. The reaction solution was naturally cooled to room temperature, poured into 200 mL of water, extracted with ethyl acetate (100 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, separated and purified by column chromatography, petroleum ether: ethyl acetate ~1:1, to obtain black oily compound 18d, MS: 130.1 [M+H] + .
[0330] Step 3: Synthesis of compound 18
[0331]
[0332] 5d (35 mg, 0.08 mmol) was dissolved in a mixed solvent of DMF and THF, DIEA (21 mg, 0.16 mmol) and HATU (37 mg, 0.09 mmol) were added and reacted for 30 minutes under nitrogen atmosphere, 18d (15.7 mg, 0.16 mmol) was added, and the reaction was completed for 4 hours. LCMS monitored the reaction to be complete. After the reaction solution was concentrated to remove THF, it was diluted with water and extracted with ethyl acetate (10 mL*3). The organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentration was separated and purified by column chromatography, methanol: water ~1:1, to obtain 17.06 mg of compound 18 as a white solid, MS: 537.3 [M+H] + .
[0333] Embodiment 19:
[0334] 3-Chloro-5-(3-(2-chloro-7-((S)-1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)-N-(butyl-3-enyl-2-oxy)picolinamide 19
[0335]
[0336] Step 1: Synthesis of compound 19
[0337]
[0338] Compound 1 (50 mg, 0.12 mmol) was dissolved in tetrahydrofuran (2 ml) and N,N-dimethylformamide (1 ml), and N,N-diisopropylethylamine (31 mg, 0.24 mmol) and O-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (53.2 mg, 0.14 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. O-(but-3-ene-2-yl)hydroxylamine hydrochloride (22.3 mg, 0.18 mmol) was added to the above reaction system, and then the reaction system was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was separated and purified by C18 reverse phase column chromatography (acetonitrile: water = 40%) to obtain compound 2 (21 mg, purity 98%) as a white solid. MS: 494.3 [M+H] + . 1H NMR (600MHz, DMSO-d6): δppm 11.45(s,1H), 10.16(s,1H), 8.94(s,1H), 8.54(s,1H), 8.51(d,1H), 8.25(d,1H), 6.94(s,1H), 5.88-5.94(m, 1H), 5.40-5.44(q,1H), 5.30(d,1H), 5.20(d,1H), 4.47-4.52(m,1H), 3.33(s,3H), 1.58(d,3H), 1.30(d,3H).
[0339] Embodiment 20:
[0340] (S)-3-Chloro-5-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)-N-(cyclopropylmethoxy)picolinamide 20
[0341]
[0342] Step 1: Synthesis of compound 20
[0343]
[0344] Compound 5d (150 mg, 0.35 mmol) was dissolved in tetrahydrofuran (6 ml) and N,N-dimethylformamide (3 ml), and N,N-diisopropylethylamine (90.3 mg, 0.7 mmol) and O-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (160 mg, 0.42 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. O-(cyclopropylmethyl)hydroxylamine 20b (61 mg, 0.7 mmol) was added to the above reaction system, and then the reaction system was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was separated and purified by C18 reverse phase column chromatography (acetonitrile: water = 40%) to obtain compound 20 (60 mg, purity 98%) as a white solid. MS: 494.3 [M+H] + . 1 H NMR (600MHz, DMSO-d6): δppm 11.62(s,1H), 10.17(s,1H), 8.54(s,1H), 8.51(d,1H), 8.25(d,1H), 6.95(s,1H), 5.39-5.44(q,1H), 3 .69-3.72(d,2H), 3.32(s,3H), 1.57(d,3H), 1.07-1.14(m,1H), 0.52-0.57(m,2H), 0.27-0.31(m,2H).
[0345] Embodiment 21:
[0346] (S)-3-Chloro-5-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)-N-(alkynylmethoxy)picolinamide 21
[0347]
[0348] Step 1: Synthesis of compound 21
[0349]
[0350] 5d (35 mg, 0.08 mmol) was dissolved in a mixed solvent of DMF and THF, DIEA (21 mg, 0.16 mmol) and HATU (37 mg, 0.09 mmol) were added and reacted for 30 minutes under nitrogen atmosphere, 21b (16.20 mg, 0.16 mmol) was added, and the reaction was continued for 4 hours. The reaction was completed by LCMS monitoring. After the reaction solution was concentrated to remove THF, it was diluted with water and extracted with ethyl acetate (10 mL*3). The organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentration was separated and purified by column chromatography, methanol: water ~1:1, to obtain 17.06 mg of compound 21 as a white solid, MS: 479.2 [M+H] + . 1 H NMR (600MHz, DMSO-d6): δppm 11.84(s,1H), 10.17(s,1H), 8.94(s,1H), 8.54(s,1H), 8.52(d,1H), 8.25(d,1H), 6 .93(s,1H), 5.39-5.44(q,1H), 4.58(d,2H), 3.61(t,1H), 3.33(s,3H), 1.58(d,3H).
[0351] Embodiment 22:
[0352] (S)-3-Chloro-5-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)-N-(furan-3-ylmethoxy)picolinamide 22
[0353]
[0354] Step 1: Synthesis of compound 22c
[0355]
[0356] Compound 22a (1 g, 10.2 mmol) was dissolved in tetrahydrofuran (20 ml), 2-hydroxyisoindoline-1,3-dione 22b (1.7 g, 10.4 mmol) and triphenylphosphine (2.7 g, 10.3 mmol) were added, and the mixture was stirred at room temperature for 10 minutes. Diisopropyl azodicarboxylate (2 g, 9.9 mmol) was dissolved in tetrahydrofuran (15 ml) and added dropwise to the above reaction system, and then the reaction system was stirred at room temperature for 20 hours. LCMS monitored the reaction to be complete. The reaction solution was poured into 200 ml of water, extracted with ethyl acetate (3*50 ml), the organic phases were combined, dried over anhydrous sodium sulfate and concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 3 / 1) to obtain compound 22c (2 g, 80.4%) as a white solid. MS: 244.2 [M+H] + .
[0357] Step 2: Synthesis of compound 22d
[0358]
[0359] Compound 22c (2 g, 8.2 mmol) was dissolved in dichloromethane (2 ml), hydrazine hydrate (500 mg, 9.85 mmol) was added, and the reaction system was stirred at room temperature for 12 hours. LCMS monitored the reaction to be complete. The reaction solution was poured into 200 ml of 0.1 M sodium hydroxide solution, and the separated liquids were extracted with dichloromethane (3*50 ml). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to obtain compound 22d (500 mg, 51.7%) as a white solid. MS: 114 [M+H] + .
[0360] Step 3: Synthesis of compound 22
[0361]
[0362] 3-Chloro-5-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)picolinic acid 5d (40 mg, 0.09 mmol) was dissolved in tetrahydrofuran (1 ml) and N,N-dimethylformamide (0.5 ml), N,N-diisopropylethylamine (23.2 mg, 0.18 mmol) and O-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (41 mg, 0.11 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. Compound 22d (15.3 mg, 0.14 mmol) was added to the above reaction system, and then the reaction system was stirred at room temperature for 2 hours. LCMS monitoring reaction was complete. The reaction solution was separated and purified by C18 reverse phase column chromatography (acetonitrile: water = 40%) to obtain compound 22 (13 mg, purity 98%) as a white solid. MS: 520.3 [M+H] + . 1 H NMR (600MHz, DMSO-d6): δppm 8.93(s,1H), 8.50(s,1H), 8.23(d,1H), 7.76(s,1H), 7.66(s,1H), 7.21(t,1H), 6. 91(s,1H), 6.57(s,1H), 5.38-5.44(q,1H), 4.80(s,2H), 3.33(s,3H), 1.58(d,3H).
[0363] Embodiment 23:
[0364] (S)-3-chloro-5-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)-N-(butyl-2-ynyl-1-methoxy)picolinamide 23
[0365]
[0366] Step 1: Synthesis of compound 23c
[0367]
[0368] N-hydroxyphthalimide (2 g, 12.3 mmol) was dissolved in tetrahydrofuran (40 mL), triphenylphosphine (3.2 g, 12.3 mmol) and compound 23a (861 mg, 12.3 mmol) were added, diisopropyl azodicarboxylate (2.43 g, 12.3 mmol) was dissolved in tetrahydrofuran (20 mL), and the mixture was slowly added dropwise to the above mixed solution, and the mixture was stirred at room temperature for 20 hours. LCMS monitored the reaction to be complete. The reaction solution was cooled naturally to room temperature and poured into 900 mL of H 2O, extracted with ethyl acetate (800 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 3:1) to obtain compound 23c (2.5 g, 95%) as a light yellow solid. MS: 216.2 [M+H] + .
[0369] Step 2: Synthesis of compound 23d
[0370]
[0371] Compound 23c (2.5 g, 11.6 mmol) was dissolved in dichloromethane (30 mL), 80% hydrazine hydrate solution (0.85 mL, 17.4 mmol) was added, and the mixture was stirred at room temperature for 20 hours. The mixture was filtered, the filtrate was diluted with 0.1 M sodium hydroxide solution, extracted with dichloromethane (30 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to obtain compound 23d (0.9 g, 91%) as a white solid.
[0372] Step 3: Synthesis of compound 23
[0373]
[0374] Compound 5d (30 mg, 0.07 mmol) was dissolved in a mixed solution of tetrahydrofuran and N,N-dimethylformamide (1.5 mL: 0.75 mL), and N,N-diisopropylethylamine (18 mg, 0.14 mmol) and HATU (32 mg, 0.084 mmol) were added. The mixture was stirred at room temperature for 1 hour. Compound 23d (9.4 mg, 0.11 mmol) was dissolved in N,N-dimethylformamide (0.5 mL), and added dropwise to the above mixed solution, and reacted at room temperature for 2 hours. The reaction was complete when monitored by LCMS. Pour 50 mL of H 2 O, extracted with ethyl acetate (50 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 23 (24 mg, 70%) as a light yellow solid, MS: 493.3 [M+H] + . 1 HNMR (600MHz, DMSO-d6): δppm 11.80(s,1H), 10.21(s,1H), 8.94(s,1H), 8.55(s,1H), 8.51(d,1H), 8.26(d,1H), 6.94 (s,1H), 5.40-5.44(q,1H), 4.52-4.54(m,2H), 3.33(s,3H), 1.87(s,3H), 1.58(d,3H).
[0375] Embodiment 24:
[0376] (S)-3-Chloro-5-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)-N-phenoxyphosphoramide 24
[0377]
[0378] Step 1: Synthesis of compound 24
[0379]
[0380] Compound 5d (30 mg, 0.071 mmol) was dissolved in ultra-dry tetrahydrofuran (1 mL) and N,N-dimethylformamide (0.5 mL) solution, DIEA (18.4 mg, 0.142 mmol) was added and stirred for 5 minutes, then HATU (32 mg, 0.085 mmol) was added and stirred for 40 minutes. O-phenylhydroxylamine 24b (15.6 mg, 0.107 mmol) and 0.5 mL N,N-dimethylformamide were then added to the above reaction solution and stirred at room temperature for 2 h. LCMS was correct and the reaction was complete. The reaction solution was subjected to column chromatography with reverse phase column to obtain compound 24 (10 mg, 31%). MS: 517.3 [M+H] + . 1 H NMR (600MHz, DMSO-d6): δppm 12.57(s,1H), 10.24(s,1H), 8.95(s,1H), 8.60(d,1H), 8.57(s,1H), 8.33(d,1H), 57.38(t ,2H), 7.12(d,2H), 7.06(t,1H), 6.95(s,1H), 5.41-5.45(q,1H), 3.33(s,3H), 1.60(d,3H).
[0381] Embodiment 25:
[0382] (S)-N-(tert-Butyloxy)-3-chloro-5-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)pyridineamide 25
[0383]
[0384] Step 1: Synthesis of compound 25
[0385]
[0386] Compound 5d (30 mg, 0.071 mmol) was dissolved in ultra-dry tetrahydrofuran (2 mL) and N,N-dimethylformamide (1 ml) solution, DIEA (18 mg, 0.14 mmol) was added and stirred for 5 minutes, then HATU (32 mg, 0.08 mmol) was added and stirred for 40 minutes. O-tert-butylhydroxylamine 25b (13 mg, 0.11 mmol) and 0.5 ml N,N-dimethylformamide were added to the above reaction solution. LCMS was correct and the reaction was complete. The reaction solution was subjected to column chromatography with reverse phase column to obtain compound 25 (15 mg, 38%), MS: 497.3 [M+H] + . 1 H NMR (600MHz, DMSO-d6): δppm 10.98(s,1H), 10.12(s,1H), 8.94(s,1H), 8.51(d,1H), 8.25(d,1H), 6.93(s,1H), 4.39-5.44(q,1H), 3.32(s,3H), 1.58(d,3H), 1.25(s,9H).
[0387] Embodiment 26:
[0388] ((S)-3-chloro-5-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)-N-isopropoxypicolinamide 26
[0389]
[0390] Step 1: Synthesis of compound 26
[0391]
[0392] Compound 5d (30 mg, 0.07 mmol) was dissolved in a mixed solution of tetrahydrofuran and N,N-dimethylformamide (1.5 mL: 0.75 mL), and N,N-diisopropylethylamine (18 mg, 0.14 mmol) and HATU (32 mg, 0.084 mmol) were added. The mixture was stirred at room temperature for 1 hour. Compound 26b (12 mg, 0.11 mmol) was dissolved in N,N-dimethylformamide (0.5 mL), and added dropwise to the above mixed solution, and reacted at room temperature for 2 hours. LCMS monitored the reaction to be complete. Pour 50 mL of H 2 O, extracted with ethyl acetate (50 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 26 (20 mg, 59.4%) as a light yellow solid. MS: 483.3 [M+H] + . 1HNMR (600MHz, DMSO-d6): δppm 11.40(s,1H), 10.14(s,1H), 8.94(s,1H), 8.51(d,2H), 8.25(d,1H), 6.93(s,1H), 5.39 -5.44(q,1H), 4.11-4.17(m,1H), 3.32(s,3H), 1.57(d,3H), 1.22(s,3H), 1.20(s,3H).
[0393] Embodiment 27:
[0394] ((((((((S)-3-chloro-5-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido))-N-(cyanomethoxy)picolinamide 27
[0395]
[0396] Step 1: Synthesis of compound 27c
[0397]
[0398] Compound 27a (1.56 g, 13 mmol) was dissolved in N,N-dimethylformamide (30 ml), 2-hydroxyisoindoline-1,3-dione 27b (2 g, 12 mmol) and 1,8-diazobispiro[5.4.0]undec-7-ene (1.8 g, 12 mmol) were added, and the reaction system was stirred at room temperature for 18 hours. LCMS monitored the reaction to be complete. The reaction solution was poured into 300 ml of 1M dilute hydrochloric acid and filtered to obtain compound 27c (1.89 g, 77.9%) as a white solid. MS: 203.1 [M+H] + .
[0399] Step 2: Synthesis of compound 27d
[0400]
[0401] Compound 2 (1.89 g, 9 mmol) was dissolved in dichloromethane (2 ml), hydrazine hydrate (500 mg, 9.9 mmol) was added, and the reaction system was stirred at room temperature for 12 hours. LCMS monitored the reaction to be complete. The reaction solution was poured into 200 ml of 0.1 M sodium hydroxide solution, and the separated liquids were extracted with dichloromethane (3*50 ml). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to obtain compound 3 (600 mg, 91.3%) as a pink solid. MS: 73 [M+H] + .
[0402] Step 3: Synthesis of compound 27
[0403]
[0404] Compound 5d (50 mg, 0.12 mmol) was dissolved in tetrahydrofuran (1 ml) and N,N-dimethylformamide (0.5 ml), and N,N-diisopropylethylamine (31 mg, 0.24 mmol) and O-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (53.2 mg, 0.14 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. Compound 27d (13 mg, 0.18 mmol) was added to the above reaction system, and then the reaction system was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was separated and purified by C18 reverse phase column chromatography (acetonitrile: water = 40%) to obtain compound 27 (16 mg, purity 98%) as a white solid. MS: 480.2 [M+H] + . 1 H NMR (600MHz, DMSO-d6): δppm 12.31(s,1H), 10.23(s,1H), 8.94(s,1H), 8.57(s,1H), 8.55(d,1H), 8.28(d, 1H), 6.95(s,1H), 5.40-5.44(q,1H), 4.93(s,2H), 3.31(s,3H), 1.58(d,3H).
[0405] Embodiment 28:
[0406] (S)-3-Chloro-5-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)-N-(3-(difluoromethoxy)cyclobutyloxy)picolinamide 28
[0407]
[0408] Step 1: Synthesis of compound 28b
[0409]
[0410] Compound 28a (500 mg, 2.84 mmol) was dissolved in methanol (5 mL), sodium borohydride (161 mg, 4.26 mmol) was added under ice bath conditions, and the mixture was stirred under ice bath conditions for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was cooled to room temperature naturally and poured into 800 mL of H 2O, extracted with ethyl acetate (500 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 4:1) to obtain compound 28b (300 mg, 59%) as a colorless liquid. MS: 179.2 [M+H] + .
[0411] Step 2: Synthesis of compound 28c
[0412]
[0413] Compound 28b (300 mg, 1.68 mmol) was dissolved in dichloromethane and water (2 mL:2 mL, 1:1), potassium acetate (1.01 g, 10.3 mmol) was added, (bromodifluoromethyl)trimethylsilane (1.364 g, 6.72 mmol) was added under ice bath conditions, and the mixture was stirred at room temperature for 20 hours. LCMS monitored the reaction to be complete. Poured into 100 mL H2O, extracted with dichloromethane (100 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to obtain compound 28c (151 mg, 39.4%) as a colorless liquid.
[0414] Step 3: Synthesis of compound 28d
[0415]
[0416] Compound 28c (151 mg, 0.66 mmol) was dissolved in tetrahydrofuran (0.5 mL), palladium carbon (16 mg, 0.15 mmol) was added, and the mixture was stirred at room temperature in a hydrogen atmosphere for 16 hours. The reaction solution was filtered through celite, and the filtrate was concentrated to obtain compound 28d (64 mg, 70%) as a colorless liquid.
[0417] Step 4: Synthesis of compound 28e
[0418]
[0419] 2-Hydroxyisoindoline-1,3-dione 28e (200 mg, 1.23 mmol) and triphenylphosphine (322 mg, 1.23 mmol) were dissolved in tetrahydrofuran (4 mL). Compound 28d (170 mg, 1.23 mmol) and DIAD (249 mg, 1.23 mmol) were dissolved in tetrahydrofuran (2 mL) and added dropwise to the above reaction solution. The mixture was stirred at room temperature overnight. LCMS monitored the reaction to be complete. Pour 100 mL of H 2O, extracted with ethyl acetate (100 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to give compound 28f (250 mg, 71.79%) as a white solid. MS: 284.2 [M+H] + .
[0420] Step 5: Synthesis of compound 28g
[0421]
[0422] Compound 28f (250 mg, 0.88 mmol) was dissolved in dichloromethane (5 mL), and 80% hydrazine hydrate (84 mg, 1.32 mmol) was added. The mixture was stirred at room temperature overnight. The mixed solution was filtered, and the filtrate was extracted with 0.1 M sodium hydroxide (30 mL) and dichloromethane (10 mL*3). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to obtain compound 28g (114 mg, 84.6%) as a colorless liquid.
[0423] Step 6: Synthesis of compound 28
[0424]
[0425] Compound 28g (30 mg, 0.07 mmol) was dissolved in a mixed solution of tetrahydrofuran and N,N-dimethylformamide (1.5 mL: 0.75 mL), and N,N-diisopropylethylamine (18 mg, 0.14 mmol) and HATU (32 mg, 0.084 mmol) were added. The mixture was stirred at room temperature for 1 hour. Compound 5d (28 mg, 0.18 mmol) was dissolved in N,N-dimethylformamide (0.5 mL), and added dropwise to the above mixed solution, and reacted at room temperature for 2 hours. LCMS monitored the reaction to be complete. Pour 50 mL of H 2 O, extracted with ethyl acetate (500 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 28 (29 mg, 74.0%) as a light yellow solid. MS: 561.3 [M+H] + . 1 H NMR (600MHz, DMSO-d6): δppm 11.71(s,1H), 10.29(s,1H), 8.93(s,1H), 8.53(d,1H), 8.27(d,1H), 6.94(s,1H), 6.67(t,1H), 5.4 0-5.44(q,1H), 4.82-4.86(m,2H), 4.63-4.65(m,2H), 3.32(s,3H), 2.30-2.37(m,2H), 1.58(d,3H).
[0426] Embodiment 29:
[0427] (S)-1-(3-chloro-5-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)pyridin-2-yl)-N-methoxy-1h-pyrazole-3-carboxamide 29
[0428]
[0429]
[0430] Step 1: Synthesis of compound 29c
[0431]
[0432] 2,3-Dichloro-5-nitropyridine 29b (2g, 10.4mmol) was dissolved in 20ml DMF, and cesium carbonate (4.89g, 15.6mmol) and compound 29a (1.44g, 11.44mmol) were added in sequence. The mixture was stirred in a 30°C oil bath under nitrogen protection for 3 hours. LCMS was correct and the reaction was complete. The mixture was then poured into 150ml water and extracted with ethyl acetate (100ml*3). The organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 3:1) to obtain compound 29c (2.635g, 87%) MS: 283.6 [M+H] + .
[0433] Step 2: Synthesis of compound 29d
[0434]
[0435] Compound 29c (2.635 g, 9.34 mmol) was dissolved in 10 ml THF, 10 ml H 2 O, 20ml MeOH, then add ammonium chloride (2.02g, 37.36mmol) and iron powder (2.62g, 46.7mmol) in sequence. Heat the oil bath to 65°C under nitrogen protection, and then stir for 1 hour. LCMS is correct, and the reaction is complete. Filter the reaction solution, extract the filtrate with water and ethyl acetate (100ml*3), combine the organic phases, dry over anhydrous sodium sulfate, and concentrate to obtain a crude product. The crude product is purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 29d (1.2g, 51%).
[0436] Step 3:
[0437]
[0438] Compound 1d (400 mg, 1.56 mmol) was added to 2 ml of ultra-dry 1,4-dioxane, then TEA (476 mg, 9.36 mmol) was added and stirred for 10 minutes, DPPA (518 mg, 3.74 mmol) was added dropwise and stirred for 30 minutes, then compound 29d (400 mg, 1.56 mmol) was dissolved in 4 ml of 1,4-dioxane solution and added dropwise to the system, the temperature was raised to 100 ° C and reacted for 1 h, LCMS was correct, and the reaction was complete. The mixture was then extracted with water and ethyl acetate (70 ml * 3), the organic phases were combined, the organic phases were dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 3: 1) to obtain compound 29e (408 mg, 51%). MS: 506.3 [M + H] + .
[0439] Step 4: Synthesis of compound 29f
[0440]
[0441] Compound 29e (400 mg, 0.79 mmol) was added to 4 ml of THF. 2 O 2ml, lithium hydroxide (114mg, 4.76mmol) was added to the mixed solution, and stirred at room temperature overnight under nitrogen protection. The reaction solution was spin-dried and water and hydrochloric acid (2mol / L) were added to adjust the pH to acidic. A white precipitate was generated, and the filter cake 29f (197mg, 50%) was obtained by filtration. MS: 492.2[M+H] + .
[0442] Step 5: Synthesis of compound 29
[0443]
[0444] Compound 29f (50 mg, 0.102 mmol) was dissolved in ultra-dry tetrahydrofuran (1 mL) and N,N-dimethylformamide (0.5 ml) solution, DIEA (26 mg, 0.204 mmol) was added and stirred for 5 minutes, then HATU (47 mg, 0.122 mmol) was added and stirred for 40 minutes. Then methoxyamine hydrochloride (13 mg, 0.153 mmol) and 0.5 ml N,N-dimethylformamide were added to the above reaction solution and stirred at room temperature for 2 h. LCMS was correct and the reaction was complete. The reaction solution was subjected to column chromatography with reverse phase column to obtain compound 29 (H 2 O:CAN=28%) (10 mg, 19%). MS:521.3[M+H] + . 1H NMR (600MHz, DMSO-d6): δppm 11.71(s,1H), 10.39(s,1H), 8.95(s,1H), 8.72(br,1H), 8.53(d,1H), 8.46(s,1H), 8.27(d ,1H), 6.95(s,1H), 6.90(d,1H), 5.40-5.44(q,1H), 3.69(s,3H), 3.32(s,3H), 1.58(d,3H).
[0445] Embodiment 30:
[0446] ((S)-3-chloro-5-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)-N-methoxyazetidine-3-carboxamide 30
[0447]
[0448]
[0449] Step 1: Synthesis of compound 30b
[0450]
[0451] Compound 30a (2 g, 19.8 mmol) was dissolved in methanol (25 ml), thionyl chloride (11.8 g, 99 mmol) was added at 0°C, the mixture was warmed to room temperature and stirred for 10 hours. TLC monitored the reaction to be complete. The reaction solution was spin-dried and washed with dichloromethane three times to obtain compound 30b (2 g, 87%) as a white solid.
[0452] Step 2: Synthesis of compound 30c
[0453]
[0454] Compound 5d (200 mg, 0.47 mmol) was dissolved in tetrahydrofuran (3 ml) and N, N-dimethylformamide (1.5 ml), N, N-diisopropylethylamine (152 mg, 1.18 mmol) and O-(7-azabenzotriazole)-N, N, N', N'-tetramethyluronium hexafluorophosphate (215 mg, 0.57 mmol) were added, and the mixture was stirred at room temperature for 30 minutes. Compound 30b (107 mg, 0.47 mmol) was dissolved in N, N-dimethylformamide (0.5 ml), added to the reaction system, and stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was concentrated and the residue was separated and purified by C18 reverse phase column chromatography (water: acetonitrile = 2: 1) to obtain compound 30c (120 mg, 49%) as a white solid, MS: 523.3 [M + H] + .
[0455] Step 3: Synthesis of compound 30d
[0456]
[0457] Compound 30c (120 mg, 0.23 mmol) was dissolved in tetrahydrofuran (2 ml) and water (1 ml), lithium hydroxide (33.2 mg, 1.38 mmol) was added, and the mixture was stirred at room temperature for 16 hours. The reaction was complete by LCMS monitoring. The pH of the reaction solution was adjusted to 2-3, and the solid was filtered and collected to obtain compound 30d (100 mg, 86%) as a white solid. MS: 508, 509.3 [M+H] + .
[0458] Step 4: Synthesis of compound 30
[0459]
[0460] Compound 30d (50 mg, 0.098 mmol) was dissolved in tetrahydrofuran (2 ml) and N,N-dimethylformamide (1 ml), and N,N-diisopropylethylamine (25.4 mg, 0.197 mmol) and O-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (44.9 mg, 0.12 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. O-methylhydroxylamine hydrochloride (12.3 mg, 0.15 mmol) was added to the above reaction system, and then the reaction system was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was separated and purified by C18 reverse phase column chromatography (acetonitrile: water = 40%) to obtain compound 30 (20 mg, purity 97%) as a white solid. MS: 538.3 [M+H] + .
[0461] Embodiment 31:
[0462] (S)-1-(5-chloro-6-(3-(propynyl-1-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)urea 31
[0463]
[0464] Step 1: Synthesis of compound 31c
[0465]
[0466] Compound 29b (1 g, 5.18 mmol) and 3-iodopyrazole (1.2 mg, 6.22 mmol) were dissolved in NN-dimethylformamide (10 ml), and cesium carbonate (2.53 g, 7.77 mmol) was added. The mixture was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was poured into 100 mL of H 2 O, extracted with ethyl acetate (60 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 3:1) to obtain compound 31c (1.1 g, 60.4%) as a light yellow solid. MS: 351.5 [M+H] + .
[0467] Step 2: Synthesis of compound 31e
[0468]
[0469] Compound 31c (200 mg, 0.57 mmol) was dissolved in 1,4-dioxane (4 ml), and cuprous iodide (32 mg, 0.17 mmol), propyne (1 ml, 1 M tetrahydrofuran solution), triethylamine (0.4 ml) and bistriphenylphosphine palladium dichloride (40 mg, 0.057 mmol) were added, and the mixture was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was poured into 50 mL H 2 O, extracted with ethyl acetate (30 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 2: 1) to obtain compound 3 (140 mg, 93%) as a dark yellow solid. MS: 263.0 [M+H] + .
[0470] Step 3: Synthesis of compound 31f
[0471]
[0472] Compound 31e (140 mg, 0.53 mmol) was dissolved in tetrahydrofuran (1 ml) and added dropwise to a methanol / water mixed solution (2 ml methanol, 1 ml water) of iron powder (150 mg, 2.67 mmol) and ammonium chloride (114 mg, 2.12 mmol). The mixture was stirred at 65 °C for 1 hour. The reaction was complete after LCMS monitoring. The reaction solution was poured into 50 mL H 2 O, extracted with ethyl acetate (30 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated and the residue was purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 31f (100 mg, 80%) as a dark yellow solid. MS: 233.6 [M+H] + .
[0473] Step 4: Synthesis of compound 31
[0474]
[0475] Compound 1d (55 mg, 0.22 mmol) was dissolved in 1,4-dioxane (1 ml), triethylamine (66 mg, 0.65 mmol) and diphenylphosphoryl azide (72 mg, 0.26 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. Compound 31f (50 mg, 0.22 mmol) was added to the above reaction system, and then the reaction system was stirred at 100 ° C for 1 hour. LCMS monitored the reaction to be complete. The reaction solution was separated and purified by C18 reverse phase column chromatography (acetonitrile: water = 40%) to obtain compound 5 (40 mg, purity 93%). After HPLC purification, the product was freeze-dried to obtain white solid compound 31 (25 mg, purity 98%). MS: 486.3 [M + H] + .
[0476] Embodiment 32:
[0477] (S)-1-(5-chloro-6-(3-(hydroxy-3-isobutyl-1-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)urea 32
[0478]
[0479] Step 1: Synthesis of compound 32b
[0480]
[0481] Compound 29b (473 mg, 2.45 mmol) and 3-iodopyrazole 32a (570 mg, 2.94 mmol) were dissolved in NN-dimethylformamide (5 ml), cesium carbonate (1.2 g, 3.675 mmol) was added, and the mixture was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was poured into 50 mL of H 2 O, extracted with ethyl acetate (30 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 3:1) to obtain compound 32b (500 mg, 58.1%) as a light yellow solid. MS: 351.5 [M+H] + .
[0482] Step 2: Synthesis of compound 32d
[0483]
[0484] Compound 32b (200 mg, 0.571 mmol) was dissolved in 1,4-dioxane (4 ml), and cuprous iodide (32.8 mg, 0.171 mmol), 2-methylbut-3-yn-2-ol 32c (72 mg, 0.857 mmol), triethylamine (0.4 ml) and bistriphenylphosphine palladium dichloride (40 mg, 0.057 mmol) were added, and the mixture was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was poured into 50 mL of H 2 O, extracted with ethyl acetate (30 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 2: 1) to obtain compound 32d (165 mg, 94%) as a dark yellow solid. MS: 307.7 [M+H] + .
[0485] Step 3: Synthesis of compound 32e
[0486]
[0487] Compound 32d (165 mg, 0.539 mmol) was dissolved in tetrahydrofuran (1 ml) and added dropwise to a methanol / water mixed solution (2 ml methanol, 1 ml water) of iron powder (151 mg, 2.695 mmol) and ammonium chloride (115.3 mg, 2.156 mmol). The mixture was stirred at 65 °C for 1 hour. The reaction was complete after LCMS monitoring. The reaction solution was poured into 50 mL H 2O, extracted with ethyl acetate (30 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 32e (140 mg, 94%) as a dark yellow solid. MS: 277.7 [M+H] + .
[0488] Step 4: Synthesis of compound 32
[0489]
[0490] Compound 1d (65 mg, 0.256 mmol) was dissolved in 1,4-dioxane (1 ml), triethylamine (77 mg, 0.759 mmol) and diphenylphosphoryl azide (84 mg, 0.304 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. Compound 32f (70 mg, 0.253 mmol) was added to the above reaction system, and then the reaction system was stirred at 100 ° C for 1 hour. LCMS monitored the reaction to be complete. The reaction solution was separated and purified by C18 reverse phase column chromatography (acetonitrile: water = 40%) to obtain compound 32 (52 mg, purity 91%). After HPLC purification, the product was freeze-dried to obtain white solid compound 32 (26 mg, purity 98%). MS: 530.3 [M + H] + . 1 H NMR (600MHz, DMSO-d6): δppm 10.21(s,1H), 8.95(s,1H), 8.57(s,1H), 8.50(d,1H), 8.42(d,1H), 8.22(s,1H), 6.95(s, 1H), 6.65(d,1H), 5.57(s,1H), 5.40-5.44(q,1H), 3.32(s,3H), 1.58(d,3H), 1.48(s,6H).
[0491] Embodiment 33:
[0492] (S)-1-(5-chloro-6-(4-(propynyl-1-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)urea 33
[0493]
[0494]
[0495] Step 1: Synthesis of compound 33c
[0496]
[0497] Compound 29b (2 g, 10.36 mmol) and 4-iodopyrazole 33a (2.4 g, 12.43 mmol) were dissolved in NN-dimethylformamide (20 ml), cesium carbonate (5.1 g, 15.54 mmol) was added, and the mixture was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was poured into 200 mL H 2 O, extracted with ethyl acetate (100 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 3:1) to obtain compound 33c (2.1 g, 57.7%) as a light yellow solid. MS: 350.9 [M+H] + .
[0498] Step 2: Synthesis of compound 33c
[0499]
[0500] Compound 33c (400 mg, 1.14 mmol) was dissolved in 1,4-dioxane (4 ml), and cuprous iodide (64 mg, 0.34 mmol), propyne 33d (2 ml, 1 M tetrahydrofuran solution), triethylamine (0.8 ml) and bistriphenylphosphine palladium dichloride (80 mg, 1.14 mmol) were added, and the mixture was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was poured into 100 mL of H 2 O, extracted with ethyl acetate (30 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 2: 1) to obtain compound 33e (260 mg, 86%) as a dark yellow solid. MS: 263.6 [M+H] + Step 3:
[0501]
[0502] Compound 33e (260 mg, 0.99 mmol) was dissolved in tetrahydrofuran (1 ml) and added dropwise to a methanol / water mixed solution (2 ml methanol, 1 ml water) of iron powder (277 mg, 4.95 mmol) and ammonium chloride (212 mg, 3.96 mmol). The mixture was stirred at 65 °C for 1 hour. The reaction was complete after LCMS monitoring. The reaction solution was poured into 50 mL H 2 O, extracted with ethyl acetate (30 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 33f (83 mg, 36%) as a dark yellow solid. MS: 233.6 [M+H] + .
[0503] Step 4: Synthesis of compound 33
[0504]
[0505] (S)-2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidine-6-carboxylic acid (91 mg, 0.36 mmol) was dissolved in 1,4-dioxane (1 ml), triethylamine (108 mg, 1.08 mmol) and diphenylphosphoryl azide (117.5 mg, 0.43 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. Compound 4 (83 mg, 0.36 mmol) was added to the above reaction system, and then the reaction system was stirred at 100°C for 1 hour. LCMS monitored the reaction to be complete. The reaction solution was separated and purified by C18 reverse phase column chromatography (acetonitrile: water = 40%) to obtain compound 33 as a white solid (22 mg, purity 98%). MS: 486.3 [M+H] + .
[0506] Embodiment 34:
[0507] (S)-1-(5-chloro-6-(4-(oxazol-2-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)urea 34
[0508]
[0509] Step 1: Synthesis of compound 34c
[0510]
[0511] Compound 34a (170 mg, 0.872 mmol) was dissolved in a mixed solvent of 1,4-dioxane and water (7.5 mL: 0.75 mL, 10: 1), and 2-iodooxazole 34b (370 mg, 1.744 mmol), dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium (64 mg, 0.0872 mmol), and cesium carbonate (853 g, 2.62 mmol) were added thereto in sequence. Nitrogen was replaced, and the mixture was refluxed in an oil bath at 100°C for 4 hours. LCMS monitored the reaction to be complete. The reaction mixture was poured into water, extracted with ethyl acetate (200 mL*3), and the organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 1: 1) to obtain compound 34c (150 mg, 73.2%). MS: 236.2 [M+H] + .
[0512] Step 2: Synthesis of compound 34d
[0513]
[0514] Compound 34c (150 mg, 0.638 mmol) was dissolved in dichloromethane (3 mL), trifluoroacetic acid (1 mL) was added thereto, and the mixture was stirred at room temperature for 3 hours. LCMS monitored the reaction to be complete. The reaction mixture was poured into water, extracted with ethyl acetate (100 mL*3), the organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 34d (80 mg, 92.8%) as a white solid. MS: 136 [M+H] + .
[0515] Step 3: Synthesis of compound 34e
[0516]
[0517] Compound 34d (80 mg, 0.593 mmol) was dissolved in N,N-dimethylformamide (5 mL), 2,3-dichloro-5-nitropyridine 29b (104 mg, 0.539 mmol) and cesium carbonate (264 mg, 0.81 mmol) were added, and the mixture was stirred at room temperature for 2 hours in a magnetic stirrer. The reaction was complete when monitored by LCMS. The reaction solution was poured into 100 mL of H 2 O, extracted with ethyl acetate (80 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 4:1) to obtain compound 34e (140 mg, 89.3%) as a white solid. MS: 292 [M+H] + .
[0518] Step 4: Synthesis of compound 34f
[0519]
[0520] Compound 34e (140 mg, 0.481 mmol) was dissolved in a mixed solution of tetrahydrofuran, water and methanol (3 mL: 3 mL: 6 mL, 1: 1: 2), iron powder (135 mg, 2.405 mmol) and ammonium chloride (103 mg, 1.924 mmol) were added, and the mixture was refluxed in an oil bath at 65°C for 2 h. LCMS monitored the reaction to be complete. Filtered with diatomaceous earth, water was added to the filtrate, extracted with ethyl acetate (80 mL*3), the organic layers were combined, dried over anhydrous sodium sulfate and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 3: 1) to obtain compound 34f (80 mg, 63.7%). MS: 262 [M+H] + .
[0521] Step 5: Synthesis of compound 34
[0522]
[0523] Compound 1d (39 mg, 0.153 mmol) was dissolved in ultra-dry 1,4-dioxane (2 mL), triethylamine (46 mg, 0.459 mmol) was added to the mixture, and stirred at room temperature for ten minutes, then DPPA (51 mg, 0.184 mmol) was added, and stirred at room temperature for thirty minutes, and then a mixed solution of compound 34f (40 mg, 0.153 mmol) and 1,4-dioxane (1 mL) was dripped into the above mixture, and the temperature was raised to 100°C for reaction for 2 hours. LCMS monitored the reaction to be complete. The reaction mixture was poured into water, extracted with ethyl acetate (80 mL*3), the organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 34 (20 mg, 25.5%) as a light yellow solid. MS: 514 [M+H] + .
[0524] Embodiment 35:
[0525] (S)-1-(5-chloro-6-(4-(pyridin-2-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)urea 35
[0526]
[0527] Step 1: Synthesis of compound 35b
[0528]
[0529] Compound 29b (500 mg, 2.59 mmol) was dissolved in 5 ml DMF, and cesium carbonate (1.3 g, 3.89 mmol) and 2-(1H-pyrazol-3-yl)pyridine 35a (415 mg, 2.85 mmol) were added. The mixture was stirred in a 90°C oil bath for 3 h under the protection of nitrogen. LCMS was correct and the reaction was complete under LCMS monitoring. The reaction solution was naturally cooled to room temperature, poured into 70 ml water, extracted with ethyl acetate (70 ml*3), the organic phases were combined, dried over anhydrous sodium sulfate and concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 3:1) to obtain compound 35b (111 mg, 14%). MS: 302.6 [M+H] + .
[0530] Step 2: Synthesis of compound 35c
[0531]
[0532] Dissolve ammonium chloride (79 mg, 1.48 mmol) in 1.5 ml water, add iron powder (104 mg, 1.85 mmol), dissolve compound 35b (111 mg, 0.37 mmol) in 1.5 ml THF, add 3 ml methanol mixture to the above mixture. Stir in a 65 ° C oil bath under nitrogen for 1 h. LCMS is correct, and the reaction is complete under LCMS monitoring. Filter while hot, pour the filtrate into 50 ml water, extract with ethyl acetate (50 ml*3), dry with anhydrous sodium sulfate, concentrate and separate and purify the residue using column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 35c (30 mg, 30%). MS: 271.3 [M+H] + .
[0533] Step 3: Synthesis of compound 35
[0534]
[0535] Compound 1d (30 mg, 0.11 mmol) was dissolved in 1 ml of 1,4-dioxane, TEA (34 mg, 0.33 mmol) was added, and the mixture was stirred at room temperature for 10 minutes. DPPA (37 mg, 1.32 mmol) was then added to the mixture and the stirring was continued for 30 minutes. A mixture of 35c (34 mg, 0.11 mmol) and 1 ml of 1,4-dioxane was then added dropwise to the mixture, the room temperature was raised to 100°C and stirred for 2 hours. The reaction was complete when monitored by LCMS. After the mixture was cooled to room temperature, it was poured into 30 ml of water and extracted with ethyl acetate (30 ml*3). The organic phases were combined and concentrated, dried over anhydrous sodium sulfate, and then concentrated in vacuo. The residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 35 (10 mg, yield: 18%). MS: 525.3 [M+H] + . 1 HNMR (600MHz, DMSO-d6): δppm 10.92(s,1H), 9.33(s,1H), 8.89(d,1H), 8.64(dt,1H), 8.57(d,1H), 8.46(d,1H), 8.29(d,1H), 8.01-8.03(dt, 1H), 7.88(dt,1H), 7.37-7.39(m,1H), 7.08(d,1H), 6.95(s,1H), 5.37-5.40(q,1H), 3.30(s,3H), 1.58(d,3H).
[0536] Embodiment 36:
[0537] (S)-1-(3-chloro-5-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)pyridin-2-yl)-N-methoxy-1h-pyrazole-4-carboxamide 36
[0538]
[0539]
[0540] Step 1: Synthesis of compound 36c
[0541]
[0542] 2,3-Dichloro-5-nitropyridine 29b (2 g, 10.4 mmol) was dissolved in 20 ml DMF, and cesium carbonate (4.89 g, 15.6 mmol) and compound 36a (1.44 g, 11.44 mmol) were added in sequence. The mixture was stirred in a 30 ° C oil bath under nitrogen protection for 3 hours. LCMS was correct and the reaction was complete. The mixture was then poured into 150 ml of water and extracted with ethyl acetate (100 ml * 3). The organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 3: 1) to obtain compound 36c (2.635 g, 87%) MS: 283.6 [M + H] + .
[0543] Step 2: Synthesis of compound 36d
[0544]
[0545] Compound 36c (2.635 g, 9.34 mmol) was dissolved in 10 ml THF, 10 ml H 2 O, 20ml MeOH, then add ammonium chloride (2.02g, 37.36mmol) and iron powder (2.62g, 46.7mmol) in sequence. Heat the oil bath to 65°C under nitrogen protection, and then stir for 1 hour. LCMS is correct, and the reaction is complete. Filter the reaction solution, extract the filtrate with water and ethyl acetate (100ml*3), combine the organic layers, dry over anhydrous sodium sulfate, and concentrate to obtain a crude product. The crude product is purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 36d (1.2g, 51%), MS: 253.0 [M+H] + .
[0546] Step 3: Synthesis of compound 36e
[0547]
[0548] Compound 1d (400 mg, 1.56 mmol) was added to 2 ml of ultra-dry 1,4-dioxane and TEA (476 mg, 9.36 mmol) and stirred for 10 minutes. DPPA (518 mg, 3.74 mmol) was added dropwise and stirred for 30 minutes. Then 4 ml of 1,4-dioxane solution of compound 36d (400 mg, 1.56 mmol) was added and the temperature was raised to 100 ° C for 1 hour. The reaction was complete after LCMS monitoring. The mixture was then extracted with water and ethyl acetate (70 ml * 3), the organic phases were combined, the organic phases were dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 3: 1) to obtain compound 36e (408 mg, 51%). MS: 504 [M + H] + .
[0549] Step 4: Synthesis of compound 36f
[0550]
[0551] Compound 36e (400 mg, 0.79 mmol) was added to 4 ml of THF and H 2 O 2ml, add lithium hydroxide (114mg, 4.76mmol), under nitrogen protection, stir at room temperature overnight. The reaction solution was concentrated to remove tetrahydrofuran, and water and hydrochloric acid (2mol / L) were added to adjust the pH to acidic. A white precipitate was produced, and the filter cake (197mg, 50%) was obtained by filtration. MS: 492.2[M+H] + .
[0552] Step 5: Synthesis of compound 36
[0553]
[0554] Compound 36f (50 mg, 0.102 mmol) was dissolved in ultra-dry tetrahydrofuran (1 mL) and N,N-dimethylformamide (0.5 ml) solution, DIEA (26 mg, 0.204 mmol) was added and stirred for 5 minutes, then HATU (47 mg, 0.122 mmol) was added and stirred for 40 minutes. Then methoxyamine hydrochloride (13 mg, 0.153 mmol) was dissolved in 0.5 ml N,N-dimethylformamide and added to the above reaction solution, and stirred at room temperature for 2 h. LCMS was correct and the reaction was complete. The reaction solution was subjected to column chromatography with reverse phase column to obtain compound 36 (10 mg, 19%). MS: 521.3 [M+H] + .
[0555] Embodiment 37:
[0556] (S)-1-(5-chloro-6-(3-(hydroxy-3-propynyl-1-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)urea 37
[0557]
[0558] Step 1: Synthesis of compound 37b
[0559]
[0560] Compound 29b (2 g, 10.3 mmol) and 3-iodopyrazole 37a (2.14 g, 11.33 mmol) were dissolved in NN-dimethylformamide (20 ml), and cesium carbonate (4.89 g, 15.45 mmol) was added. The mixture was stirred in an oil bath at 90 °C for 3 hours under nitrogen protection. LCMS was correct and the reaction was complete under LCMS monitoring. The reaction solution was cooled to room temperature naturally and poured into 50 mL of H 2 O, extracted with ethyl acetate (50 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 3:1) to obtain compound 37b (1.293 g, 36%) as a light yellow solid. MS: 351.5 [M+H] + .
[0561] Step 2: Synthesis of compound 37d
[0562]
[0563] Compound 37b (1.293 g, 3.69 mmol) was dissolved in ultra-dry 1,4-dioxane (15 ml), and tert-butyldimethyl(2-propynyloxy)silane 37c (944 mg, 5.54 mmol), triethylamine (3 ml), copper iodide (212 mg, 1.107 mmol), and triphenylphosphine palladium dichloride (260 mg, 0.369 mmol) were added in sequence. The mixture was stirred at room temperature for 2 hours under nitrogen protection. LCMS was correct and the reaction was complete under LCMS monitoring. After the reaction solution was cooled to room temperature, 70 ml of water was poured into it and extracted with ethyl acetate (70 ml*3). The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product. The crude product was separated and purified by column chromatography (petroleum ether: ethyl acetate = 3:1) to obtain compound 37d (963 mg, 67%). MS: 393.9 [M+H] + .
[0564] Step 3: Synthesis of compound 37f
[0565]
[0566] Compound 37d (963 mg, 2.66 mmol) was dissolved in a solution of ultra-dry tetrahydrofuran (10 mL), water (10 ml), and methanol (20 ml), and iron powder (1.23 g, 13.3 mmol) and ammonium chloride (502 mg, 10.64 mmol) were added thereto. The mixture was heated to 65 ° C under nitrogen protection and stirred for 1 hour. LCMS was correct, and the reaction was complete after LCMS monitoring. The reaction solution was filtered, the filtrate was poured into 50 ml of water, extracted with ethyl acetate (50*3), dried with anhydrous sodium sulfate, and concentrated. The crude product was purified by column chromatography to separate the residue (petroleum ether: ethyl acetate = 1:1) to obtain compound 37f (812 mg, yield: 84%). MS: 363.9 [M+H] + .
[0567] Step 4: Synthesis of compound 37g
[0568]
[0569] Compound 37f (200 mg, 0.552 mmol) was dissolved in ultra-dry 1,4-dioxane (2 ml), triethylamine (167 mg, 1.657 mmol) was added to the mixture, stirred at room temperature for 10 minutes, then DPPA (182 mg, 0.662 mmol) was added, stirred at room temperature for 30 minutes, then a mixture of compound 1d (167 mg, 0.552 mmol) and 1,4-dioxane (1 ml) was added dropwise to the above mixture, and then the temperature was raised to 100 ° C for 3 hours. LCMS monitored the reaction to be complete. After the reaction solution was cooled to room temperature, 50 ml of water was added to the mixture, extracted with ethyl acetate (50 ml * 3), dried with anhydrous sodium sulfate and concentrated to obtain a crude product. The crude product was separated and purified by column chromatography (petroleum ether: ethyl acetate = 1: 1) to obtain compound 37g (100 mg, yield 30%). MS: 616.5 [M + H] + .
[0570] Step 5: Synthesis of compound 37
[0571]
[0572] Compound 37f (100 mg, 0.163 mmol) was dissolved in ultra-dry tetrahydrofuran (1 ml) solution, TBAF (1 mol / L, 2 ml) was added, and stirred at room temperature for 12 h. LCMS was correct and the reaction was complete under LCMS monitoring. 30 ml of brine was added to the mixture, extracted with ethyl acetate (30 ml*3), dried with anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography to obtain 30 mg of compound 37 (HPLC purity 91%) (petroleum ether: ethyl acetate = 1:1), and compound 37 (purity 97%) was obtained after preparative purification. MS: 502.3 [M+H] + . 1 H NMR (600MHz, DMSO-d6): δppm 10.21(s,1H), 8.95(s,1H), 8.56(s,1H), 8.50(d,1H), 8.42(d,1H), 8.24(d,1H), 6.95(s, 1H), 6.69(d,1H), 5.40-5.44(m,2H), 4.32(d,2H), 3.32(s,3H), 3.18(d,1H), 1.58(d,3H).
[0573] Embodiment 38:
[0574] (S)-1-(3-chloro-5-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)pyridin-2-yl)-N-methoxy-1h-1,2,3-triazole-4-carboxamide 38
[0575]
[0576] Step 1: Synthesis of compound 38c
[0577]
[0578] Compound 38a (2 g, 10.36 mmol) was dissolved in N, N-dimethylformamide (32 ml), cesium carbonate (5.068 g, 15.55 mmol) and 1H-1,2,3-triazole-4-carboxylic acid methyl ester (1.58 g, 12.44 mmol) were added, and the mixture was stirred at 30 ° C overnight. LCMS monitored the reaction to be complete. The reaction solution was poured into 100 mL of water, extracted with ethyl acetate (35 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 3:1) to obtain compound 38c (0.556 g, 1.189 g). MS: 284.6 [M+H] +
[0579] Step 2: Synthesis of compound 38d
[0580]
[0581] Compound 38c (1.189 g, 4.201 mmol) was dissolved in tetrahydrofuran (4 ml), and added dropwise to a methanol / water mixed solution of iron powder (1.176 g, 21.007 mmol) and ammonium chloride (450 mg, 8.403 mmol) (methanol 8 ml, water 4 ml), and the mixture was stirred at 65 ° C for 1 hour. LCMS monitored the reaction to be complete. The reaction solution was poured into 200 mL of water, extracted with ethyl acetate (30 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (dichloromethane: methanol = 10: 1) to obtain compound 38d (610 mg, 57.2%) as a dark yellow solid. MS: 254.6 [M+H] + .
[0582] Step 3: Synthesis of compound 38e
[0583]
[0584] Compound 1d (257 mg, 1.00 mmol) was dissolved in 1,4-dioxane (6 ml), triethylamine (303 mg, 3.00 mmol) and diphenylphosphoryl azide (330.24 mg, 1.2 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. Compound 3 (253 mg, 1.00 mmol) was added to the above reaction system, and then the reaction system was stirred at 100 ° C for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was poured into 80 mL of water, extracted with ethyl acetate (30 mL * 3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (dichloromethane: methanol = 10: 1) to obtain compound 4 (408 mg, 81%) as a light yellow solid. MS: 507.3 [M + H] + .
[0585] Step 4: Synthesis of compound 38f
[0586]
[0587] Compound 38e (408 mg, 0.808 mmol) was dissolved in tetrahydrofuran (3 ml) and water (1.5 ml), lithium hydroxide (111.49 mg, 4.848 mmol) was added, and the mixture was stirred at room temperature for 16 hours. The reaction was complete by LCMS monitoring. The pH of the reaction solution was adjusted to 7 and purified by HPLC to obtain compound 38f (175 mg, 43.8%) as a pink solid. MS: 493.2 [M+H] + .
[0588] Step 5: Synthesis of compound 38
[0589]
[0590] Compound 38f (92 mg, 0.187 mmol) was dissolved in tetrahydrofuran (1.4 ml) and N,N-dimethylformamide (0.7 ml), and N,N-diisopropylethylamine (48.35 mg, 0.48 mmol) and O-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (85.44 mg, 0.225 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. O-methylhydroxylamine hydrochloride (23.47 mg, 0.281 mmol) was added to the above reaction system, and then the reaction system was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was separated and purified by C18 reverse phase column chromatography (acetonitrile: water = 47%) to obtain compound 38 (18.85 mg, 19.31%) as a white solid. MS: 521.1 [M+H] + .
[0591] Embodiment 39:
[0592] (S)-N-(allyloxy)-2-chloro-4-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)benzamide 39
[0593]
[0594] Step 1: Synthesis of compound 39b
[0595]
[0596] Compound 39a was dissolved in a mixed solvent of tetrahydrofuran and water, and iron powder and ammonium chloride were added at room temperature. After the addition was completed, the temperature was raised to 80°C and the reaction was allowed to proceed for 4 hours. The reaction was monitored to be complete by LCMS / TLC. The reaction solution was naturally cooled to room temperature, poured into 100 mL of water, filtered to remove solid impurities, and the filter cake was washed with ethyl acetate for more than 3 times. The filtrate was extracted (ethyl acetate / water), and the obtained organic phases were combined, dried over anhydrous sodium sulfate, concentrated, separated and purified by column chromatography, petroleum ether: ethyl acetate ~1:1, to obtain yellow solid compound 39b, MS: 186.6 [M+H] + .
[0597] Step 2: Synthesis of compound 39c
[0598]
[0599] Compound 1d (80 mg, 0.31 mmol) was dissolved in 1,4-dioxane, triethylamine (95 mg, 0.94 mmol) and DPPA (103 mg, 0.37 mmol) were added, stirred at room temperature for 30 minutes, compound 39b (72 mg, 0.37 mmol) was added, and the system temperature was raised to 100 °C for 10 minutes. TLC / LCMS monitored the reaction to be complete. The reaction solution was naturally cooled to room temperature, poured into water, extracted with ethyl acetate (30 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated. The crude product was separated and purified by column chromatography, petroleum ether: ethyl acetate ~ 1:2, to obtain 96 mg of compound 39c as a light yellow solid, MS: 439.2 [M+H] + .
[0600] Step 3: Synthesis of compound 39d
[0601]
[0602] 39c (96 mg, 0.21 mmol) was dissolved in a mixed solvent of tetrahydrofuran and water (2:1), and lithium hydroxide (15 mg, 0.64 mmol) was added. The reaction was allowed to react at room temperature for 4 hours. LCMS monitored the reaction to be complete. The reaction solution was concentrated to remove tetrahydrofuran, and then diluted to 10 mL with deionized water. The pH was adjusted to 4-5 with 1N dilute hydrochloric acid. A white solid precipitated. The white solid was collected by filtration, and the solid was washed with water 3 times. It was lyophilized to obtain 83 mg of crude product compound 39d as a white solid, which was used directly in the next step. MS: 425.2 [M+H] + .
[0603] Step 4: Synthesis of compound 39
[0604]
[0605] Compound 39d (35 mg, 0.08 mmol) was dissolved in a mixed solvent of DMF and THF, DIEA (21 mg, 0.16 mmol) and HATU (37 mg, 0.09 mmol) were added and reacted for 30 minutes under nitrogen atmosphere, and compound 39e (15.7 mg, 0.16 mmol) was added and reacted for 4 hours. LCMS monitored the reaction to be complete. After the reaction solution was concentrated to remove THF, it was diluted with water and extracted with ethyl acetate (10 mL*3). The organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentration was separated and purified by column chromatography, methanol: water ~1:1, to obtain 17.06 mg of compound 39 as a white solid, MS: 480.3 [M+H] + . 1H NMR (600MHz, DMSO-d6): δppm 11.45(s,1H), 9.93(s,1H), 8.94(s,1H), 8.40(d,1H), 7.79(s,1H), 7.37(s,1H), 6.92 (t,2H), 5.96-6.03(m,1H), 5.29-5.44(m,3H), 4.42(d,2H), 3.32(s,3H), 1.58(d,3H).
[0606] Embodiment 40:
[0607] (S)-n-(allyloxy)-4-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)-2-methoxybenzamide 40
[0608]
[0609] Step 1: Synthesis of compound 40b
[0610]
[0611] Compound 40a was dissolved in a mixed solvent of tetrahydrofuran and water, and iron powder and ammonium chloride were added at room temperature. After the addition was completed, the temperature was raised to 80°C and the reaction was allowed to proceed for 4 hours. The reaction was monitored to be complete by LCMS / TLC. The reaction solution was naturally cooled to room temperature, poured into 100 mL of water, filtered to remove solid impurities, and the filter cake was washed with ethyl acetate for more than 3 times. The filtrate was extracted (ethyl acetate / water), and the obtained organic phases were combined, dried over anhydrous sodium sulfate, concentrated, separated and purified by column chromatography, petroleum ether: ethyl acetate ~ 1:1, to obtain yellow solid compound 40b, MS: 182.1 [M+H] + .
[0612] Step 2: Synthesis of compound 40c
[0613]
[0614] Compound 1d (80 mg, 0.31 mmol) was dissolved in 1,4-dioxane, triethylamine (95 mg, 0.94 mmol) and DPPA (103 mg, 0.37 mmol) were added, stirred at room temperature for 30 minutes, compound 40b (72 mg, 0.37 mmol) was added, and the system temperature was raised to 100°C for 10 minutes. TLC / LCMS monitored the reaction to be complete. The reaction solution was naturally cooled to room temperature, poured into water, extracted with ethyl acetate (30 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated. The crude product was separated and purified by column chromatography, petroleum ether: ethyl acetate ~1:2, to obtain 96 mg of compound 40c as a light yellow solid, MS: 434.8 [M+H] + .
[0615] Step 3: Synthesis of compound 40d
[0616]
[0617] 40c (96 mg, 0.21 mmol) was dissolved in a mixed solvent of tetrahydrofuran and water (2:1), and lithium hydroxide (15 mg, 0.64 mmol) was added and reacted at room temperature for 4 hours. LCMS monitored the reaction to be complete. The reaction solution was concentrated to remove tetrahydrofuran, then diluted to 10 mL with deionized water, and the pH was adjusted to 4-5 with 1N dilute hydrochloric acid. A white solid precipitated, which was collected by filtration and washed with water 3 times. It was lyophilized to obtain 83 mg of crude product 40d as a white solid, which was used directly in the next step. MS: 420.8, [M+H] + .
[0618] Step 4: Synthesis of compound 40
[0619]
[0620] 40d (35 mg, 0.08 mmol) was dissolved in a mixed solvent of DMF and THF, DIEA (21 mg, 0.16 mmol) and HATU (37 mg, 0.09 mmol) were added and reacted for 30 minutes under a nitrogen atmosphere, and compound 40e (15.7 mg, 0.16 mmol) was added and reacted for 4 hours. LCMS monitored the reaction to be complete. After the reaction solution was concentrated to remove THF, it was diluted with water and extracted with ethyl acetate (10 mL*3). The organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentration was separated and purified by column chromatography, methanol: water ~1:1, to obtain 17.06 mg of product compound 40 as a white solid, MS: 475.9 [M+H] + . 1H NMR (600MHz, DMSO-d6): δppm10.87(s,1H), 9.89(s,1H), 8.94(s,1H), 8.34(d,1H), 7.64(d,1H), 7.38(d,1H), 7.06-7.09(dd,1H), 6.91( s,1H), 5.94-6.04(m,1H), 5.41-5.46(q,1H), 5.32-5.37(m,1H), 5.24-5.28(d,1H), 4.39(d,2H), 3.84(s,3H), 3.33(s,3H), 1.58(d,3H).
[0621] Embodiment 41:
[0622] (S)-n-(allyloxy)-4-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)-2,5-difluorobenzamide 41
[0623]
[0624]
[0625] Step 1: Synthesis of compound 41b
[0626]
[0627] Compound 41a was dissolved in a mixed solvent of tetrahydrofuran and water, and iron powder and ammonium chloride were added at room temperature. After the addition was completed, the temperature was raised to 80°C and the reaction was allowed to proceed for 4 hours. The reaction was monitored to be complete by LCMS / TLC. The reaction solution was naturally cooled to room temperature, poured into 100 mL of water, filtered to remove solid impurities, and the filter cake was washed with ethyl acetate for more than 3 times. The filtrate was extracted (ethyl acetate / water), and the obtained organic phases were combined, dried over anhydrous sodium sulfate, concentrated, separated and purified by column chromatography, petroleum ether: ethyl acetate ~ 1:1, to obtain yellow solid compound 41b, MS: 188.1 [M+H] + .
[0628] Step 2: Synthesis of compound 41c
[0629]
[0630] 1d (80 mg, 0.31 mmol) was dissolved in 1,4-dioxane, triethylamine (95 mg, 0.94 mmol) and DPPA (103 mg, 0.37 mmol) were added, stirred at room temperature for 30 minutes, compound 41b (72 mg, 0.37 mmol) was added, and the system temperature was raised to 100 °C for 10 minutes. TLC / LCMS monitored the reaction to be complete. The reaction solution was naturally cooled to room temperature, poured into water, extracted with ethyl acetate (30 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated. The crude product was separated and purified by column chromatography, petroleum ether: ethyl acetate ~ 1:2, to obtain 96 mg of compound 41c as a light yellow solid, MS: 440.8 [M+H] + .
[0631] Step 3: Synthesis of compound 41d
[0632]
[0633] Compound 41c (96 mg, 0.21 mmol) was dissolved in a mixed solvent of tetrahydrofuran and water (2:1), and lithium hydroxide (15 mg, 0.64 mmol) was added. The mixture was reacted at room temperature for 4 hours. The reaction was complete after LCMS monitoring. The reaction solution was concentrated to remove tetrahydrofuran, and then diluted to 10 mL with deionized water. The pH was adjusted to 4-5 with 1N dilute hydrochloric acid. A white solid precipitated. The white solid was collected by filtration, and the solid was washed with water 3 times. It was lyophilized to obtain 83 mg of crude product 41d as a white solid, which was used directly in the next step. MS: 426.7, [M+H] + .
[0634] Step 4: Synthesis of compound 41
[0635]
[0636] Compound 41d (35 mg, 0.08 mmol) was dissolved in a mixed solvent of DMF and THF, DIEA (21 mg, 0.16 mmol) and HATU (37 mg, 0.09 mmol) were added and reacted for 30 minutes under a nitrogen atmosphere, and compound 41e (15.7 mg, 0.16 mmol) was added and reacted for 4 hours. The reaction was complete when monitored by LCMS. After the reaction solution was concentrated to remove THF, it was diluted with water and extracted with ethyl acetate (10 mL*3). The organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentration was separated and purified by column chromatography, methanol: water ~1:1, to obtain 17.06 mg of compound 41 as a white solid, MS: 481.8 [M+H] + . 1H NMR (600MHz, DMSO-d6): δppm 11.38(s,1H), 9.83(s,1H), 8.82(s,1H), 8.75(d,1H), 8.06-8.11(dd,1H), 7.47-7.51(dd,1H) ), 6.91(s,1H), 5.92-6.02(m,1H), 5.25-5.43(m,3H), 4.38(d,2H), 3.27(s,3H), 1.54(d,3H).
[0637] Embodiment 42:
[0638] (S)-5-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)-3-cyclopropyl-N-methoxypicolinamide 42
[0639]
[0640] Step 1: Synthesis of compound 42c
[0641]
[0642] Compound 42a (200 mg, 0.925 mmol) and cyclopropylboronic acid (159 mg, 1.85 mmol) were dissolved in 1,4-dioxane and Pd(dppf)Cl was added. 2 (67 mg, 0.09 mmol) and K 2 CO 3 (255 mg, 1.85 mmol), H 2 O, replace nitrogen three times, and react at 100°C for 16 hours under nitrogen atmosphere. TLC and LCMS monitored the reaction to be complete. The reaction solution was cooled to room temperature naturally, poured into water, extracted with ethyl acetate (100 mL*2), the organic phases were combined, dried over anhydrous sodium sulfate and concentrated, and the obtained crude product was separated and purified by column chromatography, petroleum ether: ethyl acetate ~ 4:1, to obtain 320 mg of compound 42c as a yellow solid, MS: 223.2 [M+H] + .
[0643] Step 2: Synthesis of compound 42d
[0644]
[0645] 42c (320 mg, 1.4 mmol) was dissolved in tetrahydrofuran and water (2:1), iron powder (403 mg, 7.2 mmol) and ammonium chloride (155 mg, 2.8 mmol) were added, and the mixture was reacted at 80°C for 4 hours under nitrogen atmosphere. The reaction was complete as monitored by TLC / LCMS. The reaction solution was naturally cooled to room temperature, poured into 100 mL of water, extracted with ethyl acetate (60 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated. The crude product was separated and purified by column chromatography, petroleum ether: ethyl acetate ~ 1:2, to obtain 153 mg of compound 42d as a yellow solid, MS: 193.2 [M+H] + .
[0646] Step 3: Synthesis of compound 42e
[0647]
[0648] 1d (80 mg, 0.31 mmol) was dissolved in 1,4-dioxane, triethylamine (95 mg, 0.94 mmol) and DPPA (103 mg, 0.37 mmol) were added, and the mixture was stirred at room temperature for 30 minutes. Compound 42d (72 mg, 0.37 mmol) was added, and the system temperature was raised to 100°C for 10 minutes. The reaction was complete when monitored by TLC / LCMS. The reaction solution was cooled to room temperature naturally, poured into water, and extracted with ethyl acetate (30 mL*3). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated. The crude product was separated and purified by column chromatography, petroleum ether: ethyl acetate ~1:2, to obtain 96 mg of compound 42e as a light yellow solid, MS: 445.8 [M+H] + .
[0649] Step 4: Synthesis of compound 42f
[0650]
[0651] Compound 42e (96 mg, 0.21 mmol) was dissolved in a mixed solvent of tetrahydrofuran and water (2:1), and lithium hydroxide (15 mg, 0.64 mmol) was added. The mixture was reacted at room temperature for 4 hours. The reaction was complete after LCMS monitoring. The reaction solution was concentrated to remove tetrahydrofuran, and then diluted to 10 mL with deionized water. The pH was adjusted to 4-5 with 1N dilute hydrochloric acid. A white solid precipitated. The white solid was collected by filtration, and the solid was washed with water 3 times. It was lyophilized to obtain 83 mg of crude product 42f as a white solid, which was directly used in the next step. MS: 431.8 [M+H] + .
[0652] Step 5: Synthesis of compound 42
[0653]
[0654] Compound 42f (35 mg, 0.08 mmol) was dissolved in a mixed solvent of DMF and THF, and DIEA (21 mg, 0.16 mmol) and HATU (37 mg, 0.09 mmol) were added to react for 30 minutes under nitrogen atmosphere, and 42g (15.7 mg, 0.16 mmol) was added to react for 4 hours. The reaction was complete when monitored by LCMS. After the reaction solution was concentrated to remove THF, it was diluted with water and extracted with ethyl acetate (10 mL*3). The organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentration was separated and purified by column chromatography, methanol: water ~1:1, to obtain 17.06 mg of compound 42 as a white solid, MS: 474.9 [M+H] + . 1 H NMR (600MHz, DMSO-d6): δppm11.43(s,1H), 9.90(s,1H), 8.95(s,1H), 8.44(d,1H), 8.40(s,1H), 7.49(d,1H), 6.92(s,1H), 5.40-5.4 4(q,1H), 3.90-3.96(q,2H), 3.33(s,3H), 2.62-2.68(m,1H), 1.58(d,3H), 1.19-1.25(t,3H), 0.99-1.05(m,2H), 0.63-0.67(m,2H).
[0655] Embodiment 43:
[0656] (S)-n-(allyloxy)-5-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)-3-cyclopropylpyridineamide 43
[0657]
[0658] first step:
[0659]
[0660] 42f (35 mg, 0.08 mmol) was dissolved in a mixed solvent of DMF and THF, DIEA (21 mg, 0.16 mmol) and HATU (37 mg, 0.09 mmol) were added and reacted for 30 minutes under nitrogen atmosphere, 43a (15.7 mg, 0.16 mmol) was added, and the reaction was continued for 4 hours. The reaction was completed by LCMS monitoring. After the reaction solution was concentrated to remove THF, it was diluted with water and extracted with ethyl acetate (10 mL*3). The organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentration was separated and purified by column chromatography, methanol: water ~1:1, to obtain 17.06 mg of compound 43 as a white solid, MS: 486.9 [M+H] + . 1 H NMR (600MHz, DMSO-d6): δppm 11.49(s,1H), 9.91(s,1H), 8.45(d,1H), 8.42(s,1H), 7.48(d,1H), 6.92(s,1H), 5.95-6.04(m,1H), 5.24-5.44 (m,3H), 4.41-4.47(d,2H), 3.33(s,3H), 2.64-2.70(m,1H), 1.58(d,3H), 0.99-1.04(m,2H), 0.63-0.67(m,2H).
[0661] Embodiment 44:
[0662] (S)-n-(allyloxy)-5-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)-3-methylpicolinamide 44
[0663]
[0664] Step 1: Synthesis of compound 44b
[0665]
[0666] Compound 44a (320 mg, 1.4 mmol) was dissolved in tetrahydrofuran and water (2:1), iron powder (403 mg, 7.2 mmol) and ammonium chloride (155 mg, 2.8 mmol) were added, and the mixture was reacted at 80°C for 4 hours under a nitrogen atmosphere. The reaction was complete when monitored by TLC / LCMS. The reaction solution was naturally cooled to room temperature, poured into 100 mL of water, and extracted with ethyl acetate (60 mL*3). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated. The crude product was separated and purified by column chromatography, petroleum ether: ethyl acetate ~1:2, to obtain 153 mg of compound 44b as a yellow solid, MS: 167.1 [M+H] + .
[0667] Step 2: Synthesis of compound 44c
[0668]
[0669] Compound 1d (80 mg, 0.31 mmol) was dissolved in 1,4-dioxane, triethylamine (95 mg, 0.94 mmol) and DPPA (103 mg, 0.37 mmol) were added, stirred at room temperature for 30 minutes, 44b (72 mg, 0.37 mmol) was added, and the system temperature was raised to 100°C for 10 minutes. TLC / LCMS monitored the reaction to be complete. The reaction solution was naturally cooled to room temperature, poured into water, extracted with ethyl acetate (30 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated. The crude product was separated and purified by column chromatography, petroleum ether: ethyl acetate ~1:2, to obtain 96 mg of compound 44c as a light yellow solid, MS: 419.1 [M+H] + .
[0670] Step 3: Synthesis of compound 44d
[0671]
[0672] Compound 44c (96 mg, 0.21 mmol) was dissolved in a mixed solvent of tetrahydrofuran and water (2:1), and lithium hydroxide (15 mg, 0.64 mmol) was added. The mixture was reacted at room temperature for 4 hours. The reaction was complete after LCMS monitoring. The reaction solution was concentrated to remove tetrahydrofuran, and then diluted to 10 mL with deionized water. The pH was adjusted to 4-5 with 1N dilute hydrochloric acid. A white solid precipitated. The white solid was collected by filtration, and the solid was washed with water 3 times. It was lyophilized to obtain 83 mg of crude product 44d as a white solid, which was directly used in the next step. MS: 405.8 [M+H] + .
[0673] Step 4: Synthesis of compound 44
[0674]
[0675] Compound 44d (35 mg, 0.08 mmol) was dissolved in a mixed solvent of DMF and THF, DIEA (21 mg, 0.16 mmol) and HATU (37 mg, 0.09 mmol) were added and reacted for 30 minutes under nitrogen atmosphere, and 44e (15.7 mg, 0.16 mmol) was added and reacted for 4 hours. LCMS monitored the reaction to be complete. After the reaction solution was concentrated to remove THF, it was diluted with water and extracted with ethyl acetate (10 mL*3). The organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentration was separated and purified by column chromatography, methanol: water ~1:1, to obtain 17.06 mg of compound 44 as a white solid, MS: 460.8 [M+H] + .
[0676] Embodiment 45:
[0677] (S)-2-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)-N-propargyl-4-methylpyrimidine-5-carboxamide 45
[0678]
[0679] Step 1: Synthesis of compound 45b
[0680]
[0681] Compound 1d (80 mg, 0.31 mmol) was dissolved in 1,4-dioxane, triethylamine (95 mg, 0.94 mmol) and DPPA (103 mg, 0.37 mmol) were added, stirred at room temperature for 30 minutes, 45a (72 mg, 0.37 mmol) was added, and the system temperature was raised to 100 °C for 10 minutes. TLC / LCMS monitored the reaction to be complete. The reaction solution was naturally cooled to room temperature, poured into water, extracted with ethyl acetate (30 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated. The crude product was separated and purified by column chromatography, petroleum ether: ethyl acetate ~ 1:2, to obtain 96 mg of compound 45b as a light yellow solid, MS: 420.8 [M+H] + .
[0682] Step 2: Synthesis of compound 45c
[0683]
[0684] 45b (96 mg, 0.21 mmol) was dissolved in a mixed solvent of tetrahydrofuran and water (2:1), and lithium hydroxide (15 mg, 0.64 mmol) was added. The reaction was allowed to react at room temperature for 4 hours. LCMS monitored the reaction to be complete. The reaction solution was concentrated to remove tetrahydrofuran, and then diluted to 10 mL with deionized water. The pH was adjusted to 4-5 with 1N dilute hydrochloric acid. A white solid precipitated. The white solid was collected by filtration, and the solid was washed with water 3 times. It was lyophilized to obtain 83 mg of crude product 45c as a white solid, which was used directly in the next step. MS: 406.8 [M+H] + .
[0685] Step 3: Synthesis of compound 45
[0686]
[0687] Compound 45c (35 mg, 0.08 mmol) was dissolved in a mixed solvent of DMF and THF, and DIEA (21 mg, 0.16 mmol) and HATU (37 mg, 0.09 mmol) were added to react for 30 minutes under a nitrogen atmosphere, and 45d (15.7 mg, 0.16 mmol) was added to react for 4 hours. The reaction was complete when monitored by LCMS. After the reaction solution was concentrated to remove THF, it was diluted with water and extracted with ethyl acetate (10 mL*3). The organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentration was separated and purified by column chromatography, methanol: water ~1:1, to obtain 17.06 mg of compound 45 as a white solid, MS: 459.8 [M+H] + . 1 H NMR (600 MHz, DMSO-d6): δ ppm 11.91 (s, 1H), 11.40 (s, 1H), 10.70 (s, 1H), 9.06 (s, 1H), 8.59 (s, 1H), 6.94 (s, 1H), 5.48-5.53 (q, 1H), 4.64 (s, 2H), 3.68 (t, 1H), 3.33 (s, 3H), 2.58 (s, 3H), 1.54 (d, 3H). Example 46:
[0688] (S)-n-(allyloxy)-2-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)-4-methylpyrimidine-5-carboxamide 46
[0689]
[0690] Step 1: Synthesis of compound 46
[0691]
[0692] 45c (35 mg, 0.08 mmol) was dissolved in a mixed solvent of DMF and THF, DIEA (21 mg, 0.16 mmol) and HATU (37 mg, 0.09 mmol) were added and reacted for 30 minutes under nitrogen atmosphere, 46a (15.7 mg, 0.16 mmol) was added, and the reaction was continued for 4 hours. The reaction was complete after LCMS monitoring. After the reaction solution was concentrated to remove THF, it was diluted with water and extracted with ethyl acetate (10 mL*3). The organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentration was separated and purified by column chromatography, methanol: water ~1:1, to obtain 17.06 mg of compound 46 as a white solid, MS: 461.8 [M+H] + . 1 H NMR (600MHz, DMSO-d6): δppm 11.66(s,1H), 11.39(s,1H), 10.68(d,1H), 9.05(s,1H), 8.57(d,1H), 6.94(s,1H), 5.97-6.07(m,1H ), 5.48-5.53(q,1H), 5.42(d,1H), 5.30(d,1H), 4.44(d,2H), 3.33(s,3H), 2.55(s,3H), 1.54(d,3H).
[0693] Embodiment 47:
[0694] (S)-2-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)-N-(cyclopropylmethoxy)-4-methylpyrimidine-5-carboxamide 47
[0695]
[0696] Step 1: Synthesis of compound 47
[0697]
[0698] 45c (35 mg, 0.08 mmol) was dissolved in a mixed solvent of DMF and THF, DIEA (21 mg, 0.16 mmol) and HATU (37 mg, 0.09 mmol) were added and reacted for 30 minutes under nitrogen atmosphere, 47a (15.7 mg, 0.16 mmol) was added and reacted for 4 hours. The reaction was complete after LCMS monitoring. After the reaction solution was concentrated to remove THF, it was diluted with water and extracted with ethyl acetate (10 mL*3). The organic phases were combined and dried over anhydrous sodium sulfate. The crude product obtained by concentration was separated and purified by column chromatography, methanol: water ~1:1, to obtain 17.06 mg of compound 47 as a white solid, MS: 475.9 [M+H] + .
[0699] Embodiment 48:
[0700] (S)-1-(5-chloro-6-methoxypyridin-3-yl)-3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)urea 48
[0701]
[0702] Step 1: Synthesis of compound 48
[0703]
[0704] 2-Chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-amine (100 mg, 0.442 mmol) was dissolved in tetrahydrofuran (5 mL), N,N-diisopropylethylamine (68 mg, 0.53 mmol) was added, and thiophosgene (51 mg, 0.442 mmol) was added under ice bath. The mixture was stirred at room temperature for 1 hour. 5-Chloro-6-methoxypyridin-3-amine (99 mg, 0.53 mmol) was dissolved in tetrahydrofuran (2 mL), added dropwise to the above mixed solution under ice bath, and reacted at room temperature for 1 hour. LCMS monitored the reaction to be complete. Pour 50 mL of H 2 O, extracted with ethyl acetate (50 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 48 (80 mg, 42.5%) as a light yellow solid. MS: 427 [M+H] + .
[0705] Embodiment 49:
[0706] (S)-1-(5-chloro-6-(2h-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)urea49
[0707]
[0708] Compound 48a (100 mg, 0.44 mmol) was dissolved in tetrahydrofuran (2 ml), and thiophosgene (51 mg, 0.44 mmol), DIEA (68.5 mg, 0.53 mmol) and 5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine 49b (129 mg, 0.66 mmol) were added. The mixture was stirred at room temperature for 1 hour. LCMS monitored the reaction to be complete. The reaction solution was purified and separated by C18 reverse phase column chromatography to obtain compound 49 (50 mg, purity 97%) as a white solid, MS: 449.2 [M+H] + .
[0709] Embodiment 50:
[0710] (S)-1-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)-3-(7-(2-hydroxyethyl)-8-oxyl-7,8-2-hydrogen-1,7-naphthyridin-3-yl)urea 50
[0711]
[0712] Step 1: Synthesis of compound 50c
[0713]
[0714] Compound 50a (1.0 g, 4.4 mmol) was dissolved in DMF and Cs 2 CO 3 (2.8g, 8.8mmol), after stirring for 15 minutes, compound 50b (1.92g, 5.3mmol) was added at room temperature, and the temperature was raised to 80°C for 4 hours under nitrogen atmosphere. LCMS monitored the reaction to be complete. The reaction solution was poured into an aqueous solution of ammonium chloride, extracted with ethyl acetate (50mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, and the crude product obtained after concentration was separated and purified by column chromatography, petroleum ether: ethyl acetate ~70%, to obtain 1.8g of compound 50c as a yellow solid, MS: 384.3[M+H] + .
[0715] Step 2: Synthesis of compound 50e
[0716]
[0717] Compound 50c (1.0 g, 1.97 mmol) and compound 50d (277 mg, 2.36 mmol) were dissolved in 1,4-dioxane and Pd 2 (dba) 3 (180mg, 0.196mmol) and xantphos (228mg, 0.394mmol), after replacing nitrogen, the reaction solution was heated to 90℃ for 16 hours. LCMS monitored the reaction to be complete. The reaction solution was cooled to room temperature naturally, poured into 50mL of water, extracted with ethyl acetate (50mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, and the crude product obtained after concentration was separated and purified by column chromatography to obtain 720mg of compound 50e as a yellow solid, MS: 420.6[M+H] + .
[0718] Step 3: Synthesis of Compound 50f
[0719]
[0720] Compound 50e (300 mg, 0.54 mmol) was dissolved in anhydrous acetonitrile, trifluoroacetic acid (0.5 mL) was added dropwise, and the mixture was reacted at room temperature for 4 hours. The reaction was complete when monitored by LCMS. The reaction solution was poured into water and extracted with ethyl acetate (20 mL*3). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product, which was purified and separated by column chromatography to obtain 150 mg of compound 50f as a yellow oil, MS: 320.4 [M+H] + .
[0721] Step 4: Synthesis of compound 50g
[0722]
[0723] Compound 1d (60 mg, 0.23 mmol) was dissolved in 1,4-dioxane, triethylamine (71 mg, 0.70 mmol) and DPPA (88 mg, 0.32 mmol) were added, stirred at room temperature for 30 minutes, 50f (114 mg, 0.26 mmol) was added, and the system temperature was raised to 100 °C for 10 minutes. TLC / LCMS monitored the reaction to be complete. The reaction solution was naturally cooled to room temperature, poured into water, extracted with ethyl acetate (30 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated. The crude product was separated and purified by column chromatography, petroleum ether: ethyl acetate ~1:2, to obtain 38 mg of compound 50g as a light yellow solid, MS: 573.1 [M+H] + .
[0724] Step 5: Synthesis of Compound 50
[0725]
[0726] Dissolve 50 g (38 mg) of the compound in tetrahydrofuran, add TBAF (1 M tetrahydrofuran solution) dropwise, and stir at room temperature for 4 hours. TLC monitors the reaction until complete. Concentrate the reaction solution, then dissolve it in 30 mL of ethyl acetate and wash with saturated brine (20 mL*3). Combine the ethyl acetate phases, dry them over anhydrous sodium sulfate, and concentrate to obtain a crude product, which is separated and purified by column chromatography. 2 O: MeOH ~ 1: 1, to obtain 6 mg of the final product compound 50 as a white solid, MS: 458.8, [M+H] + .
[0727] Embodiment 51:
[0728] (S)-1-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)-3-(2-(2-hydroxyethyl)-1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)urea
[0729]
[0730]
[0731] Step 1: Synthesis of compound 51c
[0732]
[0733] Compound 51a (1.0 g, 4.4 mmol) was dissolved in DMF, and NaH (265 mg, 6.6 mmol) was added in an ice-water bath. After stirring for 15 minutes, 51b (1.92 g, 5.3 mmol) was added in an ice-water bath. The reaction was allowed to react at room temperature for 16 hours under a nitrogen atmosphere. LCMS monitored the reaction to be complete. The reaction solution was poured into an aqueous solution of ammonium chloride, extracted with ethyl acetate (50 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, and the crude product obtained after concentration was separated and purified by column chromatography, petroleum ether: ethyl acetate ~ 45%, to obtain 1.3 g of compound 51c as a white solid, MS: 385.3 [M+H] + .
[0734] Step 2: Synthesis of compound 51e
[0735]
[0736] Compound 51c (1.0 g, 1.96 mmol) and compound 51d (276 mg, 2.36 mmol) were dissolved in 1,4-dioxane and Pd 2 (dba) 3 (180 mg, 0.196 mmol) and xantphos (227 mg, 0.394 mmol), after replacing nitrogen, the reaction solution was heated to 90 ° C for 16 hours. LCMS monitored the reaction to be complete. The reaction solution was naturally cooled to room temperature, poured into 50 mL of water, extracted with ethyl acetate (50 mL * 3), the organic phases were combined, dried over anhydrous sodium sulfate, and the crude product obtained after concentration was separated and purified by column chromatography to obtain 1.0 g of compound 51e as a yellow oil, MS: 421.6 [M+H] + .
[0737] Step 3: Synthesis of compound 51f
[0738]
[0739] 51e (400 mg, 0.72 mmol) was dissolved in anhydrous acetonitrile, and TMSI (192 mg, 0.94 mmol) was added in batches and reacted at room temperature for 4 hours. LCMS monitored the reaction to be complete. The reaction solution was poured into water and extracted with ethyl acetate (20 mL*3). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product, which was purified and separated by column chromatography to obtain 210 mg of compound 51f as a yellow oil, MS: 321.5 [M+H] + .
[0740] Step 4: Synthesis of Compound 51g
[0741]
[0742] Compound 1d (100 mg, 0.39 mmol) was dissolved in 1,4-dioxane, triethylamine (118 mg, 1.17 mmol) and DPPA (129 mg, 0.039 mmol) were added, stirred at room temperature for 30 minutes, 51f (174 mg, 0.39 mmol) was added, and the system temperature was raised to 100 °C for 10 minutes. TLC / LCMS monitored the reaction to be complete. The reaction solution was naturally cooled to room temperature, poured into water, extracted with ethyl acetate (30 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated. The crude product was separated and purified by column chromatography, petroleum ether: ethyl acetate ~ 1:2, to obtain 112 mg of compound 51g as a light yellow solid, MS: 574.1 [M+H] + .
[0743] Step 5: Synthesis of Compound 51
[0744]
[0745] 51 g (100 mg) was dissolved in tetrahydrofuran, TBAF (1 M tetrahydrofuran solution) was added dropwise, and the reaction was stirred at room temperature for 4 hours. TLC monitored the reaction to be complete. The reaction solution was concentrated, then dissolved in 30 mL of ethyl acetate and washed with saturated brine (20 mL*3). The ethyl acetate phases were combined, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product, which was separated and purified by column chromatography. 2 O: MeOH ~ 1: 1, to give 35 mg of the final product 51 as a white solid, MS: 459.9, [M+H] + .
[0746] Embodiment 52:
[0747] (S)-1-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)-3-(2-methyl-1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea 52
[0748]
[0749]
[0750] Step 1: Synthesis of compound 52b
[0751]
[0752] Compound 52a (500 mg, 2.21 mmol) was dissolved in tetrahydrofuran (8 mL), and sodium hydride (265 mg, 6.63 mmol, 60%) and iodomethane (627 mg, 4.42 mmol) were added in turn under ice bath, and the mixture was stirred at room temperature for 3 hours in a magnetic stirrer. The reaction was complete when monitored by LCMS. The reaction solution was poured into 200 mL of H 2 O, extracted with ethyl acetate (200 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 52b (509 mg, 96.4%) as a light yellow solid. MS: 241.1 [M+H] + .
[0753] Step 2: Synthesis of compound 52d
[0754]
[0755] Compound 52b (509 mg, 2.13 mmol) was dissolved in 1,4-dioxane (10 mL), and tert-butyl carbamate (250 mg, 2.13 mmol), tris(dibenzylideneacetone)dipalladium (195 mmol, 0.213 mmol), 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene (123 mg, 0.213 mmol), and cesium carbonate (2.083 g, 6.39 mmol) were added thereto in sequence. Nitrogen was replaced, and the mixture was refluxed in an oil bath at 100°C for 3.5 hours. LCMS monitored the reaction to be complete. The reaction mixture was poured into water, extracted with ethyl acetate (70 mL*3), and the organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 52d (300 mg, 51.03%). MS: 277.34 [M+H] + .
[0756] Step 3: Synthesis of compound 52e
[0757]
[0758] Compound 52d (300 mg, 1.08 mmol) was added to dichloromethane (5 mL), trifluoroacetic acid (1 mL) was added thereto, and the mixture was stirred at room temperature for 3 hours. LCMS monitored the reaction to be complete. A small amount of saturated sodium bicarbonate solution was added, the reaction mixture was poured into water, extracted with ethyl acetate (30 mL*3), the organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product. The crude product was purified by column chromatography (dichloromethane: methanol = 9:1) to obtain compound 52e (440 mg, 95.19%) as a brown solid. MS: 177.2 [M+H] + .
[0759] Step 4: Synthesis of compound 52
[0760]
[0761] (S)-2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidine-6-carboxylic acid 1d (31 mg, 0.12 mmol) was dissolved in ultra-dry 1,4-dioxane (2 mL), triethylamine (12 mg, 0.123 mmol) was added to the mixture, stirred at room temperature for ten minutes, then DPPA (40 mg, 0.144 mmol) was added, stirred at room temperature for thirty minutes, and then a mixture of compound 52e (21 mg, 0.12 mmol) and 1,4-dioxane (1 mL) was added dropwise to the above mixture, and the temperature was raised to 100°C for 1 h. LCMS monitored the reaction to be complete. The reaction mixture was poured into water, extracted with ethyl acetate (50 mL*3), the organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 52 (20 mg, 38.94%) as a light yellow solid. MS: 429.8[M+H] + .
[0762] Embodiment 53:
[0763] (S)-1-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)-3-(2-methyl-1-oxoisoindolin-5-yl)urea 53
[0764]
[0765] Step 1: Synthesis of compound 53b
[0766]
[0767] Compound 53a (500 mg, 2.36 mmol) was dissolved in tetrahydrofuran (8 mL), sodium hydride (283 mg, 7.08 mmol, 60%) and iodomethane (670 mg, 4.72 mmol) were added in turn under ice bath, and the mixture was stirred at room temperature for 3 hours in a magnetic stirrer. The reaction was complete when monitored by LCMS. The reaction solution was poured into 200 mL of H 2 O, extracted with ethyl acetate (200 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 53b (208 mg, 39%) as a light yellow solid. MS: 227.0 [M+H] + .
[0768] Step 2: Synthesis of compound 53d
[0769]
[0770] Compound 53b (208 mg, 0.92 mmol) was dissolved in 1,4-dioxane (10 mL), and tert-butyl carbamate (108 mg, 0.92 mmol), tris(dibenzylideneacetone)dipalladium (84 mg, 0.092 mmol), 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene (53 mg, 0.092 mmol), and cesium carbonate (900 mg, 2.76 mmol) were added thereto in sequence. Nitrogen was replaced, and the mixture was refluxed in an oil bath at 100°C overnight. LCMS monitored the reaction to be complete. The reaction mixture was poured into water, extracted with ethyl acetate (100 ml*3), and the organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 53d (184 mg, 76%). MS: 263.3 [M+H] + .
[0771] Step 3: Synthesis of compound 53e
[0772]
[0773] Compound 53d (184 mg, 0.7 mmol) was added to acetonitrile (5 mL), trimethylsilyl iodide (182 mg, 0.91 mmol) was added thereto, and the mixture was stirred at room temperature for 4 hours. LCMS monitored the reaction to be complete. The reaction mixture was poured into water, extracted with ethyl acetate (50 ml*3), the organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 53e (60 mg, 52.59%) as a brown solid. MS: 163.1 [M+H] + .
[0774] Step 4: Synthesis of compound 53
[0775]
[0776] (S)-2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidine-6-carboxylic acid 1d (94 mg, 0.368 mmol) was dissolved in ultra-dry 1,4-dioxane (2 mL), triethylamine (112 mg, 1.104 mmol) was added to the mixture, stirred at room temperature for ten minutes, then DPPA (365 mg, 1.325 mmol) was added, stirred at room temperature for thirty minutes, and then a mixture of compound 53e (60 mg, 0.368 mmol) and 1,4-dioxane (1 mL) was added dropwise to the above mixture, and the temperature was raised to 100°C for 1 h. LCMS monitored the reaction to be complete. The reaction mixture was poured into water, extracted with ethyl acetate (50 mL*3), the organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 53 (20 mg, 13%) as a light yellow solid. MS: 415.8[M+H] + .
[0777] Embodiment 54:
[0778] (S)-1-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)-3-(2-methyl-1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)urea 54
[0779]
[0780] Step 1: Synthesis of compound 54b
[0781]
[0782] Compound 54a (500 mg, 2.21 mmol) was dissolved in tetrahydrofuran (8 mL), and sodium hydride (265 mg, 6.63 mmol, 60%) and iodomethane (627 mg, 4.42 mmol) were added in turn under ice bath, and the mixture was stirred at room temperature for 3 hours in a magnetic stirrer. The reaction was complete when monitored by LCMS. The reaction solution was poured into 200 mL of H 2 O, extracted with ethyl acetate (200 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 54b (550 mg, 96.2%) as a light yellow solid. MS: 241.1 [M+H] + .
[0783] Step 2: Synthesis of compound 54d
[0784]
[0785] Compound 54b (550 mg, 1.99 mmol) was dissolved in 1,4-dioxane (10 mL), and tert-butyl carbamate (233 mg, 1.99 mmol), tris(dibenzylideneacetone)dipalladium (182 mg, 0.199 mmol), 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene (115 mg, 0.199 mmol), and cesium carbonate (1.946 g, 5.97 mmol) were added thereto in sequence. The nitrogen was replaced, and the mixture was refluxed in an oil bath at 100°C for 4 hours. LCMS monitored the reaction to be complete. The reaction mixture was poured into water, extracted with ethyl acetate (200 mL*3), and the organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 54d (506 mg, 91.79%). MS: 277.3 [M+H] + .
[0786] Step 3: Synthesis of compound 54e
[0787]
[0788] Compound 54d (506 mg, 1.83 mmol) was added to acetonitrile (8 mL), trimethylsilyl iodide (476 mg, 2.38 mmol) was added thereto, and the mixture was stirred at room temperature for 4 hours. LCMS monitored the reaction to be complete. The reaction mixture was poured into water, extracted with ethyl acetate (300 mL*3), the organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 54e (120 mg, 37.05%) as a brown solid. MS: 177.2 [M+H] + .
[0789] Step 4: Synthesis of compound 54
[0790]
[0791] (S)-2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidine-6-carboxylic acid 1d (73 mg, 0.286 mmol) was dissolved in ultra-dry 1,4-dioxane (2 mL), triethylamine (87 mg, 0.858 mmol) was added to the mixture, stirred at room temperature for ten minutes, then DPPA (94 mg, 0.343 mmol) was added, stirred at room temperature for thirty minutes, and then a mixture of compound 54e (51 mg, 0.286 mmol) and 1,4-dioxane (1 mL) was added dropwise to the above mixture, and the temperature was raised to 100°C for 1 h. LCMS monitored the reaction to be complete. The reaction mixture was poured into water and extracted with ethyl acetate (200 mL*3), the organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 54 (20 mg, 16.3%) as a light yellow solid. MS: 429.8[M+H] + . 1 H NMR (600MHz, DMSO-d6): δppm 9.87(br,1H), 8.92(s,1H), 8.45(br,1H), 7.78(d,1H), 7.49(d,1H), 7.36-7.38(dd,1H), 6.91 (s,1H), 5.40-5.44(q,1H), 3.52(t,2H), 3.31(s,3H), 3.00(s,3H), 2.94(t,2H), 1.58(d,3H).
[0792] Embodiment 55:
[0793] (S)-1-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)-3-(2-methyl-1-oxo-1,2-dihydroisoquinolin-6-yl)urea 55
[0794]
[0795] Step 1: Synthesis of compound 55b
[0796]
[0797] Compound 55a (500 mg, 2.23 mmol) was dissolved in tetrahydrofuran (8 mL), sodium hydride (268 mg, 6.69 mmol, 60%) and iodomethane (633 mg, 4.46 mmol) were added in turn under ice bath, and the mixture was stirred at room temperature for 3 hours in a magnetic stirrer. The reaction was complete when monitored by LCMS. The reaction solution was poured into 100 mL of H 2O, extracted with ethyl acetate (100 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 55b (540 mg, 88%) as a light yellow solid. MS: 239.0 [M+H] + .
[0798] Step 2: Synthesis of compound 55d
[0799]
[0800] Compound 55b (540 mg, 2.27 mmol) was dissolved in 1,4-dioxane (10 mL), and tert-butyl carbamate (266 mg, 2.27 mmol), tris(dibenzylideneacetone)dipalladium (208 mg, 0.227 mmol), 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene (131 mg, 0.227 mmol), and cesium carbonate (2.22 g, 6.81 mmol) were added thereto in sequence. Nitrogen was replaced, and the mixture was refluxed in an oil bath at 100°C for 4 hours. LCMS monitored the reaction to be complete. The reaction mixture was poured into water, extracted with ethyl acetate (70 mL*3), the organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 55d (497 mg, 79.6%). MS: 275.3 [M+H] + .
[0801] Step 3: Synthesis of compound 55e
[0802]
[0803] Compound 55d (497 mg, 1.81 mmol) was added to acetonitrile (8 mL), trimethylsilyl iodide (470 mg, 2.35 mmol) was added thereto, and the mixture was stirred at room temperature for 4 hours. LCMS monitored the reaction to be complete. The reaction mixture was poured into water, extracted with ethyl acetate (100 mL*3), the organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 55e (137 mg, 17.8%) as a light yellow solid. MS: 175.2 [M+H] + .
[0804] Step 4: Synthesis of compound 55
[0805]
[0806] (S)-2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidine-6-carboxylic acid 1d (73 mg, 0.286 mmol) was dissolved in ultra-dry 1,4-dioxane (2 mL), triethylamine (87 mg, 0.858 mmol) was added to the mixture, stirred at room temperature for ten minutes, then DPPA (94 mg, 0.343 mmol) was added, stirred at room temperature for thirty minutes, and then a mixture of compound 55e (50 mg, 0.286 mmol) and 1,4-dioxane (1 mL) was added dropwise to the above mixture, and the temperature was raised to 100°C for 1 h. LCMS monitored the reaction to be complete. The reaction mixture was poured into water, extracted with ethyl acetate (50 mL*3), the organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 55 (20 mg, 16.4%) as a light yellow solid. MS: 427.8[M+H] + .
[0807] Embodiment 56:
[0808] (S)-1-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)-3-(3,5-dichloro-4-(4-(pyridin-2-yl)-1h-pyrazol-1-yl)phenyl)urea 56
[0809]
[0810] Step 1: Synthesis of compound 56c
[0811]
[0812] Compound 56a (2 g, 9.5 mmol) was dissolved in N,N-dimethylformamide (32 ml), cesium carbonate (5.068 g, 15.5 mmol) and compound 56b (1.6 g, 11.4 mmol) were added, and the mixture was stirred at 60 ° C overnight. LCMS monitored the reaction to be complete. The reaction solution was poured into 100 mL of water, extracted with ethyl acetate (35 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 3:1) to obtain compound 56c (0.556 g, 1.189 g). MS: 336.1 [M+H] +
[0813] Step 2: Synthesis of compound 56d
[0814]
[0815] Compound 56c (1.262 g, 3.76 mmol) was dissolved in THF (5 ml) and H2 O (5ml), MeOH (10ml), then add iron powder (1.05g, 18.8mmol), ammonium chloride (0.804g, 15.04mmol), under nitrogen protection, stir in 65℃ oil bath for 1h. LCMS is correct, the reaction is complete. The reaction solution is filtered, the filtrate is extracted with water and ethyl acetate (75ml*3), the organic phases are combined, the organic phases are dried over anhydrous sodium sulfate, concentrated and the residue is separated and purified by column chromatography (petroleum ether: ethyl acetate = 3:1) to obtain compound 56d (657mg, 57%). MS: 304 [M+H] + .
[0816] Step 3: Synthesis of Compound 56
[0817]
[0818] (S)-2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidine-6-carboxylic acid 1d (80 mg, 0.314 mmol) was added to ultra-dry 1,4-dioxane (1 ml), 1 ml of TEA was added and stirred for 10 minutes, DPPA (104 mg, 0.38 mmol) was added dropwise and stirred for 30 minutes, compound 56d (95 mg, 0.314 mmol) was dissolved in 1 ml of ultra-dry 1,4-dioxane solution and added dropwise to the above reaction solution, and the temperature was raised to 100°C for 3 hours. LCMS monitored the reaction to be complete. The reaction mixture was poured into 50 ml of water and extracted with ethyl acetate (45 ml*3), the organic layers were combined, dried over anhydrous sodium sulfate and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 3:1) to obtain compound 56 (35 mg, 20%), MS: 558.8 [M+H] + . 1 H NMR (600MHz, DMSO-d6): δppm10.13(br,1H), 8.95(s,1H), 8.56-8.57(m,2H), 8.52(s,1H), 8.35(s,1 H), 7.76-7.83(m,4H), 7.23-7.26(m,1H), 6.95(s,1H), 5.41-5.44(q,1H), 3.34(s,3H), 1.58(d,3H).
[0819] Embodiment 57:
[0820] (S)-4-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)-2,6-difluoro-N-methoxybenzamide 57
[0821]
[0822] Step 1: Synthesis of compound 57c
[0823]
[0824] Compound 57a (100 mg, 0.39 mmol) was dissolved in 1,4-dioxane (1 ml), 1 ml of TEA was added and stirred at room temperature for 10 minutes. DPPA (130 mg, 0.47 mmol) was added dropwise and stirring was continued for 30 minutes. 5-amino-2,4-difluoronicotinate methyl ester 57b (74 mg, 0.39 mmol) and 1 ml of 1,4-dioxane solution were added to the reaction solution, and the system was heated to 100 ° C for 1 hour. LCMS monitored the reaction to be complete. The mixture was then extracted with water and ethyl acetate (45 ml * 3), the organic phases were combined, the organic phases were dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 3: 1) to obtain compound 57c (72 mg, 42%). MS: 440.8 [M + H] + .
[0825] Step 2: Synthesis of compound 57d
[0826]
[0827] To compound 57c (72 mg, 0.164 mmol) was added 1 ml of THF, H 2 O 0.5ml, add lithium hydroxide (23.6mg, 0.984mmol) to the mixed solution, and stir at room temperature overnight under nitrogen protection. After the reaction solution is spin-dried, add water and hydrochloric acid (2mol / L) to adjust the pH to acidic. A white precipitate is generated, and the filter cake (15mg, 21%) is obtained by filtration. MS: 425[M+H] + .
[0828] Step 3: Synthesis of compound 57
[0829]
[0830] Compound 57d (15 mg, 0.035 mmol) was dissolved in ultra-dry tetrahydrofuran (1 mL) and N,N-dimethylformamide (0.5 ml) solution, DIEA (9 mg, 0.07 mmol) was added and stirred for 5 minutes, then HATU (16 mg, 0.042 mmol) was added and stirred for 40 minutes. Then methoxyamine hydrochloride (5 mg, 0.525 mmol) was dissolved in 0.5 ml N,N-dimethylformamide and added to the above reaction solution, and stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was subjected to column chromatography with reverse phase column to obtain compound 57 (7 mg, 46%). MS: 455.8 [M+H]+ .
[0831] Embodiment 58:
[0832] (S)-1-(4-(1h,1'H-[4,4'-bipyrazole]-1-yl)-3,5-difluorophenyl)-3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)urea 58
[0833]
[0834] Step 1: Synthesis of compound 58c
[0835]
[0836] Compound 58a (3 g, 16.9 mmol) and 4-iodopyrazole 58b (3.62 g, 18.6 mmol) were dissolved in NN-dimethylformamide (50 ml), cesium carbonate (8.29 g, 25.4 mmol) was added, and the mixture was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was poured into 100 mL of H 2 O, extracted with ethyl acetate (100 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 3:1) to obtain compound 58c (2.5 g, 42%) as a light yellow solid. MS: 352.0 [M+H] + .
[0837] Step 2: Synthesis of compound 58d
[0838]
[0839] Compound 58c (1.5 g, 4.27 mmol) was dissolved in tetrahydrofuran (15 ml) and added dropwise to a mixed solution of iron powder (1.88 g, 32 mmol) and ammonium chloride (1.37 g, 25.6 mmol) in water and methanol (15 ml of water, 30 ml of methanol). The mixture was stirred at 65 °C for 1 hour. The reaction was complete when monitored by LCMS. The reaction solution was filtered and the filtrate was poured into 100 mL of H 2 O, extracted with ethyl acetate (100 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 58d (1.2 g, 88%) as a dark yellow solid. MS: 322.0 [M+H] + .
[0840] Step 3: Synthesis of compound 58f
[0841]
[0842] Compound 58d (300 mg, 0.93 mmol) was dissolved in 1,4-dioxane (6 ml), 1-(tert-butyloxycarbonyl)pyrazol-4-ylboronic acid; 1-BOC-1H-pyrazole-4-boronic acid 58e (394 mg, 1.86 mmol), 1,1-bis(diphenylphosphine)diphenylferric palladium chloride (66 mg, 0.09 mmol) and cesium carbonate (913 mg, 2.8 mmol) were added, and the mixture was stirred at 100 °C for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was poured into 50 mL of H 2 O, extracted with ethyl acetate (50 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated and the residue was separated and purified by column chromatography (dichloromethane:ethyl acetate=1:1) to obtain compound 58f (100 mg, 30%) as a dark yellow solid. MS: 262.2 [M+H] + .
[0843] Step 4: Synthesis of Compound 58
[0844]
[0845] Compound 1d (43 mg, 0.19 mmol) was dissolved in ultra-dry 1,4-dioxane (1 ml), triethylamine (58 mg, 0.57 mmol) was added, and the mixture was stirred at room temperature for ten minutes. Then diphenylphosphoryl azide (63.2 mg, 0.23 mmol) was added, and the mixture was stirred at room temperature for thirty minutes. Compound 58f (50 mg, 0.19 mmol) was dissolved in 1,4-dioxane (1 ml) and added dropwise to the mixture. The mixture was heated to 100 degrees Celsius and reacted for 1 hour. The reaction was complete when monitored by LCMS. Compound 58 was prepared, separated and purified by HPLC as a white solid (purity 98%). MS: 514.8 [M+H] + .
[0846] Embodiment 59:
[0847] (S)-1-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)-3-(3,5-dichloro-4-(3-(3-hydroxy-3-methyl-1-in-1-yl)-1h-pyrazol-1-yl)phenyl)urea 59
[0848]
[0849] Step 1: Synthesis of compound 59c
[0850]
[0851] Compound 59a (3 g, 14.2 mmol) was dissolved in N,N-dimethylformamide (30 mL), and 3-iodopyrazole 59b (3.03 g, 15.62 mmol) and cesium carbonate (6.94 g, 21.3 mmol) were added in sequence. The mixture was stirred at room temperature for 2 hours in a magnetic stirrer. The reaction was complete when monitored by LCMS. The reaction solution was poured into 300 mL of H 2 O, extracted with ethyl acetate (300 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 4:1) to obtain compound 59c (5.342 g, 98.2%) as a white solid. MS: 384.9 [M+H] + .
[0852] Step 2: Synthesis of compound 59e
[0853]
[0854] Compound 59c (1 g, 2.61 mmol) was dissolved in 1,4-dioxane (10 mL), and 2-methylbut-3-yn-2-ol (330 mg, 3.92 mmol), triethylamine (2 mL), cuprous iodide (149 mg, 0.783 mmol), and bis(triphenylphosphine)palladium dichloride (183 mg, 0.261 mmol) were added thereto in sequence. Nitrogen was replaced, and the mixture was stirred at room temperature for 4 hours. LCMS monitored the reaction to be complete. The reaction mixture was poured into water, extracted with ethyl acetate (200 mL*3), and the organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product. The crude product was purified by column chromatography (dichloromethane: methanol = 3:1) to obtain compound 59e (850 mg, 96.1%). MS: 341.1 [M+H] + .
[0855] Step 3: Synthesis of compound 59f
[0856]
[0857] Iron powder (703 mg, 12.55 mmol) and ammonium chloride (537 mg, 10.04 mmol) were dissolved in a mixed solution of tetrahydrofuran, water and methanol (3 mL: 3 mL: 6 mL, 1: 1: 2), compound 59e (850 mg, 2.51 mmol) was added thereto, and the mixture was refluxed in an oil bath at 65°C for 1 h. LCMS monitored the reaction to be complete. Filtered with diatomaceous earth, water was added to the filtrate, extracted with ethyl acetate (200 mL*3), the organic layers were combined, dried over anhydrous sodium sulfate and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 3: 1) to obtain compound 59f (443 mg, 52.1%). MS: 311.1 [M+H]+ .
[0858] Step 4: Synthesis of compound 59
[0859]
[0860] (S)-2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidine-6-carboxylic acid 1d (335 mg, 1.31 mmol) was dissolved in 1,4-dioxane (5 mL), and triethylamine (397 mg, 3.93 mmol) and diphenylphosphoryl azide (432 mg, 1.57 mmol) were added. The mixture was stirred at room temperature for 30 minutes. Compound 59f (443 mg, 1.31 mmol) was dissolved in 1,4-dioxane (3 mL), and added dropwise to the above mixed solution. The mixture was reacted in an oil bath at 100°C for 1 h. The reaction was complete when monitored by LCMS. 50 mL of H 2 O, extracted with ethyl acetate (50 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 59 (411 mg, 55.9%) as a light yellow solid. MS: 563.8 [M+H] + . 1 H NMR (600MHz, DMSO-d6): δppm 10.12(br,1H), 8.94(s,1H), 8.53(br,1H), 8.02(d,1H), 7.78(s,2H), 6.94(s,1H), 6 .64(d,1H), 5.55(br,1H), 5.40-5.44(q,1H), 3.33(s,3H), 1.58(s,3H), 1.47(s,6H).
[0861] Embodiment 60:
[0862] (S)-1-(2,6-dichloro-4-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)phenyl)-N-methoxy-1h-pyrazole-3-carboxamide 60
[0863]
[0864] Step 1: Synthesis of compound 60c
[0865]
[0866] 1,3-Dichloro-2-fluoro-5-nitrobenzene 60b (2.1 g, 10 mmol) was dissolved in 20 ml DMF, and cesium carbonate (4.89 g, 15.6 mmol) and compound 60a (1.44 g, 11.44 mmol) were added in sequence. The mixture was stirred in a 30°C oil bath under nitrogen protection for 3 hours. LCMS was correct and the reaction was complete. The mixture was then poured into 150 ml of water and extracted with ethyl acetate (100 ml*3). The organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 3:1) to obtain compound 60c (1.378 g, 57%) MS: 317.0 [M+H] + .
[0867] Step 2: Synthesis of compound 60d
[0868]
[0869] Compound 60c (1.378 g, 4.36 mmol) was dissolved in 10 ml THF, 10 ml H 2 O, 20ml MeOH, then add ammonium chloride (933mg, 17.44mmol) and iron powder (1.22g, 21.8mmol) in sequence. Heat the oil bath to 65°C under nitrogen protection, and then stir for 1 hour. LCMS is correct, and the reaction is complete. Filter the reaction solution, extract the filtrate with water and ethyl acetate (100ml*3), combine the organic layers, dry over anhydrous sodium sulfate, and concentrate to obtain a crude product. The crude product is purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 60d (0.415g, 35%) MS: 287.1 [M+H] + .
[0870] Step 3: Synthesis of compound 60e
[0871]
[0872] (S)-2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidine-6-carboxylic acid 1d (257 mg, 1 mmol) was added to ultra-dry 3 ml 1,4-dioxane, then TEA (416 mg, 3 mmol) was added and stirred for 10 minutes, DPPA (300 mg, 1.2 mmol) was added dropwise and stirred for 30 minutes, then compound 60d (285 mg, 1 mmol) was added and dissolved in 3 ml 1,4-dioxane solution, the temperature was raised to 100°C and reacted for 1 hour, and the reaction was completed by LCMS monitoring. The mixture was then extracted with water and ethyl acetate (70 ml*3), the organic phases were combined, the organic phases were dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 3:1) to obtain compound 60e (292 mg, 54%). MS: 539.7 [M+H] + .
[0873] Step 4: Synthesis of compound 60f
[0874]
[0875] Compound 60e (292 mg, 0.543 mmol) was added to 4 ml of THF. 2 O 2ml, add lithium hydroxide (75mg, 3.26mmol) to the mixed solution, under nitrogen protection, stir at room temperature overnight. After the reaction solution is dried, add water, adjust the pH to acidic with hydrochloric acid (2mol / L), a white precipitate is generated, filter to obtain a filter cake (100mg, 35%). MS: 525.7[M+H] + .
[0876] Step 5: Synthesis of compound 60
[0877]
[0878] Compound 60f (100 mg, 0.191 mmol) was dissolved in ultra-dry tetrahydrofuran (5 mL) and N,N-dimethylformamide (2.5 ml) solution, DIEA (50 mg, 0.382 mmol) was added and stirred for 5 minutes, then HATU (87 mg, 0.23 mmol) was added and stirred for 40 minutes. Then methoxyamine hydrochloride (24 mg, 0.286 mmol) and 0.5 ml N,N-dimethylformamide were added to the above reaction solution and stirred at room temperature for 2 h. LCMS monitored the reaction to be complete. The reaction solution was subjected to column chromatography with reverse phase column to obtain compound 60 (43 mg, 41%), MS: 554.7 [M+H] + . 1H NMR (600MHz, DMSO-d6): δppm 11.74(s,1H), 10.16(s,1H), 8.94(s,1H), 8.53(s,1H), 8.11(d,1H), 7.80(s,2H), 6 .95(s,1H), 6.91(d,1H), 5.40-5.44(q,1H), 3.68(s,3H), 3.32(s,3H), 1.58(d,3H).
[0879] Example 61:
[0880] (S)-n-(allyloxy)-5-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)-3-(difluoromethyl)picolinamide 61
[0881]
[0882] Step 1: Synthesis of compound 61b
[0883]
[0884] Compound 61a (25 g, 101.6 mmol) was dissolved in thionyl chloride (200 ml) and stirred at room temperature for 3 hours. After the reaction solution was concentrated, chloroform (250 ml) was added and refluxed for 30 minutes. LCMS monitored the reaction to be complete. The reaction solution was filtered and the filtrate was concentrated to obtain compound 61b (23 g, 99.8%) as a dark yellow liquid. MS: 229.0 [M+H] + .
[0885] Step 2: Synthesis of compound 61c
[0886]
[0887] Compound 61b (23 g, 101 mmol) was dissolved in isopropanol (400 ml) and stirred at room temperature for 16 hours. The reaction was complete as monitored by LCMS. The reaction solution was concentrated to give compound 61c (25 g, 86%) as a dark yellow liquid. MS: 289.1 [M+H] + .
[0888] Step 3: Synthesis of compound 61d
[0889]
[0890] Compound 61c (5 g, 17.4 mmol) was dissolved in dichloromethane (50 ml), oxalyl chloride (4.4 g, 34.7 mmol) was added dropwise to the reaction solution at 0 ° C, and the mixture was stirred at 40 ° C for 3 hours. After the reaction solution was concentrated to dryness, it was dissolved in tetrahydrofuran (100 ml), cooled to 0 ° C, sodium borohydride (1 g, 26.1 mmol) was slowly added, and stirred at 0 ° C for 1 hour. LCMS monitored the reaction to be complete. The reaction solution was slowly poured into an ice-water bath (250 ml) to quench, extracted with ethyl acetate (200 mL * 3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 2: 1) to obtain compound 61d (2.5 g, 52.3%) as a light yellow solid. MS: 275.1 [M + H] + .
[0891] Step 4: Synthesis of compound 61e
[0892]
[0893] Compound 61d (5 g, 18.2 mmol) was dissolved in dichloromethane (50 ml), Dess-Martin periodinane (9.2 g, 21.8 mmol) was added, and the mixture was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was slowly poured into water (200 ml) for quenching, extracted with dichloromethane (100 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 3:1) to obtain compound 61e (2.4 g, 49.2%) as a pale white solid. MS: 273.1 [M+H] + .
[0894] Step 5: Synthesis of compound 61f
[0895]
[0896] Compound 61e (2.4 g, 8.2 mmol) was dissolved in dichloromethane (50 ml), diethylaminosulfur trifluoride (3.8 g, 24.6 mmol) was added, and the mixture was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was slowly poured into water (150 ml) for quenching, extracted with dichloromethane (100 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 3:1) to obtain compound 61f (2.4 g, 49.2%) as a light yellow solid. MS: 295.1 [M+H] + .
[0897] Step 6: Synthesis of compound 61g
[0898]
[0899] Compound 61f (1.6 g, 5.4 mmol) was dissolved in 1,4-dioxane (20 ml), tert-butyl carbamate (1.27 g, 10.8 mmol), cesium carbonate (5.26 g, 16.2 mmol), 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene (312 mg, 0.54 mmol) and tris(bis(benzylideneacetone)dipalladium (500 mg, 0.54 mmol) were added, and the mixture was stirred at 110 ° C for 3 hours. LCMS monitored the reaction to be complete. The reaction solution was slowly poured into water (150 ml) to quench, extracted with ethyl acetate (100 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 3:1) to obtain compound 61g (1 g, 55.6%) as a dark brown solid. MS: 395.4 [M+H] + .
[0900] Step 7: Synthesis of compound 61h
[0901]
[0902] Compound 61g (1g, 3.02mmol) was dissolved in tetrahydrofuran (15ml), 1N hydrochloric acid (10ml) was added, and the mixture was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was slowly poured into water (100ml), extracted with ethyl acetate (50mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 61h (500mg, 65.3%) as a white solid. MS: 231.2 [M+H] + .
[0903] Step 8: Synthesis of compound 61i
[0904]
[0905] (S)-2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidine-6-carboxylic acid 1d (500 mg, 1.96 mmol) was dissolved in 1,4-dioxane (5 ml), triethylamine (593 mg, 5.88 mmol) and diphenylphosphoryl azide (647 mg, 2.35 mmol) were added, and the mixture was stirred at room temperature for 30 minutes. Compound 61h (451 mg, 1.96 mmol) was added to the reaction system and stirred at 100 °C for 1 hour. LCMS monitored the reaction to be complete. The reaction solution was slowly poured into water (50 ml), extracted with ethyl acetate (20 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 61i (500 mg, 52.8%) as a yellow solid. MS: 483.8 [M+H] + .
[0906] Step 9: Synthesis of compound 61j
[0907]
[0908] Compound 61i (500 mg, 1.04 mmol) was dissolved in tetrahydrofuran (5 ml) and water (2.5 ml), lithium hydroxide (144 mg, 6.24 mmol) was added, and the mixture was stirred at room temperature for 16 hours. The reaction was complete as monitored by LCMS. The tetrahydrofuran in the reaction solution was dried by spin drying, and after adjusting the pH to 2 to 3 with 2N hydrochloric acid, the reaction solution was filtered to obtain compound 61j (500 mg, 52.8%) as a light yellow solid. MS: 440.8 [M+H] + .
[0909] Step 10: Synthesis of compound 61
[0910]
[0911] Compound 61j (30 mg, 0.068 mmol) was dissolved in tetrahydrofuran (1 ml) and N,N-dimethylformamide (0.5 ml), and N,N-diisopropylethylamine (17.5 mg, 0.136 mmol) and O-(7-azabenzotriazole)-N,N,N`,N`-tetramethyluronium hexafluorophosphate (31 mg, 0.082 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. o-allylhydroxylamine hydrochloride (11.12 mg, 0.102 mmol) was added to the above reaction system, and then the reaction system was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was separated and purified by C18 reverse phase column chromatography (acetonitrile: water = 40%) to obtain compound 61 (20 mg, purity 98%) as a white solid. MS: 496.8 [M+H]+ . 1 H NMR (600MHz, DMSO-d6): δppm 11.92(s,1H), 10.29(s,1H), 8.96(s,1H), 8.75(d,1H), 8.54(s,1H), 8.44(d,1H), 7.75(t,1H), 7.24 (m,1H), 6.94(s,1H), 5.94-6.04(m,1H), 5.24-5.45(m,3H), 4.42(d,1H), 3.33(s,3H), 1.58(d,3H).
[0912] Embodiment 62:
[0913] (S)-5-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)-N-(cyclopropylmethoxy)-3-(difluoromethyl)picolinamide 62
[0914]
[0915] Step 1: Synthesis of compound 62
[0916]
[0917] Compound 61j (30 mg, 0.068 mmol) was dissolved in tetrahydrofuran (1 ml) and N,N-dimethylformamide (0.5 ml), and N,N-diisopropylethylamine (17.54 mg, 0.136 mmol) and O-(7-azabenzotriazole)-N,N,N`,N`-tetramethyluronium hexafluorophosphate (31 mg, 0.082 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. O-(cyclopropylmethyl)hydroxylamine (8.87 mg, 0.102 mmol) was added to the above reaction system, and then the reaction system was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was separated and purified by C18 reverse phase column chromatography (acetonitrile: water = 40%) to obtain compound 62 (13 mg, purity 98%) as a white solid. MS: 510.9 [M+H] + .
[0918] Embodiment 63:
[0919] (S)-5-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)-3-(difluoromethyl)-N-(furan-3-ylmethoxy)picolinamide 63
[0920]
[0921] Step 1: Synthesis of compound 63
[0922]
[0923] Compound 61j (30 mg, 0.068 mmol) was dissolved in tetrahydrofuran (1 ml) and N,N-dimethylformamide (0.5 ml), and N,N-diisopropylethylamine (17.54 mg, 0.136 mmol) and O-(7-azabenzotriazole)-N,N,N`,N`-tetramethyluronium hexafluorophosphate (31 mg, 0.082 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. o-(furan-3-ylmethyl)hydroxylamine (11.5 mg, 0.102 mmol) was added to the above reaction system, and then the reaction system was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was separated and purified by C18 reverse phase column chromatography (acetonitrile: water = 40%) to obtain compound 63 (15 mg, purity 98%) as a white solid. MS: 536.8 [M+H] + .
[0924] Embodiment 64:
[0925] (S)-5-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)-3-(difluoromethyl)-N-(propargylmethoxy)picolinamide 64
[0926]
[0927] Step 1: Synthesis of compound 64
[0928]
[0929] Compound 61j (30 mg, 0.068 mmol) was dissolved in tetrahydrofuran (1 ml) and N,N-dimethylformamide (0.5 ml), and N,N-diisopropylethylamine (17.54 mg, 0.136 mmol) and O-(7-azabenzotriazole)-N,N,N`,N`-tetramethyluronium hexafluorophosphate (31 mg, 0.082 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. O-(propyl-2-alkynyl-1-yl)hydroxylamine (7.2 mg, 0.102 mmol) was added to the above reaction system, and then the reaction system was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was separated and purified by C18 reverse phase column chromatography (acetonitrile: water = 40%) to obtain compound 64 (11 mg, purity 98%) as a white solid. MS: 494.8 [M+H] + . 1H NMR (600MHz, DMSO-d6): δppm12.06(s,1H), 10.30(s,1H), 8.96(s,1H), 8.76(d,1H), 8.54(d,1H), 8.46(d ,1H), 7.74(t,1H), 6.94(s,1H), 5.40-5.45(q,1H), 4.58(d,2H), 3.60(t,1H), 3.33(s,3H), 1.58(d,3H).
[0930] Embodiment 65:
[0931] (S)-N-(2-Butynyl-methoxy)-5-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)-3-(difluoromethyl)picolinamide 65
[0932]
[0933] Step 1: Synthesis of compound 65
[0934]
[0935] Compound 61j (50 mg, 0.12 mmol) was dissolved in tetrahydrofuran (2 ml) and N,N-dimethylformamide (1 ml), and N,N-diisopropylethylamine (31 mg, 0.24 mmol) and O-(7-azabenzotriazole)-N,N,N`,N`-tetramethyluronium hexafluorophosphate (53.2 mg, 0.14 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. o-(but-2-yn-1-yl)hydroxylamine (15.3 mg, 0.18 mmol) was added to the above reaction system, and then the reaction system was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was separated and purified by C18 reverse phase column chromatography (acetonitrile: water = 40%) to obtain compound 65 (18 mg, purity 98%) as a white solid. MS: 508.8 [M+H] + .
[0936] Embodiment 66:
[0937] (S)-5-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)-n-methoxy-3-(trifluoromethyl)picolinamide 66
[0938]
[0939] Step 1: Synthesis of compound 66b
[0940]
[0941] (S)-2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidine-6-carboxylic acid 1d (417 mg, 1.63 mmol) was dissolved in 1,4-dioxane (2 mL), triethylamine (495 mg, 4.89 mmol) and diphenylphosphoryl azide (539 mg, 1.96 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. Compound 1 (359 mg, 1.63 mmol) was added to the above reaction system, and then the reaction system was stirred at 100 ° C for 1 hour. LCMS monitored the reaction to be complete. The reaction solution was poured into 50 mL of water, extracted with ethyl acetate (20 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 66b (660 mg, 85.8%) as a light yellow solid. MS: 473.8 [M+H] + .
[0942] Step 2: Synthesis of compound 66c
[0943]
[0944] Compound 66b (660 mg, 1.40 mmol) was dissolved in tetrahydrofuran (4 mL) and water (2 mL), lithium hydroxide (161 mg, 7 mmol) was added, and the mixture was stirred at room temperature for 16 hours. LCMS monitored the reaction to be complete. The pH of the reaction solution was adjusted to 2-3, and the solid was filtered and collected to obtain compound 66c (580 mg, 90.5%) as a white solid. MS: 459.7 [M+H] + .
[0945] Step 3: Synthesis of compound 66
[0946]
[0947] Compound 66c (50 mg, 0.109 mmol) was dissolved in tetrahydrofuran (2 mL) and N,N-dimethylformamide (1 mL), and N,N-diisopropylethylamine (28 mg, 0.218 mmol) and 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (50 mg, 0.131 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. O-methylhydroxylamine hydrochloride (14 mg, 0.164 mmol) was added to the above reaction system, and the mixture was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was separated and purified by C18 reverse phase column chromatography (acetonitrile: water = 40%) to obtain compound 66 (30 mg, 56.5%) as a white solid. MS: 488.8 [M+H] + .1 H NMR (600MHz, DMSO-d6): δppm 10.39(br,1H), 8.95(s,1H), 8.81(d,1H), 8.65(br,1H), 8.51(d,1H), 7.23(d ,1H), 6.95(s,1H), 5.40-5.44(q,1H), 3.70(s,3H), 3.32(s,3H), 1.58(d,3H).
[0948] Embodiment 67:
[0949] (S)-5-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)-N-ethoxy-3-(trifluoromethyl)picolinamide 67
[0950]
[0951] Step 1: Synthesis of compound 67
[0952]
[0953] Compound 66c (50 mg, 0.109 mmol) was dissolved in tetrahydrofuran (0.8 ml) and N,N-dimethylformamide (0.4 ml), and N,N-diisopropylethylamine (28.15 mg, 0.218 mmol) and O-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (49.75 mg, 0.131 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. O-ethylhydroxylamine hydrochloride (15.98 mg, 0.164 mmol) was added to the above reaction system, and then the reaction system was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was separated and purified by C18 reverse phase column chromatography (acetonitrile: water = 52%) to obtain compound 67 (14 mg, 26%) as a white solid. MS: 502.8 [M+H] + .
[0954] Embodiment 68:
[0955] (S)-5-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)-3-(trifluoromethyl)-N-(propargylmethoxy)picolinamide 68
[0956]
[0957] Step 1: Synthesis of compound 68
[0958]
[0959] Compound 66c (50 mg, 0.11 mmol) was dissolved in tetrahydrofuran (2 ml) and N,N-dimethylformamide (1 ml), and N,N-diisopropylethylamine (28.2 mg, 0.22 mmol) and O-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (49.8 mg, 0.13 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. O-(propyl-2-alkynyl-1-yl)hydroxylamine hydrochloride (17.7 mg, 0.16 mmol) was added to the above reaction system, and then the reaction system was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was separated and purified by C18 reverse phase column chromatography (acetonitrile: water = 40%) to obtain compound 68 (24 mg, purity 98%) as a white solid. MS: 512.8 [M+H] + .
[0960] Embodiment 69:
[0961] (S)-1-(5-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)-3-(trifluoromethyl)pyridin-2-yl)-N-methoxy-1h-pyrazole-4-carboxamide 69
[0962]
[0963] Step 1: Synthesis of compound 69c
[0964]
[0965] Compound 69b (3 g, 13.2 mmol) was dissolved in N,N-dimethylformamide (50 ml), cesium carbonate (6.5 g, 19.8 mmol) and 1H-pyrazole-4-carboxylic acid methyl ester 69a (1.8 g, 14.5 mmol) were added, and the mixture was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was poured into 100 mL of water, extracted with ethyl acetate (60 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 3:1) to obtain compound 69c (2 g, 47.9%) as a light yellow solid. MS: 317.2 [M+H] + .
[0966] Step 2: Synthesis of compound 69d
[0967]
[0968] Compound 69c (2 g, 6.33 mmol) was dissolved in tetrahydrofuran (10 ml), and added dropwise to a methanol / water mixed solution of iron powder (3.5 g, 63.3 mmol) and ammonium chloride (2.7 g, 50.64 mmol) (methanol 20 ml, water 10 ml), and the mixture was stirred at 65 ° C for 1 hour. LCMS monitored the reaction to be complete. The reaction solution was poured into 200 mL of water, extracted with ethyl acetate (30 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 69d (1.1 g, 60.3%) as a dark yellow solid. MS: 287.2 [M+H] + .
[0969] Step 3: Synthesis of compound 69e
[0970]
[0971] (S)-2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidine-6-carboxylic acid 1d (200 mg, 0.78 mmol) was dissolved in 1,4-dioxane (2 ml), triethylamine (238 mg, 2.34 mmol) and diphenylphosphoryl azide (52.8 mg, 0.94 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. Compound 69d (224 mg, 0.78 mmol) was added to the above reaction system, and then the reaction system was stirred at 100 ° C for 1 hour. LCMS monitored the reaction to be complete. The reaction solution was poured into 50 mL of water, extracted with ethyl acetate (20 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 4 (220 mg, 51.3%) as a light yellow solid. MS: 539.8 [M+H] + .
[0972] Step 4: Synthesis of compound 69f
[0973]
[0974] Compound 69e (220 mg, 0.41 mmol) was dissolved in tetrahydrofuran (2 ml) and water (1 ml), lithium hydroxide (59 mg, 2.46 mmol) was added, and the mixture was stirred at room temperature for 16 hours. The reaction was complete by LCMS monitoring. The pH of the reaction solution was adjusted to 2-3, and the solid was filtered and collected to obtain compound 69f (100 mg, 47.5%) as a white solid. MS: 525.8 [M+H] + .
[0975] Step 5: Synthesis of compound 69
[0976]
[0977] Compound 69f (50 mg, 0.098 mmol) was dissolved in tetrahydrofuran (2 ml) and N,N-dimethylformamide (1 ml), and N,N-diisopropylethylamine (25.4 mg, 0.197 mmol) and O-(7-azabenzotriazole)-N,N,N`,N`-tetramethyluronium hexafluorophosphate (44.9 mg, 0.12 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. O-methylhydroxylamine hydrochloride (11.9 mg, 0.15 mmol) was added to the above reaction system, and then the reaction system was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was separated and purified by C18 reverse phase column chromatography (acetonitrile: water = 40%) to obtain compound 69 (20 mg, purity 97%) as a white solid. MS: 554.8 [M+H] + . 1 H NMR (600MHz, DMSO-d6): δppm 11.62(br,1H), 10.47(br,1H), 8.95(s,1H), 8.82(d,1H), 8.73(br,1H), 8.66(d,1H), 8.64( s,1H), 8.10(s,1H), 6.96(s,1H), 5.40-5.44(q,1H), 3.72(s,3H), 3.32(s,3H), 1.58(d,3H).
[0978] Embodiment 70:
[0979] (S)-2-(5-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)-3-(trifluoromethyl)pyridin-2-yl)-N-methoxy-2h-1,2,3-triazole-4-carboxamide 70
[0980]
[0981] Step 1: Compound 70c
[0982]
[0983] Compound 70b (1 g, 3.7 mmol) was dissolved in N, N-dimethylformamide (10 ml), cesium carbonate (1.8 g, 5.5 mmol) and 1H-pyrazole-4-carboxylic acid methyl ester 70a (517 mg, 4.07 mmol) were added, and the mixture was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was poured into 100 mL of water, extracted with ethyl acetate (60 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 3:1) to obtain compound 70c (960 mg, 81.8%) as a light yellow solid. MS: 318.1 [M+H] + .
[0984] Step 2: Synthesis of compound 70d
[0985]
[0986] Compound 70c (500 mg, 1.58 mmol) was dissolved in tetrahydrofuran (5 ml), and added dropwise to a methanol / water mixed solution of iron powder (883 mg, 15.7 mmol) and ammonium chloride (675 mg, 12.6 mmol) (methanol 10 ml, water 5 ml), and the mixture was stirred at 65 ° C for 1 hour. LCMS monitored the reaction to be complete. The reaction solution was poured into 100 mL of water, extracted with ethyl acetate (30 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 70d (160 mg, 35%) as a dark yellow solid. MS: 288.2 [M+H] + .
[0987] Step 3: Synthesis of compound 70e
[0988]
[0989] (S)-2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidine-6-carboxylic acid 1d (142 mg, 0.56 mmol) was dissolved in 1,4-dioxane (2 ml), triethylamine (169 mg, 1.67 mmol) and diphenylphosphoryl azide (184 mg, 0.67 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. Compound 70d (160 mg, 0.56 mmol) was added to the above reaction system, and then the reaction system was stirred at 100 ° C for 1 hour. LCMS monitored the reaction to be complete. The reaction solution was poured into 50 mL of water, extracted with ethyl acetate (20 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 70e (160 mg, 52.8%) as a light yellow solid. MS: 540.8 [M+H] + .
[0990] Step 4: Synthesis of compound 70f
[0991]
[0992] Compound 70e (160 mg, 0.297 mmol) was dissolved in tetrahydrofuran (2 ml) and water (1 ml), lithium hydroxide (42.7 mg, 1.78 mmol) was added, and the mixture was stirred at room temperature for 16 hours. The reaction was complete as monitored by LCMS. The pH of the reaction solution was adjusted to 2-3, and the solid was filtered and collected to obtain compound 70f (80 mg, 51.2%) as a white solid. MS: 526.8 [M+H] + .
[0993] Step 5: Synthesis of Compound 70
[0994]
[0995] Compound 70f (50 mg, 0.098 mmol) was dissolved in tetrahydrofuran (2 ml) and N,N-dimethylformamide (1 ml), and N,N-diisopropylethylamine (25.4 mg, 0.197 mmol) and O-(7-azabenzotriazole)-N,N,N`,N`-tetramethyluronium hexafluorophosphate (44.9 mg, 0.12 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. O-methylhydroxylamine hydrochloride (11.9 mg, 0.15 mmol) was added to the above reaction system, and then the reaction system was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was separated and purified by C18 reverse phase column chromatography (acetonitrile: water = 40%) to obtain compound 70 (16 mg, purity 98%) as a white solid. MS: 555.8 [M+H] + .
[0996] Embodiment 71:
[0997] (S)-1-(5-(3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)ureido)-3-(trifluoromethyl)pyridin-2-yl)-N-methoxy-1h-pyrazole-3-carboxamide 71
[0998]
[0999] In the first and second steps, the synthesis steps of 71c and 71d are the same as the synthesis of 69c and 69d described above, except that 69a in Example 69: Change to 71a:
[1000] Step 3: Synthesis of compound 71e
[1001]
[1002] (S)-2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidine-6-carboxylic acid 1d (200 mg, 0.782 mmol) was dissolved in 1,4-dioxane (2 mL), triethylamine (237 mg, 2.346 mmol) and diphenylphosphoryl azide (258 mg, 0.938 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. Compound 71d (224 mg, 0.782 mmol) was added to the above reaction system, and then the reaction system was stirred at 100 ° C for 1 hour. LCMS monitored the reaction to be complete. The reaction solution was poured into 50 mL of water, extracted with ethyl acetate (20 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 71e (200 mg, 47.4%) as a light yellow solid. MS: 539.8 [M+H] + .
[1003] Step 4: Synthesis of compound 71f
[1004]
[1005] Compound 71e (200 mg, 0.372 mmol) was dissolved in tetrahydrofuran (2 mL) and water (1 mL), lithium hydroxide (54 mg, 2.232 mmol) was added, and the mixture was stirred at room temperature for 16 hours. The reaction was complete as monitored by LCMS. The pH of the reaction solution was adjusted to 2-3, and the solid was filtered and collected to obtain compound 71f (150 mg, 77.0%) as a white solid. MS: 525.8 [M+H] + .
[1006] Step 5: Synthesis of Compound 71
[1007]
[1008] Compound 71f (150 mg, 0.286 mmol) was dissolved in tetrahydrofuran (2 mL) and N,N-dimethylformamide (1 mL), and N,N-diisopropylethylamine (74 mg, 0.572 mmol) and 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (130 mg, 0.343 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. O-methylhydroxylamine hydrochloride (36 mg, 0.429 mmol) was added to the above reaction system, and the mixture was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was separated and purified by C18 reverse phase column chromatography (acetonitrile: water = 40%) to obtain compound 71 (100 mg, 63.2%) as a white solid. MS: 554.8 [M+H] + . 1 H NMR (600MHz, DMSO-d6): δppm 11.63(br,1H), 10.43(br,1H), 8.97(s,1H), 8.82(d,1H), 8.73(br,1H), 8.69(d,1H), 8.66(s,1H), 8.28(s,1H), 6.96(s,1H), 6.90(d,1H), 5.42-5.45(q,1H), 3.69(s,3H), 3.32(s,3H), 1.58(d,3H).
[1009] Embodiment 72:
[1010] (S)-1-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)-3-(6-3-(3-hydroxy-3-methylbutyl-1-methoxy-1-yl)-1-hydrogen-pyrazol-1-yl)-5-(trifluoromethyl)-pyridin-3-yl)urea 72
[1011]
[1012] Step 1: Synthesis of compound 72c
[1013]
[1014] Compound 70b (1 g, 4.42 mmol) and 3-iodopyrazole 72a (942 mg, 4.86 mmol) were dissolved in NN-dimethylformamide (10 ml), cesium carbonate (2.16 g, 6.63 mmol) was added, and the mixture was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was poured into 100 mL of H 2 O, extracted with ethyl acetate (60 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 3:1) to obtain compound 72c (1.1 g, 64.7%) as a light yellow solid. MS: 385.0 [M+H] + .
[1015] Step 2: Synthesis of compound 72d
[1016]
[1017] Compound 72c (200 mg, 0.52 mmol) was dissolved in 1,4-dioxane (4 ml), and cuprous iodide (30 mg, 0.16 mmol), 2-methylbut-3-yn-2-ol (65.6 mg, 0.78 mmol), triethylamine (0.4 ml) and bistriphenylphosphine palladium dichloride (36.8 mg, 0.052 mmol) were added, and the mixture was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was poured into 50 mL of H 2 O, extracted with ethyl acetate (30 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 2: 1) to obtain compound 72d (170 mg, 96%) as a dark yellow solid. MS: 341.2 [M+H] + .
[1018] Step 3: Synthesis of compound 72e
[1019]
[1020] Compound 72d (170 mg, 0.5 mmol) was dissolved in tetrahydrofuran (1 ml) and added dropwise to a methanol / water mixed solution (2 ml methanol, 1 ml water) of iron powder (140 mg, 2.5 mmol) and ammonium chloride (107 mg, 2 mmol). The mixture was stirred at 65 °C for 1 hour. The reaction was complete after LCMS monitoring. The reaction solution was poured into 50 mL H 2O, extracted with ethyl acetate (30 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 72e (130 mg, 84%) as a dark yellow solid. MS: 311.2 [M+H] + .
[1021] Step 4: Synthesis of Compound 72
[1022]
[1023] (S)-2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidine-6-carboxylic acid 1d (40.6 mg, 0.16 mmol) was dissolved in 1,4-dioxane (1 ml), triethylamine (48.5 mg, 0.48 mmol) and diphenylphosphoryl azide (52.8 mg, 0.19 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. Compound 72e (50 mg, 0.16 mmol) was added to the above reaction system, and then the reaction system was stirred at 100°C for 1 hour. LCMS monitored the reaction to be complete. The reaction solution was separated and purified by C18 reverse phase column chromatography (acetonitrile: water = 40%) to obtain compound 72 (32 mg, purity 92%), which was purified by HPLC and lyophilized to obtain the product as a white solid (16 mg, purity 98%). MS: 563.9 [M+H] + . 1 H NMR (600MHz, DMSO-d6): δppm 10.38(br,1H), 8.96(s,1H), 8.78(d,1H), 8.66(d,1H), 8.27(d,1H), 6.95(s,1H), 6 .67(d,1H), 2.59(s,1H), 5.41-5.44(q,1H), 3.32(s,3H), 1.60(d,3H), 1.47(s,6H).
[1024] Embodiment 73:
[1025] 2'-Chloro-N-(5-chloro-6-((prop-2-yn-1-yloxy)carbamoyl)pyridin-3-yl)spiro[cyclopropane-1,8'-pyrazolo[1,5-a]pyrrolo[2,3-e]pyrimidine]-6'(7'H)-carboxamide 73
[1026]
[1027] Step 1: Synthesis of compound 73c
[1028]
[1029] Compound 73a (20.0 g, 104 mmol) was dissolved in DMF, potassium carbonate powder (28.9 g, 208 mmol) was added at room temperature, and then 73b (25.4 g, 136 mmol) was added dropwise, and the reaction solution was heated to 38°C and reacted for 16 hours. TLC monitored the reaction to be complete. The reaction solution was naturally cooled to room temperature, poured into 1 L of water, extracted with ethyl acetate (300 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product, which was separated and purified by column chromatography, ethyl acetate: petroleum ether ~35%, to obtain 17.6 g of white solid compound 73c, MS: 218.2 [M+H] + .
[1030] Step 2: Synthesis of compound 73e
[1031]
[1032] Compound 73c (17.6 g, 75.6 mmol) was dissolved in toluene solution, TosOH (917 mg, 5.3 mmol) was added, and then compound 73d (9.4 g, 151 mmol) was added dropwise. The reaction solution was heated to 115°C for 16 hours, and the water produced during the reaction was removed by a water separator. LCMS monitored the reaction to be complete. The reaction solution was naturally cooled to room temperature, poured into 500 mL of water, extracted with ethyl acetate (300 mL*4), the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product, which was separated and purified by column chromatography, ethyl acetate: petroleum ether ~40%, to obtain yellow oily compound 73e, 11.4 g, MS: 262.3 [M+H] + .
[1033] Step 3: Synthesis of compound 73f
[1034]
[1035] Compound 73e (6.0 g, 22.9 mmol) was dissolved in 1,4-dioxane solution, and Br2 (dissolved in 20 mL 1,4-dioxane) was added dropwise under ice-water bath conditions. After the addition was complete, the reaction was allowed to react at room temperature for 5 hours. LCMS monitored the reaction to be complete. After the reaction was complete, an aqueous solution of sodium sulfite was added dropwise to the reaction solution to quench the reaction, and ethyl acetate was extracted (200 ml * 3). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product, which was separated and purified by column chromatography, ethyl acetate: petroleum ether ~ 40%, to obtain 4.2 g of yellow oily compound 73f, MS: 341.2 [M+H] + .
[1036] Step 4: Synthesis of compound 73g
[1037]
[1038] Compound 73f (4.2 g, 12.35 mmol) was dissolved in ultra-dry DMF solution, and NaH (494 mg, 14.82 mmol) was slowly added in an ice-water bath, and then reacted for 2 hours in an ice bath. TLC monitored the reaction to be complete. The reaction solution was poured into a saturated aqueous solution of ammonium chloride, extracted with ethyl acetate (50 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product, which was purified and separated by column chromatography, ethyl acetate: petroleum ether ~45%, to obtain a color-changing solid compound 73g, MS: 260.3 [M+H] + .
[1039] Step 5: Synthesis of compound 73h
[1040]
[1041] Compound 73g (500 mg) was dissolved in ultra-dry tetrahydrofuran solution, and lithium aluminum tetrahydride was slowly added under an ice-water bath, and then the temperature was raised to 65°C and the reaction was carried out for 4 hours. The reaction was completed by LCMS monitoring. After the reaction was complete, 5 mL of water, 5 mL of 15% NaOH aqueous solution, and 15 mL of water were added dropwise to the system, and then filtered, and the filter cake was washed more than 3 times. The filtrate was extracted with ethyl acetate (30 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product, which was separated and purified by column chromatography to obtain 280 mg of white solid compound 73h, MS: 246.3 [M+H] + .
[1042] Step 6: Synthesis of compound 73i
[1043]
[1044] Compound 73i (1.5 g) was dissolved in acetone solution, 5 mL of 1 M hydrochloric acid solution was added dropwise thereto, the reaction solution was heated to reflux, and the reaction was allowed to proceed for 16 hours. LCMS monitored the reaction to be complete. The reaction solution was naturally cooled to room temperature, poured into a sodium bicarbonate aqueous solution, extracted with ethyl acetate (30 mL*3), the organic phases obtained were combined, dried over anhydrous sodium sulfate, and the crude product obtained by concentration was separated and purified by column chromatography to obtain 1.0 g of white solid compound 73i, MS: 202.2 [M+H] + .
[1045] Step 7: Synthesis of compound 73j
[1046]
[1047] Compound 73i (1.0 g) was dissolved in ethanol, Pd / C (10 wt%) was added, hydrogen was replaced three times, and then reacted at 45°C for 16 hours. LCMS monitored the disappearance of the starting material. The reaction solution was naturally cooled to room temperature, filtered, and the filter cake was fully washed. The filtrate was concentrated to obtain a crude product, Compound 73j, 650 mg. The crude product was used directly in the next step without purification.
[1048] Step 8: Synthesis of compound 73k
[1049]
[1050] Compound 73j (5.5 g, 49.5 mmol) was dissolved in tetrahydrofuran (40 ml) and water (20 ml), and sodium bicarbonate (1.25 g, 148.5 mmol) and di-tert-butyl dicarbonate (1.3 g, 59.4 mmol) were added and stirred at room temperature for 3 hours. LCMS monitored the reaction to be complete. The reaction solution was poured into water (250 ml), extracted with ethyl acetate, separated, the organic phases were combined, dried over anhydrous sodium sulfate, concentrated and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 2: 1) to obtain compound 73k (6.5 g, 62.2%) as a yellow solid. MS: 212.2 [M+H] + .
[1051] Step 9: Synthesis of compound 73l
[1052]
[1053] Compound 73k (6.5 g, 30.8 mmol) was dissolved in N,N-dimethylformamide (50 ml), and N,N-dimethylformamide dimethyl acetal (6.6 g, 55.4 mmol) was added and stirred at 90°C for 2 hours. The reaction was completed by LCMS monitoring. The reaction solution was concentrated to obtain compound 73l (7 g, 85%) as a dark yellow liquid. MS: 267.3 [M+H] + .
[1054] Step 10: Synthesis of compound 73n
[1055]
[1056] Compound 73l (7 g, 26.3 mmol) was dissolved in ethanol (70 ml), acetic acid (1 ml) and 3-chloropyrazole-5-amine 73m (3.7 g, 31.56 mmol) were added, and the mixture was stirred at 80 ° C for 3 hours. LCMS monitored the reaction to be complete. The reaction solution was poured into water (250 ml) for quenching, extracted with ethyl acetate (200 mL * 3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 2: 1) to obtain compound 73n (4.5 g, 53.2%) as a yellow solid. MS: 321.7 [M + H] + Step 11: Synthesis of compound 73o
[1057]
[1058] Compound 73n (500 mg, 1.56 mmol) was dissolved in dichloromethane (5 ml), trifluoroacetic acid (2 ml) was added, and the mixture was stirred at room temperature for 3 hours. LCMS monitored the reaction to be complete. The reaction solution was poured into water (50 ml) for quenching, extracted with dichloromethane (20 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 73o (200 mg, 57.7%) as a light yellow solid. MS: 221.6 [M+H] + .
[1059] Step 12: Synthesis of compound 73q
[1060]
[1061] Compound 73o (200 mg, 0.9 mmol) was dissolved in tetrahydrofuran (2 ml), N, N-diisopropylethylamine (140 mg, 1.08 mmol) and triphosgene (134.3 mg, 0.45 mmol), and the mixture was stirred at room temperature for 30 minutes. 5-amino-3-chloropicolinic acid methyl ester (168.3 mg, 0.9 mmol) and N, N-diisopropylethylamine (350 mg, 2.7 mmol) were added and stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was poured into water (50 ml) for quenching, extracted with ethyl acetate (20 mL * 3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 3: 1) to obtain compound 73q (200 mg, 51.1%) as a light yellow solid. MS: 434.2 [M + H] + Step 13: Synthesis of compound 73r
[1062]
[1063] Compound 73q (100 mg, 0.23 mmol) was dissolved in tetrahydrofuran (2 ml) and water (1 ml), lithium hydroxide (31.7 mg, 1.38 mmol) was added, and the mixture was stirred at room temperature for 16 hours. LCMS monitored the reaction to be complete. The pH of the reaction solution was adjusted to 2 to 3, and the reaction solution was filtered to obtain compound 73r (30 mg, 30.4%) as a white solid. MS: 420.2 [M+H] + .
[1064] Step 13: Synthesis of Compound 73
[1065]
[1066] Compound 73r (30 mg, 0.07 mmol) was dissolved in tetrahydrofuran (1 ml) and N,N-dimethylformamide (0.5 ml), and N,N-diisopropylethylamine (17.5 mg, 0.14 mmol) and O-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (31 mg, 0.084 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. O-(propyl-2-alkynyl-1-yl)hydroxylamine hydrochloride (11.12 mg, 0.105 mmol) was added to the above reaction system, and then the reaction system was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was separated and purified by C18 reverse phase column chromatography (acetonitrile: water = 40%) to obtain compound 73 (8 mg, purity 98%) as a white solid. MS: 473.2 [M+H] + .
[1067] Embodiment 74:
[1068] 2'-Chloro-N-(5-chloro-6-(2h-1,2,3-triazol-2-yl)pyridin-3-yl)spiro[cyclopropane-1,8'-pyrazolo[1,5-a]pyrrolo[2,3-e]pyrimidine]-6'(7'H)-carboxamide 74
[1069]
[1070] Step 1: Synthesis of compound 74
[1071]
[1072] 5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine (26.5 mg, 0.14 mmol) was dissolved in tetrahydrofuran (1 ml), N,N-diisopropylethylamine (21 mg, 0.16 mmol) and triphosgene (20 mg, 0.07 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. Compound 73o (30 mg, 0.14 mmol) and N,N-diisopropylethylamine (52.5 mg, 0.4 mmol) were dissolved in tetrahydrofuran (0.5 ml) and added to the above reaction system, and then the reaction system was stirred at room temperature for 1 hour. LCMS monitored the reaction to be complete. The reaction solution was separated and purified by C18 reverse phase column chromatography (acetonitrile: water = 40%) to obtain compound 74 (9 mg, purity 98%) as a white solid. MS: 443.2 [M+H] + . 1 H NMR (600MHz, DMSO-d6): δppm 9.55(s,1H), 8.87(s,1H), 8.76(s,1H), 8.54(d,1H), 8.17(s,2H), 6.64(s,1H), 4.38(s,2H), 1.41-1.47(m,4H).
[1073] Embodiment 75:
[1074] 2'-Chloro-N-(2-(trifluoromethyl)pyridin-4-yl)spiro[cyclopropane-1,8'-pyrazolo[1,5-a]pyrrolo[2,3-e]pyrimidine]-6'(7'H)-carboxamide 75
[1075]
[1076] Step 1: Synthesis of Compound 75
[1077]
[1078] 2-(Trifluoromethyl)pyridine-4-amine (22 mg, 0.14 mmol) was dissolved in tetrahydrofuran (1 ml), N, N-diisopropylethylamine (21 mg, 0.16 mmol) and triphosgene (20 mg, 0.07 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. Compound 73o (30 mg, 0.14 mmol) and N, N-diisopropylethylamine (52.5 mg, 0.4 mmol) were dissolved in tetrahydrofuran (0.5 ml) and added to the above reaction system, and then the reaction system was stirred at room temperature for 1 hour. LCMS monitored the reaction to be complete. The reaction solution was separated and purified by C18 reverse phase column chromatography (acetonitrile: water = 40%) to obtain compound 75 (12 mg, purity 98%) as a white solid. MS: 409.7 [M+H] + .1 H NMR (600MHz, DMSO-d6): δppm 9.61(s,1H), 8.86(s,1H), 8.62(d,1H), 8.17(d,1H), 7.92-7.94(dd,1H), 6.64(s,1H), 4.39(s,2H), 1.39-1.46(m,4H).
[1079] Embodiment 76:
[1080] (R)-2-Chloro-N-(5-chloro-6-((cyclopropylmethoxy)carbamoyl)pyridin-3-yl)-8-methyl-8-(trifluoromethyl)-7,8-dihydro-6H-pyrazolo[1,5-a]pyrrolo[2,3-e]pyrimidine-6-carboxamide 76
[1081]
[1082]
[1083] Step 1: Synthesis of compound 76b
[1084]
[1085] In a three-necked flask, compound 76a (60 g, 310.9 mmol) was dissolved in chloroform (600 ml), and triethylamine (62.8 g, 621.8 mmol) was added. Propionyl chloride (34.3 g, 373.1 mmol) was dissolved in chloroform (25 ml) and added dropwise to the reaction solution at 0 ° C. The mixture was stirred at room temperature for 1 hour. LCMS monitored the reaction to be complete. The reaction solution was poured into water (1000 ml), extracted with dichloromethane (200 mL * 3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 2: 1) to obtain compound 76b (70 g, 90.4%) as a light yellow oily liquid. MS: 250.3 [M + H] + .
[1086] Step 2: Synthesis of compound 76c
[1087]
[1088] In a three-necked flask, sodium hydride (4g, 168.7mmol) was dissolved in tetrahydrofuran (400ml). Compound 76b (35g, 140.6mmol) was dissolved in tetrahydrofuran (350ml), added dropwise to the reaction system in the three-necked flask at 75°C, and stirred at 75°C for 12 hours. LCMS monitored the reaction to be complete. After the reaction solution was cooled to room temperature, the pH was adjusted to 2 to 3, and extracted with ethyl acetate (200mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, washed and filtered with petroleum ether to obtain a solid, and the mother liquor was separated and purified by column chromatography (petroleum ether: ethyl acetate = 2:1) to obtain compound 76c (17g, 59.2%) as a light yellow solid. MS: 204.2[M+H] + .
[1089] Step 3: Synthesis of compound 76e
[1090]
[1091] Compound 76c (17 g, 83.3 mmol) was dissolved in N, N-dimethylformamide (350 ml), sodium hydride (2 g, 83.3 mmol) was added to the reaction solution at 0 ° C, and the mixture was stirred at room temperature for 0.5 hours. After the mixture was cooled to -55 ° C, 5-trifluoromethyl-5H-dibenzothiophene-5-ium trifluoromethanesulfonate (33.5 g, 83.3 mmol) was slowly added and stirred at -55 ° C for 1 hour. LCMS monitored the reaction to be complete. After the reaction solution was warmed to room temperature, it was slowly poured into an ice-water bath (1000 ml) to quench, extracted with ethyl acetate (1000 mL * 3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 4: 1) to obtain compound 76e (20.5 g, 90.5%) as a light yellow oily liquid. MS: 272.2 [M + H] + .
[1092] Step 4: Synthesis of compound 76f
[1093]
[1094] Compound 76e (20.5 g, 75.6 mmol) was dissolved in tetrahydrofuran (400 ml), and lithium aluminum hydride (181.6 ml, 453.9 mmol, 2.5 M tetrahydrofuran solution) was added at 0°C, and the mixture was heated to 80°C and stirred for 12 hours. LCMS monitored the reaction to be complete. The reaction solution was cooled to 0°C, and water (181.6 ml), sodium hydroxide solution (15%, 181.6 ml) and water (181.6 ml) were slowly added in sequence while stirring to quench, and the reaction system was stirred at room temperature for 10 minutes, and the reaction solution was filtered through diatomaceous earth. After the filtrate was concentrated, the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 3:1) to obtain compound 76f (17.6 g, 89.9%) as a colorless oily liquid. MS: 260.2 [M+H] + .
[1095] Step 5: Synthesis of compound 76g
[1096]
[1097] Compound 76f (17.6 g, 67.9 mmol) was dissolved in ethanol (540 ml), diluted hydrochloric acid (70 ml, 1 M) and palladium carbon (4 g, 10%) were added, the reaction system was replaced with nitrogen three times, and then replaced with hydrogen, and stirred at room temperature for 18 hours. LCMS monitored the reaction to be complete. Dilute hydrochloric acid (70 ml, 1 M) was added while stirring at room temperature. After stirring for 15 minutes, the solid was filtered off and the filtrate was concentrated to obtain compound 76g (14 g, 99%) as a light yellow solid. MS: 170.1 [M+H] + .
[1098] Step 6: Synthesis of compound 76h
[1099]
[1100] Compound 76g (14 g, 67.9 mmol) was dissolved in tetrahydrofuran (400 ml) and water (100 mL), sodium bicarbonate was added, and then di-tert-butyl dicarbonate (22.2 g, 101.9 mmol) was added, and the mixture was stirred at room temperature for 3 hours. LCMS monitored the reaction to be complete. The reaction solution was concentrated and the residue was purified by column chromatography (petroleum ether: ethyl acetate = 4: 1) to obtain compound 76h (12.8 g, 70.1%) as a white solid. MS: 270.2 [M+H] + .
[1101] Step 7: Synthesis of compound 76i
[1102]
[1103] Compound 76h (12.8 g, 47.6 mmol) was dissolved in dichloromethane (350 ml), pyridinium chlorochromate (51.3 g, 238 mmol) and silica gel (25.6 g) were added, and the mixture was stirred at 40 ° C for 12 hours. LCMS monitored the reaction to be complete. The reaction solution was concentrated and the residue was purified by column chromatography (petroleum ether: ethyl acetate = 10: 1) to obtain compound 76i (9.5 g, 74.8%) as a white solid. MS: 268.2 [M + H] + .
[1104] Step 8: Synthesis of compound 76j
[1105]
[1106] Compound 76i (9.5 g, 35.6 mmol) was dissolved in N,N-dimethylformamide dimethyl acetal (50 ml), and the mixture was stirred at 35°C for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was concentrated and filtered through silica gel, washed with dichloromethane, and the filtrate was concentrated to obtain compound 76j (9.5 g, 82.8%) as a brown liquid. MS: 323.3 [M+H] + .
[1107] Step 9: Synthesis of compound 76k
[1108]
[1109] Compound 76j (9.5 g, 29.5 mmol) was dissolved in toluene (90 ml), acetic acid (12 ml) and 3-chloropyrazole-5-amine (3.8 g, 32.4 mmol) were added, and the mixture was stirred at 95 ° C for 15 hours. LCMS monitored the reaction to be complete. After the reaction solution was cooled to room temperature, it was concentrated and sodium bicarbonate solution (500 ml) was added, and extracted with ethyl acetate (300 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 4:1) to obtain compound 76k (3.6 g, 32.5%) as a yellow solid. MS: 377.7 [M+H] + .
[1110] Step 10: Synthesis of compound 76l
[1111]
[1112] Compound 76k (1 g, 2.66 mmol) was dissolved in dichloromethane (20 ml), trifluoroacetic acid (5 ml) was added, and the mixture was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was poured into a sodium bicarbonate solution (50 ml), extracted with ethyl acetate (20 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (dichloromethane: methanol = 35: 1) to obtain compound 76l (330 mg, 73.5%) as a yellow solid. MS: 277.6 [M+H] + .
[1113] Step 11: Synthesis of compound 76m
[1114]
[1115] Compound 76l (330 mg, 1.2 mmol) was dissolved in tetrahydrofuran (3 ml), N, N-diisopropylethylamine (185 mg, 1.13 mmol) and triphosgene (177.6 mg, 0.6 mmol) were added, and the mixture was stirred at room temperature for 30 minutes. 5-amino-3-chloropicolinic acid methyl ester (244.6 mg, 1.31 mmol) and N, N-diisopropylethylamine (464.4 mg, 3.6 mmol) were added to the reaction system and stirred at room temperature for 1 hour. LCMS monitored the reaction to be complete. The reaction solution was slowly poured into water (50 ml), extracted with ethyl acetate (20 mL * 3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 3: 1) to obtain compound 76m (288 mg, 49.2%) as a yellow solid. MS: 490.2 [M + H] + .
[1116] Step 12: Synthesis of compound 76n
[1117]
[1118] Compound 76m (288 mg, 0.59 mmol) was dissolved in tetrahydrofuran (3 ml) and water (1.5 ml), lithium hydroxide (85 mg, 3.54 mmol) was added, and the mixture was stirred at room temperature for 16 hours. The reaction was complete as monitored by LCMS. The tetrahydrofuran in the reaction solution was dried by spin drying, and after adjusting the pH to 2 to 3 with 2N hydrochloric acid, the reaction solution was filtered to obtain compound 76n (180 mg, 64.4%) as a light yellow solid. MS: 476.2 [M+H] + .
[1119] Step 13: Synthesis of Compound 76
[1120]
[1121] Compound 76n (50 mg, 0.105 mmol) was dissolved in tetrahydrofuran (2 ml) and N,N-dimethylformamide (1 ml), and N,N-diisopropylethylamine (27 mg, 0.21 mmol) and O-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (48 mg, 0.126 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. O-(propyl-2-alkynyl-1-yl)hydroxylamine hydrochloride (16.85 mg, 0.158 mmol) was added to the above reaction system, and then the reaction system was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was separated and purified by C18 reverse phase column chromatography (acetonitrile: water = 40%) to obtain the racemate of compound 76, and then chiral separation was performed to obtain a single configuration of compound 76 (20 mg, purity 98%) as a white solid. MS: 545.3[M+H] + . 1 H NMR (600MHz, DMSO-d6): δppm 11.67(s,1H), 9.57(s,1H), 9.35(d,1H), 8.71(d,1H), 8.27(d,1H), 7.08(s,1H), 4.84(d,1H), 4 .28(d,1H), 3.72(d,2H), 1.98(s,3H), 1.09-1.14(m,1H), 0.54-0.57(m,2H), 0.29-0.31(m,2H).
[1122] Embodiment 77:
[1123] (R)-2-Chloro-N-(5-chloro-6-(methoxycarbamoyl)pyridin-3-yl)-8-methyl-8-(trifluoromethyl)-7,8-dihydro-6H-pyrazolo[1,5-a]pyrrolo[2,3-e]pyrimidine-6-carboxamide 77
[1124]
[1125] Compound 76n (50 mg, 0.11 mmol) was dissolved in tetrahydrofuran (2 ml) and N,N-dimethylformamide (1 ml), and N,N-diisopropylethylamine (28.2 mg, 0.22 mmol) and O-(7-azabenzotriazole)-N,N,N`,N`-tetramethyluronium hexafluorophosphate (49.8 mg, 0.13 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. O-methylhydroxylamine hydrochloride (13.3 mg, 0.16 mmol) was added to the above reaction system, and then the reaction system was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was separated and purified by C18 reverse phase column chromatography (acetonitrile: water = 40%) to obtain the racemate of compound 77, and the R-configuration compound 77 (15 mg, purity 98%) was obtained as a white solid after chiral separation. MS: 505.2 [M+H] + . 1 H NMR (600MHz, DMSO-d6): δppm 11.77(s,1H), 9.56(s,1H), 9.36(s,1H), 8.71(s,1H), 8.28(d,1H), 7.07(s,1H), 4.82(d,1H), 4.28(d,1H), 3.72(s,3H), 1.98(s,3H).
[1126] Embodiment 78:
[1127] (R)-2-Chloro-N-(5-chloro-6-(ethoxycarbamoyl)pyridin-3-yl)-8-methyl-8-(trifluoromethyl)-7,8-dihydro-6H-pyrazolo[1,5-a]pyrrolo[2,3-e]pyrimidine-6-carboxamide 78
[1128]
[1129] Compound 76n (50 mg, 0.11 mmol) was dissolved in tetrahydrofuran (2 ml) and N,N-dimethylformamide (1 ml), and N,N-diisopropylethylamine (28.2 mg, 0.22 mmol) and O-(7-azabenzotriazole)-N,N,N`,N`-tetramethyluronium hexafluorophosphate (49.8 mg, 0.13 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. o-Ethylhydroxylamine (9.76 mg, 0.16 mmol) was added to the above reaction system, and then the reaction system was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was separated and purified by C18 reverse phase column chromatography (acetonitrile: water = 40%) to obtain the racemate of compound 78, and the single R configuration compound 78 (15 mg, purity 98%) was obtained as a white solid after chiral separation. MS: 519.2 [M+H]+ .
[1130] Embodiment 79:
[1131] (R)-2-Chloro-N-(5-chloro-6-((2-hydroxyethoxy)carbamoyl)pyridin-3-yl)-8-methyl-8-(trifluoromethyl)-7,8-dihydro-6H-pyrazolo[1,5-a]pyrrolo[2,3-e]pyrimidine-6-carboxamide 79
[1132]
[1133] Compound 76n (50 mg, 0.11 mmol) was dissolved in tetrahydrofuran (2 ml) and N,N-dimethylformamide (1 ml), and N,N-diisopropylethylamine (28.2 mg, 0.22 mmol) and O-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (49.8 mg, 0.13 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. 2-(Aminooxy)ethane-1-ol (12.3 mg, 0.16 mmol) was added to the above reaction system, and then the reaction system was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was separated and purified by C18 reverse phase column chromatography (acetonitrile: water = 40%) to obtain the racemate of compound 79, and the single R configuration compound 79 (24 mg, purity 98%) was obtained as a white solid after chiral separation. MS: 535.2[M+H] + .
[1134] Embodiment 80:
[1135] (R)-2-Chloro-N-(5-chloro-6-((prop-2-yn-1-yloxy)carbamoyl)pyridin-3-yl)-8-methyl-8-(trifluoromethyl)-7,8-dihydro-6H-pyrazolo[1,5-a]pyrrolo[2,3-e]pyrimidine-6-carboxamide 80
[1136]
[1137] Compound 76n (50 mg, 0.1 mmol) was dissolved in tetrahydrofuran (2 ml) and N,N-dimethylformamide (1 ml), and N,N-diisopropylethylamine (27.1 mg, 0.2 mmol) and O-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (47.9 mg, 0.12 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. O-(propyl-2-alkynyl-1-yl)hydroxylamine hydrochloride (17.1 mg, 0.16 mmol) was added to the above reaction system, and then the reaction system was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was separated and purified by C18 reverse phase column chromatography (acetonitrile: water = 40%) to obtain the racemate of compound 80, and the single R configuration compound 80 (23 mg, purity 98%) was obtained as a white solid after chiral separation. MS: 529.2[M+H] + .
[1138] Embodiment 81:
[1139] (R)-2-Chloro-N-(5-chloro-6-(isopropoxycarbamoyl)pyridin-3-yl)-8-methyl-8-(trifluoromethyl)-7,8-dihydro-6H-pyrazolo[1,5-a]pyrrolo[2,3-e]pyrimidine-6-carboxamide 81
[1140]
[1141] Compound 76n (50 mg, 0.11 mmol) was dissolved in tetrahydrofuran (2 ml) and N,N-dimethylformamide (1 ml), and N,N-diisopropylethylamine (28.2 mg, 0.22 mmol) and O-(7-azabenzotriazole)-N,N,N`,N`-tetramethyluronium hexafluorophosphate (49.8 mg, 0.13 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. o-isopropylhydroxylamine (12.3 mg, 0.16 mmol) was added to the above reaction system, and then the reaction system was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was separated and purified by C18 reverse phase column chromatography (acetonitrile: water = 40%) to obtain the racemate of compound 81, and the single R configuration compound 81 (15 mg, purity 98%) was obtained as a white solid after chiral separation. MS: 533.3 [M+H] + .
[1142] Embodiment 82:
[1143] (R)-2-Chloro-N-(6-(ethoxycarbamoyl)-5-(trifluoromethyl)pyridin-3-yl)-8-methyl-8-(trifluoroethyl)-7,8-dihydro-6H-pyrazolo[1,5-a]pyrrolo[2,3-e]pyrimidine-6-carboxamide 82
[1144]
[1145]
[1146] Step 1: Synthesis of compound 82c
[1147]
[1148] Compound 82a (2 g, 7.04 mmol) was dissolved in 1,4-dioxane (20 ml), and benzophenone imine 82b (1.4 g, 7.75 mmol), tris(bisbenzylideneacetone)dipalladium (728.6 mg, 0.7 mmol), 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene (407 mg, 0.7 mmol) and cesium carbonate (6.9 g, 21.12 mmol) were added. The mixture was heated to 100 ° C and stirred for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was poured into 500 ml of water, extracted with ethyl acetate (200 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 3:1) to obtain compound 82c (2.1 g, 77.7%) as a dark yellow oil. MS: 385.3 [M+H] + (Xantphos shown in the figure is 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene)
[1149] Step 2: Synthesis of compound 82d
[1150]
[1151] Compound 82c (2 g, 5.2 mmol) was dissolved in 1,4-dioxane (20 ml), 12 ml of dilute hydrochloric acid (1 N) was added, and the mixture was stirred at room temperature for 1 hour. LCMS monitored the reaction to be complete. The reaction solution was poured into 500 mL of H 2 O, extracted with ethyl acetate (300 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (dichloromethane:ethyl acetate=1:1) to obtain compound 82d (1.1 g, 96.2%) as a light yellow solid. MS: 221.1 [M+H] + .
[1152] Step 3: Synthesis of compound 82e
[1153]
[1154] Compound 82d (500 mg, 0.23 mmol) was dissolved in tetrahydrofuran (5 ml), N,N-diisopropylethylamine (584 mg, 4.52 mmol) and triphosgene (806 mg, 2.71 mmol) were added, and the mixture was stirred at room temperature for 30 minutes. 2-Chloro-8-methyl-8-trifluoromethyl-7,8-dihydro-6H-pyrazolo[1,5-a]pyrrolo[2,3-e]pyrimidine 76l (624 mg, 2.26 mmol) was added. The reaction was complete when monitored by LCMS. The reaction solution was poured into 250 mL H 2 O, extracted with ethyl acetate (100 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 2: 1) to obtain compound 82e (510 mg, 43.2%) as a dark yellow solid. MS: 523.7 [M+H] + (The triphosgene in the picture is triphosgene)
[1155] Step 4: Synthesis of compound 82f
[1156]
[1157] Compound 82e (300 mg, 0.57 mmol) was dissolved in tetrahydrofuran (3 ml) and water (1.5 ml)
[1158] Lithium hydroxide (82.6 mg, 3.44 mmol) was added to the reaction mixture, and the mixture was stirred at room temperature for 16 hours.
[1159] The reaction was complete after LCMS monitoring. The pH of the reaction solution was adjusted to 2-3, and the solid was collected by filtration to obtain compound 82f (200 mg, 68.4%) as a white solid. MS: 509.7 [M+H] + .
[1160] Step 5: Synthesis of Compound 82
[1161]
[1162] Compound 82f (50 mg, 0.098 mmol) was dissolved in tetrahydrofuran (2 ml) and N,N-dimethylformamide (1 ml), and N,N-diisopropylethylamine (25.4 mg, 0.197 mmol) and O-(7-azabenzotriazole)-N,N,N`,N`-tetramethyluronium hexafluorophosphate (44.9 mg, 0.12 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. O-ethylhydroxylamine hydrochloride (14.3 mg, 0.15 mmol) was added to the above reaction system, and then the reaction system was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was separated and purified by C18 reverse phase column chromatography (acetonitrile: water = 40%) to obtain the racemate of compound 82, and the single R configuration compound 82 (26 mg, purity 97%) was obtained as a white solid after chiral separation. MS: 552.8 [M+H] + .
[1163] Embodiment 83:
[1164] (R)-2-chloro-8-methyl-N-(6-((prop-2-yn-1-yloxy)carbamoyl)-5-(trifluoromethyl)pyridin-3-yl)-8-(trifluorocarbonyl)-7,8-dihydro-6H-pyrazolo[1,5-a]pyrrolo[2,3-e]pyrimidine-6-carboxamide 83
[1165]
[1166] Compound 82f (50 mg, 0.1 mmol) was dissolved in tetrahydrofuran (2 ml) and N,N-dimethylformamide (1 ml), and N,N-diisopropylethylamine (25.8 mg, 0.2 mmol) and O-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (45.6 mg, 0.12 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. O-(propyl-2-alkynyl-1-yl)hydroxylamine hydrochloride (16.2 mg, 0.15 mmol) was added to the above reaction system, and then the reaction system was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was separated and purified by C18 reverse phase column chromatography (acetonitrile: water = 40%) to obtain the racemate of compound 83, and the single R configuration compound 83 (23 mg, purity 98%) was obtained as a white solid after chiral separation. MS: 562.8[M+H] + .
[1167] Embodiment 84:
[1168] (R)-2-Chloro-N-(6-(methoxycarbamoyl)-5-(trifluoromethyl)pyridin-3-yl)-8-methyl-8-(trifluorocarbonyl)-7,8-dihydro-6H-pyrazolo[1,5-a]pyrrolo[2,3-e]pyrimidine-6-carboxamide 84
[1169]
[1170] Compound 82f (51 mg, 0.1 mmol) was dissolved in tetrahydrofuran (0.8 ml) and N,N-dimethylformamide (0.4 ml), and N,N-diisopropylethylamine (25.8 mg, 0.2 mmol) and O-(7-azabenzotriazole)-N,N,N`,N`-tetramethyluronium hexafluorophosphate (45.65 mg, 0.12 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. O-methylhydroxylamine hydrochloride (14.63 mg, 0.15 mmol) was added to the above reaction system, and then the reaction system was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was separated and purified by C18 reverse phase column chromatography (acetonitrile: water = 51%) to obtain the racemate of compound 84, and the single R configuration compound 84 (27 mg, 51%) was obtained as a white solid after chiral separation. MS: 538.8 [M+H] + . 1 H NMR (600MHz, DMSO-d6): δppm 11.85(s,1H), 9.69(s,1H), 9.36(s,1H), 9.03(s,1H), 8.51(d,1H), 7.08(s,1H), 4.84(d,1H), 4.30(d,1H), 3.71(s,3H), 1.99(s,3H).
[1171] Embodiment 85:
[1172] (R)-2-Chloro-N-(6-(3-(methoxycarbamoyl)-1H-pyrazol-1-yl)-5-(trifluoromethyl)pyridin-3-yl)-8-methyl-8-(trifluoromethane)-7,8-dihydro-6H-pyrazolo[1,5-a]pyrrolo[2,3-e]pyrimidine-6-carboxamide 85
[1173]
[1174] Step 1: Synthesis of compound 85b
[1175]
[1176] Compound 85a (3 g, 13.2 mmol) was dissolved in N,N-dimethylformamide (30 mL), and 1H-pyrazole-3-carboxylic acid methyl ester (1.83 g, 14.52 mmol) and cesium carbonate (6.45 g, 19.8 mmol) were added in sequence. The mixture was stirred at room temperature for 2 hours in a magnetic stirrer. The reaction was complete when monitored by LCMS. The reaction solution was poured into 800 mL of H 2 O, extracted with ethyl acetate (700 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 4:1) to obtain compound 85b (2.56 g, 61.4%) as a white solid. MS: 317.2 [M+H] + .
[1177] Step 3: Synthesis of compound 85c
[1178]
[1179] Iron powder (1.15 g, 20.55 mmol) and ammonium chloride (880 mg, 16.44 mmol) were dissolved in a mixed solution of tetrahydrofuran, water and methanol (3 mL: 3 mL: 6 mL, 1: 1: 2), compound 85b (1.3 g, 4.11 mmol) was added thereto, and the mixture was refluxed in an oil bath at 65°C for 1 h. LCMS monitored the reaction to be complete. Filtered with diatomaceous earth, water was added to the filtrate, extracted with ethyl acetate (400 mL*3), the organic layers were combined, dried over anhydrous sodium sulfate and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 3: 1) to obtain compound 85c (820 mg, 69.8%). MS: 287.2 [M+H] + .
[1180] Step 3: Synthesis of compound 85d
[1181]
[1182] Compound 85c (200 mg, 0.699 mmol) was dissolved in tetrahydrofuran (2 mL), and N, N-diisopropylethylamine (99 mg, 0.769 mmol) and triphosgene (104 mg, 0.35 mmol) were added. The mixture was stirred at room temperature for 1 hour. 2-Chloro-8-methyl-8-trifluoromethyl-7,8-dihydro-6H-pyrazolo[1,5-a]pyrrolo[2,3-e]pyrimidine 76l (194 mg, 0.699 mmol) was dissolved in tetrahydrofuran (2 mL), and a mixed solution of N, N-diisopropylethylamine (271 mg, 2.1 mmol) was added dropwise to the above mixed solution, and the mixture was reacted at room temperature for 1 hour. The reaction was complete when monitored by LCMS. 80 mL of H 2O, extracted with ethyl acetate (80 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 85d (245 mg, 59.6%) as a white solid. MS: 589.8 [M+H] + .
[1183] Step 4: Synthesis of compound 85e
[1184]
[1185] Compound 85d (245 mg, 0.417 mmol) was dissolved in tetrahydrofuran (4 mL) and water (2 mL), lithium hydroxide (60 mg, 2.5 mmol) was added, and the mixture was stirred at room temperature for 16 hours. The reaction was complete by LCMS monitoring. The pH of the reaction solution was adjusted to 2-3, and the solid was filtered and collected to obtain compound 85e (100 mg, 41.8%) as a white solid. MS: 575.8 [M+H] + .
[1186] Step 5: Synthesis of Compound 85
[1187]
[1188] Compound 85e (100 mg, 0.174 mmol) was dissolved in tetrahydrofuran (2 mL) and N,N-dimethylformamide (1 mL), and N,N-diisopropylethylamine (45 mg, 0.348 mmol) and 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (79 mg, 0.21 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. O-methylhydroxylamine hydrochloride (22 mg, 0.261 mmol) was added to the above reaction system, and the mixture was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was separated and purified by C18 reverse phase column chromatography (acetonitrile: water = 40%) to obtain the racemic compound 85, and the single R configuration compound 85 (50 mg, 47.7%) was obtained as a white solid after chiral separation. MS: 604.8 [M+H] + . 1 H NMR (600MHz, DMSO-d6): δppm 11.67(s,1H), 9.47(s,1H), 8.86(s,1H), 8.68(d,1H), 8.26(d,1H), 7.03( s,1H), 6.88(d,1H), 4.78(d,1H), 4.24(d,1H), 3.69(s,3H), 1.97(s,3H).
[1189] Embodiment 86:
[1190] (R)-2-Chloro-N-(5-(difluoromethyl)-6-(methoxycarbamoyl)pyridin-3-yl)-8-methyl-8-(trifluoromethyl)-7,8-dihydro-6H-pyrazolo[1,5-a]pyrrolo[2,3-e]pyrimidine-6-carboxamide 86
[1191]
[1192] Step 1: Synthesis of compound 86a
[1193] Compound 76l (200 mg, 0.72 mmol) was dissolved in tetrahydrofuran (2 ml), N, N-diisopropylethylamine (112.2 mg, 0.87 mmol) and triphosgene (107.6 mg, 0.36 mmol) were added, and the mixture was stirred at room temperature for 30 minutes. 5-amino-3-(difluoromethyl)picolinic acid isopropyl ester 61h (250 mg, 1.09 mmol) and N, N-diisopropylethylamine (280.4 mg, 2.17 mmol) were added to the reaction system and stirred at room temperature for 1 hour. LCMS monitored the reaction to be complete. The reaction solution was slowly poured into water (50 ml), extracted with ethyl acetate (20 mL * 3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated and separated and purified by column chromatography (petroleum ether: ethyl acetate = 3: 1) to obtain compound 86a (180 mg, 46.9%) as a yellow solid. MS: 505.8[M+H] + .
[1194] Step 2: Synthesis of compound 86b
[1195]
[1196] Compound 86a (180 mg, 0.34 mmol) was dissolved in tetrahydrofuran (2 ml) and water (1 ml), lithium hydroxide (48.6 mg, 2.03 mmol) was added, and the mixture was stirred at room temperature for 16 hours. The reaction was complete as monitored by LCMS. The tetrahydrofuran in the reaction solution was dried by spin drying, and after adjusting the pH to 2 to 3 with 2N hydrochloric acid, the reaction solution was filtered to obtain compound 86b (120 mg, 72%) as a light yellow solid. MS: 491.7 [M+H] + .
[1197] Step 3: Synthesis of Compound 86
[1198]
[1199] Compound 86b (49 mg, 0.1 mmol) was dissolved in tetrahydrofuran (0.8 ml) and N,N-dimethylformamide (0.4 ml), and N,N-diisopropylethylamine (25.8 mg, 0.2 mmol) and O-(7-azabenzotriazole)-N,N,N`,N`-tetramethyluronium hexafluorophosphate (45.6 mg, 0.12 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. O-methylhydroxylamine hydrochloride (12.53 mg, 0.15 mmol) was added to the above reaction system, and then the reaction system was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was separated and purified by C18 reverse phase column chromatography (acetonitrile: water = 48%) to obtain the racemate of compound 86, and the single R configuration compound 86 (31 mg, 60%) was obtained as a white solid after chiral separation. MS: 520.8 [M+H] + . 1 H NMR (600MHz, DMSO-d6): δppm 11.76(br,1H), 9.64(br,1H), 9.38(s,1H), 8.96(s,1H), 8.47(d,1H), 7.74 (t,1H), 7.07(s,1H), 4.84(d,1H), 4.30(d,1H), 3.69(s,3H), 1.98(s,3H).
[1200] Embodiment 87:
[1201] (R)-2-Chloro-N-(5-(difluoromethyl)-6-(isopropoxycarbamoyl)pyridin-3-yl)-8-methyl-8-(trifluoromethyl)-7,8-dihydro-6H-pyrazolo[1,5-a]pyrrolo[2,3-e]pyrimidine-6-carboxamide 87
[1202]
[1203] Compound 86b (49 mg, 0.1 mmol) was dissolved in tetrahydrofuran (0.8 ml) and N,N-dimethylformamide (0.4 ml), and N,N-diisopropylethylamine (25.8 mg, 0.2 mmol) and O-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (45.6 mg, 0.12 mmol) were added dropwise, and the mixture was stirred at room temperature for 30 minutes. O-(tert-butyl)hydroxylamine hydrochloride (16.74 mg, 0.15 mmol) was dissolved in N,N-dimethylformamide (0.2 ml) and added to the above reaction system, and then the reaction system was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was separated and purified by C18 reverse phase column chromatography (acetonitrile: water = 55%) to obtain the racemate of compound 87, and the single R-configuration compound 87 (21 mg, 39%) was obtained as a white solid after chiral separation. MS: 548.8 [M+H] + .
[1204] Embodiment 88:
[1205] (R)-2-Chloro-N-(5-(difluoromethyl)-6-(ethoxycarbamoyl)pyridin-3-yl)-8-methyl-8-(trifluoromethyl)-7,8-dihydro-6H-pyrazolo[1,5-a]pyrrolo[2,3-e]pyrimidine-6-carboxamide 88
[1206]
[1207] Compound 86b (50 mg, 0.102 mmol) was dissolved in ultra-dry tetrahydrofuran (1 mL) and N,N-dimethylformamide (0.5 ml) solution, DIEA (26 mg, 0.204 mmol) was added and stirred for 5 minutes, then HATU (52 mg, 0.122 mmol) was added and stirred for 40 minutes. Then methoxyamine hydrochloride (15 mg, 0.153 mmol) and 0.5 ml N,N-dimethylformamide were added to the above reaction solution and stirred at room temperature for 2 hours. LCMS was correct and the reaction was complete. The reaction solution was subjected to column chromatography with reverse phase column to obtain the racemate of compound 88, and after chiral separation, a single R-configuration compound 88 (38 mg, 70%) was obtained, MS: 534.8 [M+H] + .
[1208] Embodiment 89:
[1209] 2-Chloro-6-((5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)carbamoyl)-8-methyl-7,8-dihydro-6H-pyrazolo[1,5-a]pyrrolo[2,3-e]pyrimidine-8-carboxylic acid ethyl ester 89
[1210]
[1211] Step 1: Synthesis of compound 89b
[1212]
[1213] Compound 89a (500 mg, 2.84 mmol) was dissolved in methanol (5 mL), sodium borohydride (161 mg, 4.26 mmol) was added under ice bath conditions, and the mixture was stirred under ice bath conditions for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was cooled to room temperature naturally and poured into 100 mL of H 2 O, extracted with ethyl acetate (100 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 4:1) to obtain compound 89b (300 mg, 59%) as a white solid. MS: 272.3 [M+H] + .
[1214] Step 2: Synthesis of compound 89c
[1215]
[1216] Compound 89b (13.6 g, 50 mmol) was dissolved in N,N-dimethylformamide dimethyl acetal (35 mL), and the mixture was stirred in an oil bath at 35°C for 2 hours. LCMS monitored the reaction to be complete. Concentration and purification of the residue by column chromatography (petroleum ether: ethyl acetate = 1:1) gave compound 89c (15 g, 92%) as a colorless liquid. MS: 327.3 [M+H] + .
[1217] Step 3: Synthesis of compound 89d
[1218]
[1219] Compound 89c (15 g, 46 mmol) was dissolved in toluene (50 mL), 3-chloro-1H-pyrazole-5-amine (8.07 g, 69 mmol) and acetic acid (5 mL) were added, and the mixture was refluxed in an oil bath at 35°C overnight. LCMS monitored the reaction to be complete. The reaction solution was concentrated and the pH value was adjusted to 7-8, and then poured into 900 mL of H 2 O, extracted with ethyl acetate (300 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 2: 1) to obtain compound 89d (5.2 g, 29.7%) as a colorless liquid. MS: 381.8 [M+H] + .
[1220] Step 4: Synthesis of compound 89e
[1221]
[1222] Compound 89d (5.2 g, 13.7 mmol) was dissolved in dichloromethane (60 mL). Trifluoroacetic acid (20 mL) was added and the mixture was stirred at room temperature for 3 hours. LCMS monitored the reaction to be complete. After concentration, the mixture was poured into 200 mL of H 2 O, extracted with ethyl acetate (150 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 89e (2.9 g, 75.6%) as a colorless liquid. MS: 281.7 [M+H] + .
[1223] Step 5: Synthesis of compound 89
[1224]
[1225] 5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine (16 mg, 0.082 mmol) was dissolved in tetrahydrofuran (2 mL), and N,N-diisopropylethylamine (12 mg, 0.09 mmol) and triphosgene (12 mg, 0.041 mmol) were added. The mixture was stirred at room temperature for 1 hour. Compound 89e (23 mg, 0.082 mmol) was dissolved in tetrahydrofuran (2 mL), and a mixed solution of N,N-diisopropylethylamine (32 mg, 0.246 mmol) was added dropwise to the above mixed solution, and the mixture was reacted at room temperature for 1 hour. The reaction was complete when monitored by LCMS. 80 mL of H 2 O, extracted with ethyl acetate (70 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain the racemate of compound 89. After chiral separation, a pair of enantiomers were obtained: 89-P1 (12 mg) and 89-P2 (10 mg) as light yellow solids. MS: 503.3 [M+H] + .
[1226] Embodiment 90:
[1227] 2-Chloro-8-methyl-6-((2-(trifluoromethyl)pyridin-4-yl)carbamoyl)-7,8-dihydro-6H-pyrazolo[1,5-a]pyrrolo[2,3-e]pyrimidine-8-carboxylic acid ethyl ester 90
[1228]
[1229] 2-(Trifluoromethyl)pyridin-4-amine (180 mg, 1.11 mmol) was dissolved in tetrahydrofuran (3 mL), and N, N-diisopropylethylamine (158 mg, 1.22 mmol) and triphosgene (181 mg, 0.61 mmol) were added. The mixture was stirred at room temperature for 1 hour. Compound 89e (311 mg, 1.11 mmol) was dissolved in tetrahydrofuran (2 mL), and a mixed solution of N, N-diisopropylethylamine (430 mg, 3.33 mmol) was added dropwise to the above mixed solution, and the mixture was reacted at room temperature for 1 hour. The reaction was complete when monitored by LCMS. 80 mL of H 2 O, extracted with ethyl acetate (80 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain the racemate of compound 90. After chiral separation, 90-P1 (9.5 mg) and 90-P2 (10.2 mg) were obtained as light yellow solids. MS: 469.8 [M+H] + .
[1230] Embodiment 91:
[1231] 2-Chloro-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-8-(fluoromethyl)-8-methoxy-7,8-dihydro-6H-pyrazolo[1,5-a]pyrrolo[2,3-e]pyrimidine-6-carboxamide 91
[1232]
[1233]
[1234] Step 1: Synthesis of compound 91b
[1235]
[1236] Dissolve trimethylsilyl iodide (44.08 g, 216 mmol) in tetrahydrofuran (145 mL), replace nitrogen, slowly add n-butyl lithium (80 mL, 199.8 mmol, 2.5 M) at -5 to -10 °C, 30 minutes later, dissolve compound 91a (10 g, 54 mmol) in tetrahydrofuran and slowly add it to the mixture, stirring at room temperature for 12 hours. Pour the reaction solution into 800 mL of H 2 O, extracted with tert-butyl methyl ether (600 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 4: 1) to obtain compound 91b (7.8 g, 72.6%) as a yellow liquid. 1H NMR (600MHz, DMSO-d6): δppm 5.36-5.35(d, 1H), 5.14-5.05(d, 2H), 5.44(s, 1H), 3.94-3.82(m, 2H), 3.57-3.53(m, 1H), 3.04-2.99(m, 1H), 1.40(s, 9H).
[1237] Step 2: Synthesis of compound 91c
[1238]
[1239] Compound 91b (2 g, 10 mmol) was dissolved in dichloromethane (20 mL), and sodium hydride (0.724 g, 18 mmol, 60%) and benzyl bromide (2.05 g, 12 mmol) were slowly added at 0°C to replace nitrogen, and the mixture was reacted at room temperature for 12 hours. Water (200 mL) was added for quenching, and dichloromethane was extracted (200 mL*3). The organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 3:1) to obtain compound 91c (720 mg, 24.9%) as a colorless liquid. 1 H NMR (600MHz, DMSO-d6): δppm 7.38-7.27(m, 5H), 5.28-5.26(d, 2H), 4.55-4.43(m, 2H), 4.30(s, 1H), 3.97-3.92(m, 2H), 3.54-3.46(m, 1H), 3.40-3.34(m, 1H), 1.40(s, 9H).
[1240] Step 3: Synthesis of compound 91d
[1241]
[1242] Potassium osmate (89 mg, 0.242 mmol) was dissolved in water (20 mL), and quinuclidine (135 mg, 1.21 mmol) and N-methylmorpholine oxide (5.67 g, 48.4 mmol) were added in sequence. Compound 91c (7 g, 24.2 mmol) was dissolved in acetone (70 mL), and the above reaction solution was slowly added dropwise, nitrogen was replaced, and the reaction was carried out at room temperature for 48 hours. Sodium sulfite (70 g) was added and stirred for 1 hour, and dichloromethane (100 mL) was added for dilution, filtered with diatomaceous earth, and 800 mL of H 2 O, extracted with dichloromethane (500 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated and the residue was separated and purified by column chromatography (petroleum ether:ethyl acetate=1:1) to give compound 91d (5.7 g, 72.9%) as a colorless liquid. 1H NMR (600MHz, DMSO-d6): δppm7.38-7.27(m, 5H), 4.97(s, 1H), 4.65-4.64(t, 1H), 4.59-4.56(dd, 1H), 4.51-4.47(t, 1H), 4.04 -4.02(q, 1H), 3.74-3.71(dd, 1H), 3.62-3.55(m, 2H), 3.47-3.39(m, 2H), 3.37-3.35(m, 2H), 3.24-3.17(m, 2H), 1.40(s, 9H).
[1243] Step 4: Synthesis of compound 91e
[1244]
[1245] Compound 91d (5.7 g, 17.6 mmol) was dissolved in N, N-dimethylformamide (60 mL), imidazole (2.4 g, 35.2 mmol), 4-dimethylaminopyridine (215 g, 1.76 mmol) were added, tert-butyldimethylsilyl chloride (2.92 g, 19.36 mmol) was added at 0°C, nitrogen was replaced, and the mixture was reacted at room temperature for 12 hours. Water (600 mL) was added to quench the mixture, and ethyl acetate (500 mL×3) was used for extraction. The organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether:ethyl acetate=1:1) to obtain compound 91e (6.3 g, 81.9%) as a colorless liquid. 1 H NMR (600MHz, DMSO-d6): δppm 7.38-7.27(m, 5H), 4.93(s, 1H), 4.61-4.57(d, 1H), 4.51-4.47(d, 1H), 3.78-3.68(m , 3H), 3.48-3.36(m, 2H), 3.24-3.11(m, 2H), 1.40(s, 9H), 0.90(s, 9H), 0.10(s, 6H).
[1246] Step 5: Synthesis of compound 91f
[1247]
[1248] Compound 91e (5.33 g, 12.2 mmol) was dissolved in tetrahydrofuran (55 mL), sodium hydride (1.464 g, 36.6 mmol, 60%) and iodomethane (3.463 g, 24.4 mmol) were added in turn under ice bath, and the mixture was stirred at room temperature for 24 hours in a magnetic stirrer. The reaction was complete when monitored by LCMS. The reaction solution was poured into 900 mL of H 2O, extracted with ethyl acetate (700 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 6:1) to obtain compound 91f (5.4 g, 98.1%) as a colorless liquid. MS: 452.6 [M+H] + .
[1249] Step 6: Synthesis of Compound 91g
[1250]
[1251] Compound 91f (4.9 g, 10.9 mmol) was dissolved in tetrahydrofuran (50 mL), tetrabutylammonium fluoride (21.8 mL, 21.8 mmol) was added thereto, and the mixture was stirred at room temperature for 12 hours. The reaction mixture was poured into water, extracted with ethyl acetate (700 mL*3), the organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 2:1) to obtain compound 91g (3.25 g, 84.5%) as a colorless liquid. MS: 338.4 [M+H] + .
[1252] Step 7: Synthesis of compound 91h
[1253]
[1254] Compound 91g (3.25g, 9.64mmol) was dissolved in tetrahydrofuran (80mL), and triethylamine (15.12g, 149.42mmol), perfluorobutylsulfonyl fluoride (11.94g, 39.524mmol), and triethylamine trihydrofluoride (6.37g, 39.524mmol) were added in turn under ice bath, and the mixture was stirred at room temperature overnight. LCMS monitored the reaction to be complete. The reaction solution was poured into 500mL H 2 O, extracted with dichloromethane (400 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 2:1) to obtain compound 91h (2.94 g, 90%) as a colorless liquid. MS: 340.4 [M+H] + .
[1255] Step 8: Synthesis of compound 91i
[1256]
[1257] Compound 91h (1.16 g, 3.42 mmol) was dissolved in methanol (100 mL), palladium hydroxide (1.16 g) and palladium carbon (1.16 g) were added, hydrogen was replaced, and the mixture was stirred overnight in an oil bath at 40°C. The reaction was complete as monitored by LCMS. The mixture was cooled to room temperature, filtered through celite, and the filtrate was concentrated and the residue was purified by column chromatography (petroleum ether: ethyl acetate = 2: 1) to obtain compound 91i (729 mg, 85.6%) as a colorless liquid. MS: 250.2 [M+H] + .
[1258] Step 9: Synthesis of compound 91j
[1259]
[1260] Compound 91i (580 mg, 2.33 mmol) was dissolved in dichloromethane (10 mL). Dess-Martin periodinane (1.98 g, 4.66 mmol) was added, and the mixture was stirred at room temperature for 5 hours. Saturated sodium bicarbonate solution was added to quench the reaction, extracted with ethyl acetate (100 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was purified by column chromatography (petroleum ether: ethyl acetate = 2: 1) to obtain compound 91j (363 mg, 63.1%) as a colorless liquid. MS: 248.2 [M+H] + .
[1261] Step 10: Synthesis of compound 91k
[1262]
[1263] Compound 91j (363 mg, 1.47 mmol) was dissolved in N,N-dimethylformamide dimethyl acetal (2 mL), and the mixture was stirred in an oil bath at 35°C for 2 hours. LCMS monitored the reaction to be complete. Concentration and purification of the residue by column chromatography (petroleum ether: ethyl acetate = 1:1) gave compound 91k (430 mg, 96.9%) as a colorless liquid. MS: 303.2 [M+H] + .
[1264] Step 11: Synthesis of compound 91l
[1265]
[1266] Compound 91k (430 mg, 1.42 mmol) was dissolved in toluene (10 mL), 3-chloro-1H-pyrazole-5-amine (249 mg, 2.13 mmol) and acetic acid (0.2 mL) were added, and the mixture was refluxed in an oil bath at 35°C overnight. LCMS monitored the reaction to be complete. Concentrate and adjust the pH to 7-8, pour into 100 mL of H2 O, extracted with ethyl acetate (80 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 911 (137 mg, 27.1%) as a colorless liquid. MS: 357.7 [M+H] + .
[1267] Step 12: Synthesis of compound 91m
[1268]
[1269] Compound 91l (137 mg, 0.385 mmol) was dissolved in acetonitrile (4 mL), trimethylsilyl iodide (92 mg, 0.462 mmol) was added thereto, and the mixture was stirred at room temperature for 4 hours. LCMS monitored the reaction to be complete. The reaction mixture was poured into water, extracted with ethyl acetate (80 mL*3), the organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 91m (50 mg, 50.7%) as a colorless liquid. MS: 257.6 [M+H] + .
[1270] Step 13: Synthesis of Compound 91
[1271]
[1272] 5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine (38 mg, 0.195 mmol) was dissolved in tetrahydrofuran (2 mL), and N,N-diisopropylethylamine (28 mg, 0.215 mmol) and triphosgene (30 mg, 0.1 mmol) were added. The mixture was stirred at room temperature for 1 hour. Compound 91m (50 mg, 0.195 mmol) was dissolved in tetrahydrofuran (2 mL), and a mixed solution of N,N-diisopropylethylamine (76 mg, 0.585 mmol) was added dropwise to the above mixed solution, and the mixture was reacted at room temperature for 1 hour. The reaction was complete when monitored by LCMS. 20 mL of H 2 O, extracted with ethyl acetate (15 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain the racemate of compound 91, and 91-P1 (4.7 mg) and 91-P2 (4.6 mg) were obtained as light yellow solids after chiral separation. MS: 479.2 [M+H] + .
[1273] Embodiment 92:
[1274] 2-Chloro-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-8-(methoxymethyl)-8-methyl-7,8-dihydro-6H-pyrazolo[1,5-a]pyrrolo[2,3-e]pyrimidine-6-carboxamide 92
[1275]
[1276]
[1277] Step 1: Synthesis of compound 92a
[1278]
[1279] Compound 89e (1.59 g, 5.66 mmol) was dissolved in tetrahydrofuran (15 mL), and lithium triethylborohydride (17 mL, 16.98 mmol, 1 M) was added under ice bath conditions. The mixture was stirred under ice bath conditions for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was cooled to room temperature naturally, and 200 mL of H 2 O, extracted with ethyl acetate (60 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 92a (445 mg, 33%) as a colorless liquid. MS: 239.6 [M+H] + .
[1280] Step 2: Synthesis of compound 92b
[1281]
[1282] Compound 92a (747 mg, 3.14 mmol) was dissolved in tetrahydrofuran (15 mL), di-tert-butyl dicarbonate (685 mg, 3.14 mmol) and sodium bicarbonate (791 mg, 9.42 mmol) were added, and the mixture was stirred at room temperature for 20 hours. The reaction was complete after LCMS monitoring. 200 mL of H 2 O, extracted with ethyl acetate (200 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate,...
Claims
1. A compound, wherein the compound is a compound represented by formula (I), or an isomer, isotope derivative, polymorph, prodrug, chelate, non-covalent complex, pharmaceutically acceptable salt or solvate thereof: in, X is O or S; R 1 and R 2 are independently selected from H, halogen, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl and C 1-6 Preferably, R 1 is H; preferably, R 2 is halogen; more preferably, R 2 is F, Cl, Br or I; M 1 is C or N; preferably, M 1 is N; When M 1 When N, R 3 does not exist; When M 1 When C, R 3 Selected from H, halogen, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl and C 1-6 Haloalkoxy; R 4 Selected from hydrogen, C 1-6 Alkyl, C 1-6 Alkoxy and C 3-6 Cycloalkyl, wherein the C 1-6 Alkyl, C 1-6 Alkoxy and C 3-6 The cycloalkyl group is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 groups independently selected from halogen, cyano, nitro, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , hydroxyl, R 4a AND-OR 4a substituted by a substituent; Among them, R 4a Selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, -N,N-di-C 1-6 Alkylamino, -N-mono-C 1-6 Alkylamino, C 6-10 Aryl and C 5-10 Heteroaryl, the C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, -N,N-di-C 1-6 Alkylamino, -N-mono-C 1-6 Alkylamino, C 6-10 Aryl and C 5-10 The heteroaryl group is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 groups independently selected from halogen, cyano, nitro, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 and substituted with a hydroxy substituent; Preferably, R 4 Selected from C 1-6 Alkyl and C 1-6 Alkoxy, the C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 groups independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy and C 1-6 The substituent of the haloalkoxy group is substituted; preferably, R 4 Selected from C 1-3 Alkoxy, C 1-3 Alkylene-OC 1-3 Alkyl, C 1-3 Alkylene-OC 1-3 More preferably, R 4 -C(CH 3 )-O-CH 3 or -C(CH 3 )-O-CHF 2 ; R 5 is hydrogen or C 1-6 Alkyl; or R 4 and R 5 The atoms connected together form a five-membered or six-membered heterocyclic ring, or a 7-12-membered spirocyclic ring, wherein the five-membered or six-membered heterocyclic ring or the 7-12-membered spirocyclic ring is optionally substituted by 0-3 independently selected from halogen, cyano, amino, hydroxyl, -C(=O)OC 1-6 Alkyl, -C 1-6 Alkylene -OH, -C 1-6 Alkylene-OC 1-6 Alkyl, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, -N,N-di-C 1-6 Alkylamino, -N-mono-C 1-6 Alkylamino, -C(=O)NH-alkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl and -OC 3-6 Preferably, the five-membered or six-membered heterocyclic ring or the 7-12-membered spirocyclic ring is optionally substituted by 0, 1, 2, or 3 independently selected from halogen, hydroxyl, -C(=O)OC 1-6 Alkyl, -C 1-6 Alkylene -OH, -C 1-6 Alkylene-OC 1-6 Alkyl, C 1-6 Alkyl and C 1-6 Preferably, the five-membered or six-membered heterocyclic ring or the 7-12-membered spirocyclic ring is a heterocyclic ring or spirocyclic ring containing one N and is optionally substituted by 0, 1 or 2 independently selected from F, Cl, Br, I, hydroxyl, -C(=O)OC 1-3 Alkyl, -C 1-3 Alkylene-OH, C 1-3 Alkyl, -C 1-3 Alkylene-OC 1-3 Alkyl, C 1-3 Alkoxy and C 1-3 Substitution of haloalkyl groups; Ring A is selected from the group consisting of the structural formulae (II), (III), (IV), (V), (VI), (VII) and (VIII): R 6a and R 6b , or R 8a and R 8b , or R 8a and R 8c , or R 9a and R 9b , or R 10a and R 10b , or R 11a and R 11b The atoms connected together form a four-membered, five-membered, six-membered or seven-membered saturated or unsaturated carbocyclic ring or a heterocyclic ring containing 1, 2 or 3 N atoms, wherein the carbocyclic ring or the N-containing heterocyclic ring is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 independently selected from halogen, oxo, NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , hydroxyl, cyano, amino, carboxyl, haloalkyl, alkoxy, -C 1-6 Alkylene carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 、-OC 1-6 Alkyl, C 1-6 Alkyl, C 3-6 Cycloalkyl and -C 1-6 Preferably, the carbocyclic ring or N-containing heterocyclic ring is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 independently selected from halogen, oxo, haloalkyl, C 1-6 Alkyl, C 3-6 Cycloalkyl and -C 1-6 substituted by a substituent of alkylene-OH; or R 6b Selected from hydrogen, halogen, hydroxyl, cyano, nitro, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, alkoxy, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl and C 1-6 Haloalkyl; wherein the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl and C 1-6 The haloalkyl group is optionally substituted with 0, 1, 2, 3, 4, 5 or 6 groups independently selected from halogen, hydroxy, cyano, amino, carboxyl, haloalkyl, alkoxy, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 Preferably, the R 6b Selected from hydrogen, halogen, hydroxyl, C 3-6 Cycloalkyl, C 1-6 Alkyl, and C 1-6 Haloalkyl; R 6a Selected from -OC 1-6 Alkyl, C 3-10 Cycloalkyl, C 3-10 Heterocyclic group, Said-OC 1-6 Alkyl, C 3-10 Cycloalkyl, C 3-10 The heterocyclic group is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 groups independently selected from halogen, hydroxy, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, halogenated alkyl, alkoxy, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , C 1-6 Alkyl and -C 1-6 Preferably, the C 3-10 The heterocyclyl group contains 1, 2, 3 or 4 heteroatoms independently selected from O, N, P and S; R 7 Selected from hydrogen, halogen, hydroxyl, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, halogenated alkyl, alkoxy, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , C 1-6 Alkyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, Wherein C 1-6 Alkyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 The cycloalkyl group is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 groups independently selected from halogen, hydroxy, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 Preferably, R 7 Selected from hydrogen, halogen, hydroxyl, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, C 1-6 Haloalkyl and alkoxy groups; When the A ring is a structure of Formula III, R 4 and R 5 The atoms connected together form a five-membered or six-membered heterocyclic ring, or a 7-12-membered spirocyclic ring, wherein the five-membered or six-membered heterocyclic ring or the 7-12-membered spirocyclic ring is optionally substituted by 0, 1, 2 or 3 independently selected from halogen, cyano, amino, hydroxyl, -C(=O)OC 1-6 Alkyl, -C 1-6 Alkylene -OH, -C 1-6 Alkylene-OC 1-6 Alkyl, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, -N,N-di-C 1-6 Alkylamino, -N-mono-C 1-6 Alkylamino, -C(=O)NH-alkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl and -OC 3-6 Preferably, the five-membered or six-membered heterocyclic ring or the 7-12-membered spirocyclic ring is optionally substituted by 0, 1, 2 or 3 independently selected from halogen, hydroxyl, -C(=O)OC 1-6 Alkyl, -C 1-6 Alkylene -OH, -C 1-6 Alkylene-OC 1-6 Alkyl, C 1-6 Alkyl and C 1-6 Preferably, the five-membered or six-membered heterocyclic ring or the 7-12-membered spirocyclic ring is a heterocyclic ring or spirocyclic ring containing one N and is optionally substituted by 0, 1 or 2 independently selected from F, Cl, Br, I, hydroxyl, -C(=O)OC 1-3 Alkyl, -C 1-3 Alkylene-OH, C 1-3 Alkyl, -C 1-3 Alkylene-OC 1-3 Alkyl, C 1-3 Alkoxy and C 1-3 Substitution of the haloalkyl substituent; and When the A ring is a structure of formula III, R 4 and R 5 When the atoms connected to them form a five-membered heterocyclic ring, the five-membered heterocyclic ring is not simultaneously substituted by methyl and -CF 3 replace; R 8a Selected from R 8b , R 8c , R 8d are independently selected from hydrogen, halogen, hydroxyl, cyano, nitro, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 ,-COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , carboxyl, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl and -C 1-3 Haloalkyl; When R 8a yes or R 8a and R 8b , or R 8a and R 8c When R and the atoms connected to it form a four-membered, five-membered, six-membered or seven-membered saturated or unsaturated carbon ring or a nitrogen-containing heterocyclic ring, 4 It is not isopropyl; When R 4 and R 5 The atoms connected to it form a five-membered heterocycloalkyl group, which is simultaneously substituted by methyl and -CF 3 When replaced, R 8a Not -S(O)-CH 3 and -O-CH 3 ; R 9a , R 9b are independently selected from hydrogen, halogen, hydroxyl, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 ,-COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , carboxyl, C 1-6 Alkyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, Wherein C 1-6 Alkyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 The cycloalkyl group is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 groups independently selected from halogen, hydroxy, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 ,-COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , substituted by a substituent of the carboxyl group; R 10a , R 10b are independently selected from hydrogen, halogen, hydroxyl, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 ,-COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkylCONH 2 , carboxyl, C 1-6 Alkyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, Wherein C 1-6 Alkyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 The cycloalkyl group is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 groups independently selected from halogen, hydroxy, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , substituted by a substituent of the carboxyl group; R 11a , R 11b are independently selected from hydrogen, halogen, hydroxyl, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene-NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , carboxyl, C 1-6 Alkyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, Wherein C 1-6 Alkyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 The cycloalkyl group is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 groups independently selected from halogen, hydroxy, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 ,-COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , substituted by a substituent of the carboxyl group; Preferably, R 11b Selected from hydrogen, halogen, hydroxyl, C 1-6 Alkyl and C 3-6 Cycloalkyl; R 11a Selected from hydrogen, halogen, hydroxyl, C 1-6 Alkyl, C 3-6 Cycloalkyl and The C 1-6 Alkyl and C 3-6 Cycloalkyl is optionally substituted with 0, 1, 2, 3, 4, 5 or 6 substituents independently selected from halogen, hydroxy, cyano, amino, carboxyl, ester; Y 1 , Y 2 , Y 3 , Y 4 are independently selected from C, N and S; preferably, Y 2 and Y 4 C, and / or Y 1 and Y 3 are independently selected from C, N and S; R 12 Selected from hydrogen, halogen, hydroxyl, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 ,-COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , carboxyl, C 1-6 Haloalkyl, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 5-10 Heteroaryl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, Wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 5-10 Heteroaryl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 The cycloalkyl group is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 groups independently selected from halogen, hydroxy, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 ,-COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , substituted by a substituent of the carboxyl group; The condition is that when Y 1 It's S, Y 3 When N is 12 Yes - CF 3 When R 4 no The condition is that when Y 1 It's S, Y 4 When N is 12 Yes - CF 3 or -CH 3 When R 4 no The condition is that when Y 3 Is S or N, Y 4 When N is 12 Not-CF 3 , -CHF 2 ; Preferably, Y 1 YesS,Y 2 YesC,Y 3 YesN,Y 4 It is C; Preferably, R 12 Selected from hydrogen, halogen, hydroxyl, cyano, amino, C 1-6 Haloalkyl, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 3-6 Cycloalkyl, n6, n7, n8, n9, n10, n11, n12 are independently selected from 1, 2, 3 and 4; R 6c1 , R 6c2 , R 7c1 , R 7c2 , R 8d1 , R 8d2 , R 9c1 , R 9c2 , R 10c1 , R 10c2 , R 11c1 , R 11c2 , R 12c1 , R 12c2 are independently selected from hydrogen, hydroxyl, C 1-6 Alkyl, C 1-6 Alkyleneamino, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Heterocycloalkyl, pyrazolyl, phenoxy, cyano, C 1-6 Alkoxy, C 2-6 Alkenyloxy, C 2-6 Alkynyloxy, -OC 3-6 Cycloalkyl, C 6-10 Aryl and C 5-10 Heteroaryl, wherein the C 1-6 Alkyl, C 1-6 Alkylamino, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, pyrazolyl, phenoxy, cyano, C 1-6 Alkoxy, C 2-6 Alkenyloxy, C 2-6 Alkynyloxy, -OC 3-6 Cycloalkyl, C 6-10 Aryl and C 5-10 Heteroaryl is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 groups independently selected from halogen, oxo, nitro, hydroxy, cyano, furan, C 3-6 Cycloalkyl, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 1-6 Haloalkyl, -OC 3-6 Cycloalkyl, -alkoxy-3-6 membered heterocyclic ring, C 3-8 Cycloalkenyloxy, C 6-10 The aryl group and the C group containing 1 to 4 heteroatoms independently selected from N, O, P and S 5-10 is substituted by a substituent of a heteroaryl group; or R 6c1 and R 6c2 , R 7c1 and R 7c2 , R 8d1 and R 8d2 , R 9c1 and R 9c2 , R 10c1 and R 10c2 , R 11c1 and R 11c2 , R 12c1 and R 12c2 The N atoms to which they are connected independently form a 3-6 membered heterocyclic ring, wherein the heterocyclic ring is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 independently selected from halogen, oxo, hydroxyl, nitro, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkyl NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkyl-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkylCONH 2 、-C(O)-NH-C 1-6 Alkoxy, C 1-6 Alkyl, -C 1-6 Alkylene-hydroxyl, C 1-6 Alkoxy, C 2-6 Alkenyloxy, C 2-6 Alkynyloxy, C 3-6 Cycloalkoxy, 3-6 membered heterocycloalkoxy, C 3-8 Cycloalkenyloxy, C 6-10 Aryl and C 5-10 wherein the -C(O)-NH-C 1-6 Alkoxy, C 1-6 Alkyl, C 1-6 Alkoxy, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, -alkoxy-3-6 membered heterocyclic group, C 3-8 Cycloalkenyloxy, C 6-10 Aryl and C 5-10 The heteroaryl group is optionally substituted with 0, 1, 2, 3, 4, 5 or 6 substituents independently selected from halogen, hydroxyl, oxo, nitro and cyano; preferably, the heterocycle is optionally substituted with 0, 1, 2, 3, 4, 5 or 6 substituents independently selected from halogen, oxo, hydroxyl, nitro, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkyl NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkyl-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkylCONH 2 、--C(O)-NH-C 1-6 Alkoxy, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyloxy, C 2-6 Alkynyloxy, C 3-6 Cycloalkoxy, 3-6 membered heterocycloalkoxy, C 3-8 Cycloalkenyloxy, C 6-10 Aryl and C 5-10 wherein the -C(O)-NH-C 1-6 Alkoxy, C 1-6 Alkyl, C 1-6 Alkoxy, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, -alkoxy-3-6 membered heterocyclic group, C 3-8 Cycloalkenyloxy, C 6-10 Aryl and C 5-10 The heteroaryl group is optionally substituted with 0, 1, 2, 3, 4, 5 or 6 substituents independently selected from halogen, hydroxy, oxo, nitro and cyano; preferably, R 6c1 and R 6c2 , R 7c1 and R 7c2 , R 8d1 and R 8d2 , R 9c1 and R 9c2 , R 10c1 and R 10c2 , R 11c1 and R 11c2 , R 12c1 and R 12c2 The N atoms to which they are connected independently form a 4-5 membered heterocyclic ring, wherein the 4-5 membered heterocyclic ring is optionally substituted by 0, 1 or 2 independently selected from halogen, hydroxyl, C 1-3 Alkyl, C 1-3 Alkylene-hydroxyl, C(O)-NH-C 1-6 substituted by an alkoxy substituent; R 6d , R 7d , R 8e , R 9d , R 10d , R 11d , R 12d are independently selected from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl and C 3-6 Cycloalkyl, wherein the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl and C 3-6 Cycloalkyl is optionally substituted by 0-6 independently selected from halogen, hydroxy, oxo, nitro, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyloxy, C 2-6 Alkynyloxy, C 3-6 Cycloalkoxy, 3-6 membered heterocycloalkoxy, C 3-8 Cycloalkenyloxy, C 6-10 Aryl and C 5-10 Preferably, R 6d , R 7d , R 8e , R 9d , R 10d , R 11d , R 12d are independently selected from hydrogen, C 1-3 Alkyl; preferably, R 6d , R 7d , R 8e , R 9d , R 10d , R 11d , R 12d Each independently selected from methyl and ethyl; Y 5 , Y 6 , Y 7 , Y 8 are independently selected from C and N; preferably, Y 6 Yes N, Y 5 , Y 7 , Y 8 Different from all N; R 6e , R 6f , R 6g , R 7e , R 7f , R 7g , R 8f , R 8g , R 8h , R 9e , R 9f , R 9g , R 10e , R 10f , R 10g , R 11e , R 11f , R 11g , R 12e , R 12f , R 12g are independently absent or selected from hydrogen, halogen, hydroxyl, cyano, nitro, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, carboxyl, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -C 2-6 Alkynyl-NH 2 、-OC 3-6 Cycloalkyl, -C(O)NH-OC 1-6 Alkyl, -C(=O)NH-OC 2-6 Alkenyl, -C(=O)NH-OC 2-6 Alkynyl, -C(=O)NH-OC 3-6 Cycloalkyl, -NH-C(=O)-C 2-6 Alkynyl, -NH-C(=O)-C 1-6 Alkyl, -NH-C(=O)-C 3-6 Cycloalkyl, -NH-C(=O)-C 3-6 Heterocycloalkyl, the C 3-6 The heterocycloalkyl group contains 1, 2, 3 or 4 heteroatoms independently selected from N, O, P and S, -NH-C(=S)-C 3-6 Heterocycloalkyl, the C 3-6 The heterocycloalkyl group contains 1, 2, 3 or 4 heteroatoms independently selected from N, O, P and S, -NH-C(=O)-C 1-6 Alkylene-OC 1-6 Alkyl, -NH-C(=O)-C 1-6 Alkylene-OC(=O)-C 1-6 Alkyl, -NH-C(=O)-C 1-6 Alkylene-SC 1-6 Alkyl, -NH-C(=O)-C 2-6 Alkenyl, -NH-C(=O)-C 2-6 Alkynyl, -C(=O)NH-C 1-6 Alkyl, -NH-C(=O)-N-(C 1-6 alkyl) 2 、-C(=O)NH-C 2-6 Alkenyl, -C(=O)NH-C 2-6 Alkynyl, -C(=O)NH-C 3-6 Cycloalkyl, -NH-C 1-6 Alkyl, -NH-C(=O)-NH-C 1-6 Alkyl, -NH-C(=O)-C 5-10 Heteroaryl, the C 5-10 The membered heteroaryl group contains 1, 2, 3 or 4 heteroatoms independently selected from N, O, P and S, -NH-C(=O)-C 6-10 Aryl, C 6-10 The aryl group and the C group containing 1, 2, 3 or 4 heteroatoms independently selected from N, O, P and S are 5-10 Heteroaryl, wherein the -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, carboxyl, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, -C(O)NH-OC 1-6 Alkyl, -C(=O)NH-OC 2-6 Alkenyl, -C(=O)NH-OC 2-6 Alkynyl, -C(=O)NH-OC 3-6 Cycloalkyl, -NH-C(=O)-C 1-6 Alkyl, -NH-C(=O)-C 1-6 Alkynyl, -NH-C(=O)-C 3-6 Cycloalkyl, -NH-C(=O)-C 3-6 Heterocycloalkyl, -NH-C(=S)-C 3-6 Heterocycloalkyl, -NH-C(=O)-C 1-6 Alkylene-OC 1-6 Alkyl, -NH-C(=O)-C 1-6 Alkylene-OC(=O)-C 1-6 Alkyl, -NH-C(=O)-C 1-6 Alkylene-SC 1-6 Alkyl, -NH-C(=O)-C 2-6 Alkenyl, -NH-C(=O)-C 2-6 Alkynyl, -C(=O)NH-C 1-6 Alkyl, NH-C(=O)-N-(C 1-6 alkyl) 2 、-C(=O)NH-C 2-6 Alkenyl, -C(=O)NH-C 2-6 Alkynyl, -C(=O)NH-C 3-6 Cycloalkyl, -NH-C 1-6 Alkyl, -NH-C(=O)-NH-C 1-6 Alkyl, -NH-C(=O)-C 5-10 Heteroaryl, -NH-C(=O)-C 6-10 Aryl, C 6-10 The aryl group and the C group containing 1, 2, 3 or 4 heteroatoms independently selected from N, O, P and S are 5-10 Heteroaryl, optionally substituted by 0, 1, 2, 3, 4, 5 or 6 groups independently selected from halogen, hydroxy, nitro, cyano, amino, -N(CH 3 ) 2 , C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and C 3-6 Preferably, when Y 6 and Y 7 N, Y 8 C or N, Y 9 When C, R 6e , R 6f , R 6g , R 7e , R 7f , R 7g , R 8f , R 8g , R 8h , R 9e , R 9f , R 9g , R 10e , R 10f , R 10g , R 11e , R 11f , R 11g , R 12e , R 12f , R 12g are independently absent or selected from hydrogen, halogen, -NHC 1-6 Alkyl, -COOC 1-6 Alkyl, C 2-6 Alkynyl, -C(O)NH-OC 1-6 Alkyl, -NH-C(=O)-N-(C 1-6 alkyl) 2 、-C(=O)NH-OC 2-6 Alkenyl, -C(=O)NH-OC 2-6 Alkynyl, -C(=O)NH-OC 3-6 Cycloalkyl, -NH-C(=O)-C 1-6 Alkynyl, -NH-C(=O)-C 1-6 Alkyl, -NH-C(=O)-C 3-6 Cycloalkyl, -NH-C(=O)-C 3-6 Heterocycloalkyl, the C 3-6 The heterocycloalkyl group contains 1, 2, 3 or 4 heteroatoms independently selected from N, O, P and S, -NH-C(=S)-C 3-6 Heterocycloalkyl, the C 3-6 The heterocycloalkyl group contains 1, 2, 3 or 4 heteroatoms independently selected from N, O, P and S, -NH-C(=O)-C 1-6 Alkylene-OC 1-6 Alkyl, -NH-C(=O)-C 1-6 Alkylene-OC(=O)-C 1-6 Alkyl, -NH-C(=O)-C 1-6 Alkylene-SC 1-6 Alkyl, -NH-C(=O)-C 2-6 Alkenyl, -NH-C(=O)-C 2-6 Alkynyl, -C(=O)NH-C 1-6 Alkyl, -NH-C(=O)-N-(C 1-6 alkyl) 2 、-C(=O)NH-C 2-6 Alkenyl, -C(=O)NH-C 2-6 Alkynyl, -C(=O)NH-C 3-6 Cycloalkyl, -NH-C 1-6 Alkyl, -NH-C(=O)-NH-C 1-6 Alkyl, -NH-C(=O)-C 5-10 Heteroaryl, the C 5-10 The membered heteroaryl group contains 1, 2, 3 or 4 heteroatoms independently selected from N, O, P and S, -NH-C(=O)-C 6-10 Aryl, C 6-10 The aryl group and the C group containing 1, 2, 3 or 4 heteroatoms independently selected from N, O, P and S are 5-10 Heteroaryl, wherein the -NHC 1-6 Alkyl, -COOC 1-6 Alkyl, C 2-6 Alkynyl, -C(O)NH-OC 1-6 Alkyl, -C(=O)NH-OC 2-6 Alkenyl, -C(=O)NH-OC 2-6 Alkynyl, -C(=O)NH-OC 3-6 Cycloalkyl, -NH-C(=O)-C 1-6 Alkynyl, -NH-C(=O)-C 1-6 Alkyl, -NH-C(=O)-C 3-6 Cycloalkyl, -NH-C(=O)-C 3-6 Heterocycloalkyl, the C 3-6 The heterocycloalkyl group contains 1, 2, 3 or 4 heteroatoms independently selected from N, O, P and S, -NH-C(=S)-C 3-6 Heterocycloalkyl, the C 3-6 The heterocycloalkyl group contains 1, 2, 3 or 4 heteroatoms independently selected from N, O, P and S, -NH-C(=O)-C 1-6 Alkylene-OC 1-6 Alkyl, -NH-C(=O)-C 1-6 Alkylene-OC(=O)-C 1-6 Alkyl, -NH-C(=O)-C 1-6 Alkylene-SC 1-6 Alkyl, -NH-C(=O)-C 2-6 Alkenyl, -NH-C(=O)-C 2-6 Alkynyl, -C(=O)NH-C 1-6 Alkyl, -C(=O)NH-C 2-6 Alkenyl, -C(=O)NH-C 2-6 Alkynyl, -C(=O)NH-C 3-6 Cycloalkyl, -NH-C 1-6 Alkyl, -NH-C(=O)-NH-C 1-6 Alkyl, -NH-C(=O)-C 5-10 Heteroaryl, the C 5-10 The membered heteroaryl group contains 1, 2, 3 or 4 heteroatoms independently selected from N, O, P and S, -NH-C(=O)-C 6-10 Aryl, C 6-10 The aryl group and the C group containing 1 to 4 heteroatoms independently selected from N, O, P and S 5-10 Heteroaryl, optionally substituted by 0, 1, 2, 3, 4, 5 or 6 groups independently selected from halogen, hydroxy, nitro, cyano, amino, -N(CH 3 ) 2 , C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and C 3-6 is substituted by a cycloalkyl substituent; and R 6e and R 6f , or R 7e and R 7f , or R 8f and R 8g , or R 9e and R 9f , or R 10e and R 10f , or R 11e and R 11f , or R 12e and R 12f Not H at the same time or not present; R 6h , R 7h , R 8i , R 9h , R 10h , R 11h , R 12h are independently selected from hydrogen, halogen, hydroxyl, cyano, amino, carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, -C(=O)N-(R 6h2 )R 6h3 and C 6-10 Aryl, wherein the -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, -C(=O)N-(R 6h2 )R 6h3 and C 6-10 Aryl is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 groups independently selected from halogen, hydroxy, oxo, nitro, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, C 3-6 Cycloalkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , C 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, -OC 3-6 Heterocyclic group, C 3-8 cycloalkenyloxy, 6-10 membered aryl and 6-10 membered heteroaryl substituents; wherein R 6h2 , R 6h3 are independently selected from hydrogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and C 3-6 Cycloalkyl; or R 6h2 and R 6h3 The N atom to which they are commonly connected forms a 3-8 membered heterocyclic ring, wherein the 3-8 membered ring is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 independently selected from halogen, hydroxyl, C 1-6 Alkoxy, -C 1-6 Alkylene - hydroxyl, nitro, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , C 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, -OC 3-6 Heterocycloalkyl, C 3-8 Cycloalkenyloxy, C 6-10 Aryl and C 5-10 The substituents of the heteroaryl group are substituted; preferably, R 6h2 and R 6h3 The N atom to which they are commonly connected forms a 4-membered heterocyclic ring, wherein the 4-membered ring is optionally substituted by 0, 1 or 2 independently selected from halogen, hydroxyl, -C 1-6 Substitution of alkylene-hydroxy groups; The condition is that when R 6b When selected from Cl, R 6a no The condition is that when R 6b is CHF 2 When R 6a no The condition is that when R 6a yes When X is S; or when X is O, the compound is selected from The condition is that Y 5 , Y 6 Both are N, and Y 7 , Y 8 When both are C, R 6e , R 6f , R 6g Not H at the same time or not present; The condition is that Y 5 , Y 6 Both are N, and Y 7 , Y 8 Both are C, and R 6e and R 6g When all are H or do not exist, R 6f Not -OH, -C≡N, CH 2 OH, -COO-C 2 H 5 , CH 2 NH 2 ; The condition is that when Y 5 , Y 6 Both are N, and R 6f When H, R 6e or R 6g Not -C≡N.
2. The compound according to claim 1, in: X is O or S; preferably, X is O; and / or R 1 and R 2 are independently selected from H and halogen; preferably, R 1 Yes H, R 2 is halogen, the halogen is selected from Cl, Br and F; preferably selected from Cl, F; and / or M 1 Yes N, R 3 Does not exist; R 4 It is for -C 1-6 Alkyl-C 1-6 Alkoxy or -C 1-6 Alkyl-OC 1-6 haloalkyl; further preferably, R 4 -C(CH 3 )-O-CH 3 or -C(CH 3 )-O-CHF 2 ; and / or R 5 is hydrogen or C 1-6 Alkyl; preferably, R 5 is hydrogen; or R 4 and R 5 The atoms connected together form a five-membered or six-membered heterocyclic ring, or a 7-12-membered spirocyclic ring, wherein the five-membered or six-membered heterocyclic ring or the 7-12-membered spirocyclic ring is optionally substituted by 0, 1, 2 or 3 independently selected from halogen, hydroxyl, -C(=O)OC 1-6 Alkyl, -C 1-6 Alkylene-OH, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 The substituent of the haloalkyl group is substituted; preferably, R 4 and R 5 The atoms connected together form the following structure: and / or Ring A is selected from the group consisting of formula (II), formula (III), formula (IV), formula (VII) and formula (VIII); R 6a and R 6b , or R 8a and R 8b , or R 8a and R 8c , or R 9a and R 9b , or R 10a and R 10b , or R 11a and R 11b The atoms connected to it together form a four-membered, five-membered, six-membered or seven-membered saturated or unsaturated carbocyclic ring or a heterocyclic ring containing 1-3 N atoms, wherein the C atoms or N atoms on the carbocyclic ring or the N-containing heterocyclic ring are optionally substituted by 0-6 independently selected halogen, oxo, haloalkyl, C 1-6 Alkyl, C 3-6 Cycloalkyl and -C 1-6 Preferably, the C atom or N atom on the carbocyclic ring or N-containing heterocyclic ring is optionally substituted by 0-2 independently selected C 1-3 Alkyl, C 1-3 substituted by a substituent of alkylene-OH; or R 6b Selected from hydrogen, halogen, hydroxyl, C 3-6 Cycloalkyl and C 1-6 Preferably, the R 6b Selected from chlorine, fluorine, hydroxyl, C 3-6 Cycloalkyl, C 1-3 Alkyl and C 1-3 Haloalkyl; R 6a Selected from -OC 1-6 Alkyl, C 3-10 Cycloalkyl, heterocyclic group, The -OC 1-6 Alkyl, C 3-10 The cycloalkyl group is optionally substituted by 0, 1, 2, 3, 4, 5 or 6 groups independently selected from halogen, hydroxy, cyano, amino, carboxyl, ester, C 1-6 Alkyl and -C 1-6 Preferably, the -OC 1-6 The alkyl group is -OC 1-3 Alkyl; preferably -O-methyl; and / or R 7 Selected from hydrogen, halogen, hydroxyl, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, C 1-6 Haloalkyl and alkoxy; preferably -CF 3 ; and / or R 8a Selected from and / or R 8b , R 8c , R 8d are independently selected from hydrogen, halogen, hydroxyl, cyano, nitro, amino, carboxyl, ester, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl and -C 1-3 Preferably, the R 8b , R 8c , R 8d are independently selected from hydrogen, halogen and -OC 1-6 More preferably, the R 8b , R 8c , R 8d are independently selected from hydrogen, F, Cl and -OC 1-6 Alkyl; and / or Y 5 , Y 6 , Y 7 , Y 8 At least 2 of them are N and the rest are C; and / or R 11b Selected from hydrogen, halogen, hydroxyl, C 1-6 Alkyl and C 3-6 Cycloalkyl; R 11a Selected from hydrogen, halogen, hydroxyl, C 1-6 Alkyl, C 3-6 Cycloalkyl and The C 1-6 Alkyl and C 3-6 Cycloalkyl is optionally substituted with 0, 1, 2, 3, 4, 5 or 6 substituents independently selected from halogen, hydroxy, cyano, amino, carboxyl, ester; and / or Y 2 and Y 4 For C, Y 1 and Y 3 are independently selected from N and S; preferably, Y 1 It's S, Y 3 is N; and / or R 12 Selected from hydrogen, halogen, hydroxyl, cyano, amino, carboxyl, ester, C 1-6 Haloalkyl, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 5-10 Aryl, C 5-10 Heteroaryl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, Wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 5-10 Aryl, C 5-10 Heteroaryl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl is optionally substituted by 0-6 substituents independently selected from halogen, hydroxy, cyano, amino, carboxyl, ester; and / or n6, n8, n11, n12 are independently selected from 1, 2 and 3; and / or R 6c1 , R 7c1 , R 8d1 , R 9c1 , R 10c1 , R 11c1 , R 12c1 are independently selected from hydrogen, hydroxyl, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkylene-NC 1-6 Alkyl, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -OC 1-6 Alkylene hydroxyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 1-3 Alkylene-OC 1-3 Alkyl, -OC 1-3 Alkylene-OC 2-6 Alkenyl, -OC 1-3 Alkylene-NC 1-6 Alkyl, C 3-6 Cycloalkyl, C substituted by 1-3 halogens 3-6 Cycloalkyl, -OC 3-6 Cycloalkyl, -OC 1-6 Alkylene-C 3-6 Cycloalkyl, -OC 1-6 Alkylene-C 3-6 Heterocycloalkyl, -OC 3-6 Heterocycloalkyl, -O-aryl, -OC 1-3 Alkylene-C 5-7 Heteroaryl, the heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O, S, -C 5-7 Heteroarylene-C 1-6 The heteroarylene group contains 1, 2 or 3 heteroatoms selected from N, O, S and the C 1-6 Alkyl is substituted by 0-3 halogens, -OC 1-3 Alkylene-cyano, -OC 3-6 Cycloalkyl-OC 1-6 Alkyl, R 6c2 , R 7c2 , R 8d2 , R 9c2 , R 10c2 , R 11c2 , R 12c2 is hydrogen or C 1-3 Alkyl; preferably, R 6c1 , R 7c1 , R 8d1 , R 9c1 , R 10c1 , R 11c1 , R 12c1 are independently selected from hydroxyl, methyl, ethyl, propyl, R 6c2 , R 7c2 , R 8d2 , R 9c2 , R 10c2 , R 11c2 , R 12c2 is hydrogen or methyl, or R 6c1 and R 6c2 , R 7c1 and R 7c2 , R 8d1 and R 8d2 , R 9c1 and R 9c2 , R 10c1 and R 10c2 , R 11c1 and R 11c2 , R 12c1 and R 12c2 The N atoms to which they are connected independently form a 3-6 membered heterocyclic ring, wherein the heterocyclic ring is optionally substituted by 1, 2, 3, 4, 5 or 6 groups independently selected from halogen, oxo, hydroxyl, nitro, cyano, amino, -NHC 1-4 Alkyl, -C 1-4 Alkyl NH 2 , carboxyl, -COOC 1-4 Alkyl, -C 1-4 Alkyl-COO-C 1-6 Alkyl, -NHCOC 1-4 Alkyl, -C 1-4 AlkylCONH 2 、-C(O)-NH-C 1-4 Alkoxy, C 1-4 Alkyl, C 1-6 Alkylene-hydroxyl, C 1-4 Alkoxy, C 2-4 Alkenyloxy, C 2-4 Alkynyloxy, C 3-6 Cycloalkoxy, 3-6 membered heterocycloalkoxy, C 3-6 Cycloalkenyloxy, C 6-8 Aryl and C 5-8 wherein the -C(O)-NH-C 1-6 Alkoxy, C 1-6 Alkyl, C 1-6 Alkoxy, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, -alkoxy-3-6 membered heterocyclic group, C 3-8 Cycloalkenyloxy, C 6-10 Aryl and C 5-10 The heteroaryl group is optionally substituted with 0, 1, 2 or 3 substituents independently selected from halogen, hydroxy, oxo, nitro and cyano; preferably, R 6c1 and R 6c2 , R 7c1 and R 7c2 , R 8d1 and R 8d2 , R 9c1 and R 9c2 , R 10c1 and R 10c2 , R 11c1 and R 11c2 , R 12c1 and R 12c2 The N atoms to which they are connected independently form a 4-5 membered heterocyclic ring, wherein the 4-5 membered heterocyclic ring is optionally substituted by 0-2 independently selected from F, Cl, hydroxyl, C 1-3 Alkyl, C 1-3 The alkylene-hydroxy group is substituted with an alkylene-hydroxy group.
3. A compound, wherein the compound is a compound represented by formula (I), or an isomer, isotope derivative, polymorph, prodrug, chelate, non-covalent complex, pharmaceutically acceptable salt or solvate thereof: in, X is O or S; R 1 and R 2 are independently selected from H, halogen, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl and C 1-6 Preferably, R1 is H; Preferably, R2 is halogen; M 1 C or N; When M 1 When N, R 3 does not exist; R 4 Selected from hydrogen, C 1-6 Alkyl, C 1-6 Alkoxy and C 3-6 Cycloalkyl, wherein the C 1-6 Alkyl, C 1-6 Alkoxy and C 3-6 Cycloalkyl is optionally substituted by 0-6 groups independently selected from halogen, cyano, nitro, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , hydroxyl, R 4a AND-OR 4a substituted by a substituent; Among them, R 4a Selected from C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, -N,N-di-C 1-6 Alkylamino, -N-mono-C 1-6 Alkylamino, C 6-10 Aryl and C 5-10 Heteroaryl, the C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, -N,N-di-C 1-6 Alkylamino, -N-mono-C 1-6 Alkylamino, C 6-10 Aryl and C 5-10 The heteroaryl group is optionally substituted by 0-6 groups independently selected from halogen, cyano, nitro, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 and hydroxyl substituents; preferably, R 4 Selected from C 1-6 Alkyl and C 1-6 Alkoxy, the C 1-6 Alkyl and C 1-6 Alkoxy is optionally substituted by 0-6 independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy and C 1-6 The substituent of the haloalkoxy group is substituted; more preferably, R 4 -C(CH 3 )-O-CH 3 or -C(CH 3 )-O-CHF 2 ; R 5 is hydrogen or C 1-6 Alkyl; or R 4 and R 5 The atoms connected together form a five-membered or six-membered heterocyclic ring, or a 7-12-membered spirocyclic ring, wherein the five-membered or six-membered heterocyclic ring or the 7-12-membered spirocyclic ring is optionally substituted by 0-3 independently selected from halogen, cyano, amino, hydroxyl, -C(=O)OC 1-6 Alkyl, -C 1-6 Alkylene-OH, C 1-6 Alkyl, C 1-6 Haloalkyl, -N,N-di-C 1-6 Alkylamino, -N-mono-C 1-6 Alkylamino, -C(=O)NH-alkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl and -OC 3-6 Preferably, the five-membered or six-membered heterocyclic ring or the 7-12-membered spirocyclic ring is optionally substituted by 0-3 independently selected from halogen, hydroxyl, -C(=O)OC 1-6 Alkyl, -C 1-6 Alkylene-OH, C 1-6 Alkyl and C 1-6 Substitution of haloalkyl groups; Ring A is selected from the group consisting of the structural formulae (II), (III), (IV), (V), (VI), (VII) and (VIII): Preferably, ring A is selected from formula (II), formula (III), formula (IV), formula (VII) and formula (VIII); R 6a and R 6b , or R 8a and R 8b , or R 8a and R 8c , or R 9a and R 9b , or R 10a and R 10b , or R 11a and R 11b The atoms connected to it together form a four-membered, five-membered, six-membered or seven-membered saturated or unsaturated carbocyclic ring or a heterocyclic ring containing 1-3 N atoms, wherein the C atoms or N atoms on the carbocyclic ring or the N-containing heterocyclic ring are optionally substituted by 0-6 independently selected halogens, oxo groups, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , hydroxyl, cyano, amino, carboxyl, haloalkyl, alkoxy, -C 1-6 Alkylene carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 、-OC 1-6 Alkyl, C 1-6 Alkyl, C 3-6 Cycloalkyl and -C 1-6 Preferably, the C atom or N atom on the carbocyclic ring or N-containing heterocyclic ring is optionally substituted by 0-6 independently selected from halogen, oxo, haloalkyl, C 1-6 Alkyl, C 3-6 Cycloalkyl and -C 1-6 substituted by a substituent of alkylene-OH; or R 6b Selected from hydrogen, halogen, hydroxyl, cyano, nitro, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, alkoxy, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl and C 1-6 Haloalkyl; wherein the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl and C 1-6 The haloalkyl group is optionally substituted by 0-6 groups independently selected from halogen, hydroxy, cyano, amino, carboxyl, haloalkyl, alkoxy, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 Preferably, the R 6b Selected from hydrogen, halogen, hydroxyl, C 3-6 Cycloalkyl and C 1-6 Haloalkyl; R 6a Selected from -OC 1-6 Alkyl, C 3-10 Cycloalkyl, Said-OC 1-6 Alkyl, C 3-10 Cycloalkyl is optionally substituted by 0-6 independently selected from halogen, hydroxy, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, halogenated alkyl, alkoxy, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , C 1-6 Alkyl and -C 1-6 Alkyl hydroxyl group is substituted by a substituent; R 7 Selected from hydrogen, halogen, hydroxyl, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, halogenated alkyl, alkoxy, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , C 1-6 Alkyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, Wherein C 1-6 Alkyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl is optionally substituted by 0-6 independently selected from halogen, hydroxy, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 Preferably, R 7 Selected from hydrogen, halogen, hydroxyl, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, C 1-6 Haloalkyl and alkoxy groups; When the A ring is a structure of Formula III, R 4 and R 5 When the atoms connected to them form a five-membered heterocyclic ring, the five-membered heterocyclic ring is not simultaneously substituted by methyl and -CF 3 replace; R 8a Selected from R 8b , R 8c , R 8d are independently selected from hydrogen, halogen, hydroxyl, cyano, nitro, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 ,-COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , carboxyl, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl and -C 1-3 Haloalkyl; When R 8a yes or R 8a and R 8b , or R 8a and R 8c When R and the atoms connected to it form a four-membered, five-membered, six-membered or seven-membered saturated or unsaturated carbon ring or a nitrogen-containing heterocyclic ring, 4 It is not isopropyl; When R 4 and R 5 The atoms connected to it form a five-membered heterocycloalkyl group, which is simultaneously substituted by methyl and -CF 3 When replaced, R 8a Not -S(O)-CH 3 and -O-CH 3 ; R 9a , R 9b are independently selected from hydrogen, halogen, hydroxyl, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 ,-COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , carboxyl, C 1-6 Alkyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, Wherein C 1-6 Alkyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl is optionally substituted by 0-6 independently selected from halogen, hydroxy, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 ,-COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , substituted by a substituent of the carboxyl group; R 10a , R 10b are independently selected from hydrogen, halogen, hydroxyl, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 ,-COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkylCONH 2 , carboxyl, C 1-6 Alkyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, Wherein C 1-6 Alkyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl is optionally substituted by 0-6 independently selected from halogen, hydroxy, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , substituted by a substituent of the carboxyl group; R 11a , R 11b are independently selected from hydrogen, halogen, hydroxyl, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene-NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , carboxyl, C 1-6 Alkyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, Wherein C 1-6 Alkyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl is optionally substituted by 0-6 independently selected from halogen, hydroxy, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 ,-COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , substituted by a substituent of the carboxyl group; Preferably, R 11b Selected from hydrogen, halogen, hydroxyl, C 1-6 Alkyl and C 3-6 Cycloalkyl; R 11a Selected from hydrogen, halogen, hydroxyl, C 1-6 Alkyl, C 3-6 Cycloalkyl and The C 1-6 Alkyl and C 3-6 The cycloalkyl group is optionally substituted with 0-6 substituents independently selected from halogen, hydroxy, cyano, amino, carboxyl, and ester; Y 1 , Y 2 , Y 3 , Y 4 are independently selected from C, N and S; R 12 Selected from hydrogen, halogen, hydroxyl, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 ,-COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , carboxyl, C 1-6 Haloalkyl, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 5-10 Heteroaryl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, Wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 5-10 Heteroaryl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl is optionally substituted by 0-6 independently selected from halogen, hydroxy, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 ,-COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , substituted by a substituent of the carboxyl group; The condition is that when Y 1 , Y 3 One of them is N, the other is S, R 12 Yes - CF 3 When R 4 no The condition is that when Y 1 It's S, Y 4 When N is 12 Not-CF 3 、-CH 3 ; The condition is that when Y 3 Is S or N, Y 4 When N is 12 Not-CF 3 , -CHF 2 ; Preferably, Y 1 YesS,Y 2 YesC,Y 3 YesN,Y 4 It is C; Preferably, R 12 Selected from hydrogen, halogen, hydroxyl, cyano, amino, C 1-6 Haloalkyl, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 3-6 Cycloalkyl, n6, n7, n8, n9, n10, n11, n12 are independently selected from 1, 2, 3 and 4; R 6c1 , R 6c2 , R 7c1 , R 7c2 , R 8d1 , R 8d2 , R 9c1 , R 9c2 , R 10c1 , R 10c2 , R 11c1 , R 11c2 , R 12c1 , R 12c2 are independently selected from hydrogen, hydroxyl, C 1-6 Alkyl, C 1-6 Alkyleneamino, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Heterocycloalkyl, pyrazolyl, phenoxy, cyano, C 1-6 Alkoxy, C 2-6 Alkenyloxy, C 2-6 Alkynyloxy, -OC 3-6 Cycloalkyl, C 6-10 Aryl and C 5-10 Heteroaryl, wherein the C 1-6 Alkyl, C 1-6 Alkylamino, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, pyrazolyl, phenoxy, cyano, C 1-6 Alkoxy, C 2-6 Alkenyloxy, C 2-6 Alkynyloxy, -OC 3-6 Cycloalkyl, C 6-10 Aryl and C 5-10 Heteroaryl is optionally substituted by 0-6 independently selected from halogen, oxo, nitro, hydroxy, cyano, furan, C 3-6 Cycloalkyl, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, -alkoxy-3-6 membered heterocyclic ring, C 3-8 Cycloalkenyloxy, C 6-10 The aryl group and the C group containing 1 to 4 heteroatoms independently selected from N, O, P and S 5-10 is substituted by a substituent of a heteroaryl group; or R 6c1 and R 6c2 , R 7c1 and R 7c2 , R 8d1 and R 8d2 , R 9c1 and R 9c2 , R 10c1 and R 10c2 , R 11c1 and R 11c2 , R 12c1 and R 12c2 The N atoms to which they are connected independently form a 3-6 membered heterocyclic ring, wherein the heterocyclic ring is optionally substituted by 0-6 independently selected from halogen, oxo, hydroxyl, nitro, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkyl NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkyl-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkylCONH 2 、--C(O)-NH-C 1-6 Alkoxy, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyloxy, C 2-6 Alkynyloxy, C 3-6 Cycloalkoxy, 3-6 membered heterocycloalkoxy, C 3-8 Cycloalkenyloxy, C 6-10 Aryl and C 5-10 wherein the -C(O)-NH-C 1-6 Alkoxy, C 1-6 Alkyl, C 1-6 Alkoxy, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, -alkoxy-3-6 membered heterocyclic group, C 3-8 Cycloalkenyloxy, C 6-10 Aryl and C 5-10 The heteroaryl group is optionally substituted with 0-6 substituents independently selected from halogen, hydroxy, oxo, nitro and cyano; preferably, the heterocycle is optionally substituted with 1, 2, 3, 4, 5 or 6 substituents independently selected from halogen, oxo, hydroxy, nitro, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkyl NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkyl-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkylCONH 2 、--C(O)-NH-C 1-6 Alkoxy, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyloxy, C 2-6 Alkynyloxy, C 3-6 Cycloalkoxy, 3-6 membered heterocycloalkoxy, C 3-8 Cycloalkenyloxy, C 6-10 Aryl and C 5-10 wherein the -C(O)-NH-C 1-6 Alkoxy, C 1-6 Alkyl, C 1-6 Alkoxy, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, -alkoxy-3-6 membered heterocyclic group, C 3-8 Cycloalkenyloxy, C 6-10 Aryl and C 5-10 Heteroaryl is optionally substituted with 0-6 substituents independently selected from halogen, hydroxy, oxo, nitro and cyano; R 6d , R 7d , R 8e , R 9d , R 10d , R 11d , R 12d are independently selected from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl and C 3-6 Cycloalkyl, wherein the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl and C 3-6 Cycloalkyl is optionally substituted by 0-6 independently selected from halogen, hydroxy, oxo, nitro, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyloxy, C 2-6 Alkynyloxy, C 3-6 Cycloalkoxy, 3-6 membered heterocycloalkoxy, C 3-8 Cycloalkenyloxy, C 6-10 Aryl and C 5-10 substituted by a heteroaryl substituent; Y 5 , Y 6 , Y 7 , Y 8 are independently selected from C and N; R 6e , R 6f , R 6g , R 7e , R 7f , R 7g , R 8f , R 8g , R 8h , R 9e , R 9f , R 9g , R 10e , R 10f , R 10g , R 11e , R 11f , R 11g , R 12e , R 12f , R 12g are independently absent or selected from hydrogen, halogen, hydroxyl, cyano, nitro, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, carboxyl, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, -C(O)NH-OC 1-6 Alkyl, -C(=O)NH-OC 2-6 Alkenyl, -C(=O)NH-OC 2-6 Alkynyl, -C(=O)NH-OC 3-6 Cycloalkyl, -NH-C(=O)-C 1-6 Alkynyl, -NH-C(=O)-C 1-6 Alkyl, -NH-C(=O)-C 3-6 Cycloalkyl, -NH-C(=O)-C 3-6 Heterocycloalkyl, the C 3-6 The heterocycloalkyl group contains 1, 2, 3 or 4 heteroatoms independently selected from N, O, P and S, -NH-C(=S)-C 3-6 Heterocycloalkyl, the C 3-6 The heterocycloalkyl group contains 1, 2, 3 or 4 heteroatoms independently selected from N, O, P and S, -NH-C(=O)-C 1-6 Alkylene-OC 1-6 Alkyl, -NH-C(=O)-C 1-6 Alkylene-OC(=O)-C 1-6 Alkyl, -NH-C(=O)-C 1-6 Alkylene-SC 1-6 Alkyl, -NH-C(=O)-C 2-6 Alkenyl, -NH-C(=O)-C 2-6 Alkynyl, -C(=O)NH-C 1-6 Alkyl, -C(=O)NH-C 2-6 Alkenyl, -C(=O)NH-C 2-6 Alkynyl, -C(=O)NH-C 3-6 Cycloalkyl, -NH-C 1-6 Alkyl, -NH-C(=O)-NH-C 1-6 Alkyl, -NH-C(=O)-C 5-10 Heteroaryl, the C 5-10 The membered heteroaryl group contains 1, 2, 3 or 4 heteroatoms independently selected from N, O, P and S, -NH-C(=O)-C 6-10 Aryl, C 6-10 The aryl group and the C group containing 1 to 4 heteroatoms independently selected from N, O, P and S 5-10 Heteroaryl, wherein the -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, carboxyl, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, -C(O)NH-OC 1-6 Alkyl, -C(=O)NH-OC 2-6 Alkenyl, -C(=O)NH-OC 2-6 Alkynyl, -C(=O)NH-OC 3-6 Cycloalkyl, -NH-C(=O)-C 1-6 Alkyl, -NH-C(=O)-C 1-6 Alkynyl, -NH-C(=O)-C 3-6 Cycloalkyl, -NH-C(=O)-C 3-6 Heterocycloalkyl, -NH-C(=S)-C 3-6 Heterocycloalkyl, -NH-C(=O)-C 1-6 Alkylene-OC 1-6 Alkyl, -NH-C(=O)-C 1-6 Alkylene-OC(=O)-C 1-6 Alkyl, -NH-C(=O)-C 1-6 Alkylene-SC 1-6 Alkyl, -NH-C(=O)-C 2-6 Alkenyl, -NH-C(=O)-C 2-6 Alkynyl, -C(=O)NH-C 1-6 Alkyl, -C(=O)NH-C 2-6 Alkenyl, -C(=O)NH-C 2-6 Alkynyl, -C(=O)NH-C 3-6 Cycloalkyl, -NH-C 1-6 Alkyl, -NH-C(=O)-NH-C 1-6 Alkyl, -NH-C(=O)-C 5-10 Heteroaryl, -NH-C(=O)-C 6-10 Aryl, C 6-10 The aryl group and the C group containing 1 to 4 heteroatoms independently selected from N, O, P and S 5-10 Heteroaryl, optionally substituted by 0-6 independently selected from halogen, hydroxy, nitro, cyano, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and C 3-6 Preferably, when Y 6 and Y 7 N, Y 8 C or N, Y 9 When C, R 6e , R 6f , R 6g , R 7e , R 7f , R 7g , R 8f , R 8g , R 8h , R 9e , R 9f , R 9g , R 10e , R 10f , R 10g , R 11e , R 11f , R 11g , R 12e , R 12f , R 12g are independently absent or selected from hydrogen, halogen, -NHC 1-6 Alkyl, -COOC 1-6 Alkyl, C 2-6 Alkynyl, -C(O)NH-OC 1-6 Alkyl, -C(=O)NH-OC 2-6 Alkenyl, -C(=O)NH-OC 2-6 Alkynyl, -C(=O)NH-OC 3-6 Cycloalkyl, -NH-C(=O)-C 1-6 Alkynyl, -NH-C(=O)-C 1-6 Alkyl, -NH-C(=O)-C 3-6 Cycloalkyl, -NH-C(=O)-C 3-6 Heterocycloalkyl, the C 3-6 The heterocycloalkyl group contains 1, 2, 3 or 4 heteroatoms independently selected from N, O, P and S, -NH-C(=S)-C 3-6 Heterocycloalkyl, the C 3-6 The heterocycloalkyl group contains 1, 2, 3 or 4 heteroatoms independently selected from N, O, P and S, -NH-C(=O)-C 1-6 Alkylene-OC 1-6 Alkyl, -NH-C(=O)-C 1-6 Alkylene-OC(=O)-C 1-6 Alkyl, -NH-C(=O)-C 1-6 Alkylene-SC 1-6 Alkyl, -NH-C(=O)-C 2-6 Alkenyl, -NH-C(=O)-C 2-6 Alkynyl, -C(=O)NH-C 1-6 Alkyl, -C(=O)NH-C 2-6 Alkenyl, -C(=O)NH-C 2-6 Alkynyl, -C(=O)NH-C 3-6 Cycloalkyl, -NH-C 1-6 Alkyl, -NH-C(=O)-NH-C 1-6 Alkyl, -NH-C(=O)-C 5-10 Heteroaryl, the C 5-10 The membered heteroaryl group contains 1, 2, 3 or 4 heteroatoms independently selected from N, O, P and S, -NH-C(=O)-C 6-10 Aryl, C 6-10 The aryl group and the C group containing 1 to 4 heteroatoms independently selected from N, O, P and S 5-10 Heteroaryl, wherein the -NHC 1-6 Alkyl, -COOC 1-6 Alkyl, C 2-6 Alkynyl, -C(O)NH-OC 1-6 Alkyl, -C(=O)NH-OC 2-6 Alkenyl, -C(=O)NH-OC 2-6 Alkynyl, -C(=O)NH-OC 3-6 Cycloalkyl, -NH-C(=O)-C 1-6 Alkynyl, -NH-C(=O)-C 1-6 Alkyl, -NH-C(=O)-C 3-6 Cycloalkyl, -NH-C(=O)-C 3-6 Heterocycloalkyl, the C 3-6 The heterocycloalkyl group contains 1, 2, 3 or 4 heteroatoms independently selected from N, O, P and S, -NH-C(=S)-C 3-6 Heterocycloalkyl, the C 3-6 The heterocycloalkyl group contains 1, 2, 3 or 4 heteroatoms independently selected from N, O, P and S, -NH-C(=O)-C 1-6 Alkylene-OC 1-6 Alkyl, -NH-C(=O)-C 1-6 Alkylene-OC(=O)-C 1-6 Alkyl, -NH-C(=O)-C 1-6 Alkylene-SC 1-6 Alkyl, -NH-C(=O)-C 2-6 Alkenyl, -NH-C(=O)-C 2-6 Alkynyl, -C(=O)NH-C 1-6 Alkyl, -C(=O)NH-C 2-6 Alkenyl, -C(=O)NH-C 2-6 Alkynyl, -C(=O)NH-C 3-6 Cycloalkyl, -NH-C 1-6 Alkyl, -NH-C(=O)-NH-C 1-6 Alkyl, -NH-C(=O)-C 5-10 Heteroaryl, the C 5-10 The membered heteroaryl group contains 1, 2, 3 or 4 heteroatoms independently selected from N, O, P and S, -NH-C(=O)-C 6-10 Aryl, C 6-10 The aryl group and the C group containing 1 to 4 heteroatoms independently selected from N, O, P and S 5-10 Heteroaryl, optionally substituted by 0-6 independently selected from halogen, hydroxy, nitro, cyano, amino, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and C 3-6 is substituted by a cycloalkyl substituent; and R 6e and R 6f , or R 7e and R 7f , R 8f and R 8g , or R 9e and R 9f , or R 10e and R 10f , or R 11e and R 11f , or R 12e and R 12f are not H or absent; when R6a is When , the condition is that X is S; R 6h , R 7h , R 8i , R 9h , R 10h , R 11h , R 12h are independently selected from hydrogen, halogen, hydroxyl, cyano, amino, carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, -C(=O)N-(R 6h2 )R 6h3 and C 6-10 Aryl, wherein the -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, -C(=O)N-(R 6h2 )R 6h3 and C 6-10 Aryl is optionally substituted by 0-6 independently selected from halogen, hydroxy, oxo, nitro, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, C 3-6 Cycloalkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , C 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, -OC 3-6 Heterocyclic group, C 3-8 cycloalkenyloxy, 6-10 membered aryl and 5-10 membered heteroaryl; wherein R 6h2 , R 6h3 are independently selected from hydrogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and C 3-6 Cycloalkyl; or R 6h2 and R 6h3 The N atom commonly connected thereto forms a 3-8 membered heterocyclic ring, wherein the 3-8 membered ring is optionally substituted by 0-6 independently selected from halogen, hydroxyl, C 1-6 Alkoxy, -C 1-6 Alkylene - hydroxyl, nitro, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , C 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, -OC 3-6 Heterocycloalkyl, C 3-8 Cycloalkenyloxy, C 6-10 Aryl and C 5-10 Substitution of heteroaryl groups by substituents; The condition is that when R 6b When selected from Cl, R 6a no The condition is that when R 6b is CHF 2 When R 6a no The condition is that when R 6a yes When X is S; The condition is that Y 5 , Y 6 Both are N, and Y 7 , Y 8 When both are C, R 6e , R 6f , R 6g Not H at the same time or not present; The condition is that Y 5 , Y 6 Both are N, and Y 7 , Y 8 Both are C, and R 6e and R 6g When all are H or do not exist, R 6f Not -OH, -C≡N; The condition is that when Y 5 , Y 6 Both are N, and R 6f When H, R 6e or R 6g Not -C≡N.
4. The compound according to claim 3, in: X is O or S; R 1 and R 2 are independently selected from H and halogen; preferably, the halogen is selected from Cl, Br and F; M 1 When N is 3 Does not exist; R 4 It is for -C 1-6 Alkyl-C 1-6 Alkoxy or -C 1-6 Alkyl-OC 1-6 haloalkyl; further preferably, R 4 -C(CH 3 )-O-CH 3 or -C(CH 3 )-O-CHF 2 ;; R 5 is hydrogen or C 1-6 Alkyl; or R 4 and R 5 The atoms connected together form a five-membered or six-membered heterocyclic ring, or a 7-12-membered spirocyclic ring, wherein the five-membered or six-membered heterocyclic ring or the 7-12-membered spirocyclic ring is optionally substituted by 0-3 independently selected from halogen, hydroxyl, -C(=O)OC 1-6 Alkyl, -C 1-6 Alkylene-OH, C 1-6 Alkyl and C 1-6 Substitution of haloalkyl groups; Ring A is selected from the group consisting of formula (II), formula (III), formula (IV), formula (VII) and formula (VIII); R 6a and R 6b , or R 8a and R 8b , or R 8a and R 8c , or R 9a and R 9b , or R 10a and R 10b , or R 11a and R 11b The atoms connected to it together form a four-membered, five-membered, six-membered or seven-membered saturated or unsaturated carbocyclic ring or a heterocyclic ring containing 1-3 N atoms, wherein the C atoms or N atoms on the carbocyclic ring or the N-containing heterocyclic ring are optionally substituted by 0-6 independently selected halogen, oxo, haloalkyl, C 1-6 Alkyl, C 3-6 Cycloalkyl and -C 1-6 substituted by a substituent of alkylene-OH; or R 6b Selected from hydrogen, halogen, hydroxyl, C 3-6 Cycloalkyl and C 1-6 Preferably, the R 6b Selected from chlorine, fluorine, C 3-6 Cycloalkyl, C 1-3 Alkyl and C 1-3 Haloalkyl; R 6a Selected from -OC 1-6 Alkyl, C 3-10 Cycloalkyl, The -OC 1-6 Alkyl, C 3-10 The cycloalkyl group is optionally substituted by 0-6 groups independently selected from halogen, hydroxy, cyano, amino, carboxyl, ester, C 1-6 Alkyl and -C 1-6 Alkyl hydroxyl group is substituted by a substituent; R 7 Selected from hydrogen, halogen, hydroxyl, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, C 1-6 Haloalkyl and alkoxy; R 8a Selected from R 8b , R 8c , R 8d are independently selected from hydrogen, halogen, hydroxyl, cyano, nitro, amino, carboxyl, ester, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl and -C 1-3 Preferably, the R 8b , R 8c , R 8d are independently selected from hydrogen, halogen and -OC 1-6 More preferably, the R 8b , R 8c , R 8d are independently selected from hydrogen, F, Cl and -OC 1-6 alkyl; R 11b Selected from hydrogen, halogen, hydroxyl, C 1-6 Alkyl and C 3-6 Cycloalkyl; R 11a Selected from hydrogen, halogen, hydroxyl, C 1-6 Alkyl, C 3-6 Cycloalkyl and The C 1-6 Alkyl and C 3-6 The cycloalkyl group is optionally substituted with 0-6 substituents independently selected from halogen, hydroxy, cyano, amino, carboxyl, and ester; Y 1 , Y 2 , Y 3 , Y 4 are independently selected from C, N and S; R 12 Selected from hydrogen, halogen, hydroxyl, cyano, amino, carboxyl, ester, C 1-6 Haloalkyl, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 5-10 Aryl, C 5-10 Heteroaryl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, Wherein C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 5-10 Aryl, C 5-10 Heteroaryl, C 3-6 Cycloalkyl, -OC 1-6 Alkyl, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 The cycloalkyl group is optionally substituted with 0-6 substituents independently selected from halogen, hydroxy, cyano, amino, carboxyl, and ester; n6, n8, n11, n12 are independently selected from 1, 2, 3 and 4; R 6c1 , R 6c2 , R 7c1 , R 7c2 , R 8d1 , R 8d2 , R 9c1 , R 9c2 , R 10c1 , R 10c2 , R 11c1 , R 11c2 , R 12c1 , R 12c2 are independently selected from hydrogen, hydroxyl, C 1-6 Alkyl, C 1-6 Alkyleneamino, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Heterocycloalkyl, pyrazolyl, phenoxy, cyano, C 1-6 Alkoxy, C 2-6 Alkenyloxy, C 2-6 Alkynyloxy, -OC 3-6 Cycloalkyl, C 6-10 Aryl and C 5-10 Heteroaryl, wherein the C 1-6 Alkyl, C 1-6 Alkylamino, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, pyrazolyl, phenoxy, cyano, C 1-6 Alkoxy, C 2-6 Alkenyloxy, C 2-6 Alkynyloxy, -OC 3-6 Cycloalkyl, C 6-10 Aryl and C 5-10 Heteroaryl is optionally substituted by 0-6 independently selected from halogen, oxo, nitro, hydroxy, cyano, furan, C 3-6 Cycloalkyl, amino, -NHC 1-6 Alkyl, -C 1-6 Alkylene NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkylene-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkyleneCONH 2 , C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, -alkoxy-3-6 membered heterocyclic ring, C 3-8 Cycloalkenyloxy, C 6-10 The aryl group and the C group containing 1 to 4 heteroatoms independently selected from N, O, P and S 5-10 is substituted by a substituent of a heteroaryl group; or R 6c1 and R 6c2 , R 7c1 and R 7c2 , R 8d1 and R 8d2 , R 9c1 and R 9c2 , R 10c1 and R 10c2 , R 11c1 and R 11c2 , R 12c1 and R 12c2 The N atoms to which they are connected independently form a 3-6 membered heterocyclic ring, wherein the heterocyclic ring is optionally substituted by 1, 2, 3, 4, 5 or 6 groups independently selected from halogen, oxo, hydroxyl, nitro, cyano, amino, -NHC 1-6 Alkyl, -C 1-6 Alkyl NH 2 , carboxyl, -COOC 1-6 Alkyl, -C 1-6 Alkyl-COO-C 1-6 Alkyl, -NHCOC 1-6 Alkyl, -C 1-6 AlkylCONH 2 、--C(O)-NH-C 1-6 Alkoxy, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyloxy, C 2-6 Alkynyloxy, C 3-6 Cycloalkoxy, 3-6 membered heterocycloalkoxy, C 3-8 Cycloalkenyloxy, C 6-10 Aryl and C 5-10 wherein the -C(O)-NH-C 1-6 Alkoxy, C 1-6 Alkyl, C 1-6 Alkoxy, -OC 2-6 Alkenyl, -OC 2-6 Alkynyl, -OC 3-6 Cycloalkyl, -alkoxy-3-6 membered heterocyclic group, C 3-8 Cycloalkenyloxy, C 6-10 Aryl and C 5-10 Heteroaryl is optionally substituted with 0-6 substituents independently selected from halo, hydroxy, oxo, nitro and cyano.
5. The compound according to any one of claims 1 to 4, wherein the ring A is selected from the following structures:
6. The compound according to any one of claims 1 to 5, wherein the compound is selected from the following structures:
7. A pharmaceutical composition, Features The pharmaceutical composition comprises a therapeutically effective dose of the compound according to any one of claims 1 to 6 and a pharmaceutically acceptable carrier or excipient.
8. Use of the compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 7 for preparing a medicament for treating a MALT1-related disease; preferably, the MALT1-related disease is an autoimmune disease, an inflammatory disease, a cancer or a tumor.
9. A method for treating a MALT1-related disease in a patient, the method comprising administering to the patient a therapeutically effective amount of one or more compounds described in any one of claims 1 to 6 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition described in claim 7; preferably, the MALT1-related disease is an autoimmune disease, an inflammatory disease, a cancer or a tumor.
10. The compound according to any one of claims 1 to 6 or the pharmaceutical composition according to claim 7, for use in treating a MALT1-related disease; preferably, the MALT1-related disease is an autoimmune disease, an inflammatory disease, a cancer or a tumor.
